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Abstract 
 
Interferences and subsequent errors in biochemistry results can be generated in any part of the testing 
cycle and have significant impact on patient care outcomes. Irrespective of how well a laboratory adheres 
to accreditation/certification protocols and irrespective of whether it uses the latest automation and 
information systems, a laboratory will not be immune from such errors. Sample quality produced from 
current blood collection tubes is an area that has not received the intense scrutiny it deserves which will 
be the scope of this thesis.  
 
The biochemistry laboratory continues to be plagued by variability in analytical sample quality. The 
distinct differences that exist between sample types (e.g. serum and lithium heparin plasma), the extent to 
which “true” serum is formed in healthy and anticoagulated patient blood samples, and maintaining the 
sample integrity remain problematic with current blood collection tubes, even with adherence to 
recommended collections/processing/storage procedures. The use of lithium heparin plasma as an 
alternative to serum resolves one major clinical demand, improvement in turn-around time (TAT) in 
critical hospital situations, but continues to cause problems. It is not cell-free, and thus suffers from poor 
stability of some analytes on prolonged storage and is unsuitable for some assays. Serum from a 
completely coagulated blood sample is the preferred specimen type for most biochemical assays as it is 
theoretically cell-free and coagulation factor free, especially of fibrinogen (plus partly degraded 
fibrinogen and insoluble fibrin) which is the “fuel” for latent clotting. However, 30 minutes is the 
recommended clotting time for blood to clot completely, adding to increased TAT if serum is used instead 
of plasma. Furthermore complete clotting may not be achieved in anticoagulated patients using current 
commercial tubes. Incomplete clotting can lead to undesirable outcomes; including inaccurate results, 
analytical system problems and patient outcomes. In turn these impact on costs for service providers and 
reputation. With medical care decisions being so reliant on pathology data it is important that sample 
quality be improved.  
 
The thesis research in Chapter 2 has provided some examples of critical pathology errors linked to sample 
type and quality. The errors are with two of the most critical analytes, troponin and potassium and on the 
deficiencies of plasma as well as how to determine the most appropriate centrifugation setting to obtain 
highest quality lithium and citrate plasma samples.  
 
In response, the research has identified and evaluated snake venom prothrombin activators(s) as a clotting 
tube additive capable of providing highest quality serum sample produced in a very short time, (< 5 
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minutes) to meet TAT demands of any laboratory while assuring quality in serum from healthy and 
heavily anticoagulated patients. The incorporation of these materials in collection containers to produce 
serum for biochemistry and other pathology testing will allow greater confidence of laboratory staff, 
medical staff, service providers and patients in the results and their accuracy, and in turn improve patient 
care plus reduce inappropriate use of scare resources.   
 
In Chapters 3 and 4, enzyme activity and clotting studies with pure prothrombin, plasma, and 
whole blood have provided a detailed overview of the ability of the snake procoagulants to clot 
blood rapidly even in the presence of different anticoagulants and concentration levels. The 
kinetic studies using the four groups of snake venom prothrombin activators (PAs) demonstrated 
that the group C (Pseudonaja textilis prothrombin activator - PtPA and Oxyuranus scutellatus 
prothrombin activator - OsPA) were very effective in clotting plasma and blood with and without 
anticoagulants. Clotting was achieved with ~6 nM concentration of PtPA and OsPA in all 
samples including those on higher heparin doses within 5 minutes. PtPA was the procoagulant 
most extensively evaluated in this thesis.  Use of these procoagulants offers the opportunity to 
provide a superior serum product in almost all patient samples than is provided by current 
routinely used commercial tubes including the recently released Becton Dickinson rapid serum 
tube (BD RST).   
 
In Chapter 5 the BD RST tube which contains added thrombin was evaluated demonstrating it is 
a step in the right direction towards meeting the TAT demands with the recommended clotting 
time of 5 minutes. However, it is not able to clot heparinised blood samples, especially those 
containing > 2 IU/mL heparin, resulting in no clotting at all or latent clotting. To improve its 
effectiveness in heparinised patients it requires much higher thrombin concentration.  
 
In Chapter 6 the quality of serum produced by using the venom prothrombin activators was 
evaluated. The experiments demonstrated that high quality serum with significantly reduced cell 
numbers, less haemolysis, and consistently low residual fibrinogen concentration, < 30 mg/L.  
Serum with these properties was shown to provide a vastly improved stability in analytes, and is 
unlikely to result in analytical and patient care errors contributed to cellular activity, or cellular 
content. The PAs (PtPA, OsPA and ecarin) being proteases have been shown not to affect any of 
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the analytical principles or analytes tested that are proteins or using proteins as testing reagents, 
and do not alter cellular membranes that may lead to cellular lysis despite the fact that they are 
proteolytic enzymes. Simply, they offer biochemistry laboratories standardisation on a single 
specimen type, serum. With such rapid clotting there is an opportunity to perform an extended 
range of testing from a single tube for both urgent and non-urgent tests. These products not only 
meet the World Health Organisation definition of serum from the healthy to the most extreme 
example of anticoagulated patients, but exceed it. Based on the findings here the suggested 
definition of high quality serum is “serum is the undiluted, extracellular portion of blood after 
complete coagulation, that is devoid of consumable coagulation factor (fibrinogen < 30 mg/L) 
and it’s cell numbers and cell content is low such that the lactate dehydrogenase (LD) activity 
change is < 2% when measured immediately post cell separation (centrifugation) and upon 6-8 
hours of storage at room temperature”.  
 
The studies reported in this thesis provide convincing evidence for use of snake venom 
prothrombin activators to produce high quality serum in blood containers and devices. Producing 
the highest quality serum sample for biochemical, other pathology and research analyses will 
lead to in more accurate results and improved patient healthcare outcomes.  
 
Keywords 
laboratory errors, serum, plasma, sample quality, interferences, tubes, anticoagulant, 
procoagulant, prothrombin activator  
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CHAPTER 1 
 
GENERAL 
INTRODUCTION 
 31 
1.1 The Pathology Testing Cycle and Quality Considerations   
A laboratory test on a blood sample from a human being has been defined as an intervention that 
should be used to improve the outcome for the patient’s or public health. The emphasis is on the 
interpretation of the test results and subsequent action which is required before the test loop is 
completed [1]. The main role of clinical laboratories is to quickly produce reliable data in 
response to clinical requests so clinicians can then make correct clinical decisions [2]. A clinical 
laboratory seeks to guarantee a satisfactory answer to a clinical question posed: it must (a) 
produce a correct result; (b) define an appropriate reference range (decision level); (c) provide, 
whenever appropriate, suitable interpretative comments and diagnostic algorithms to help 
clinicians to make informed decisions [3].  
 
Patient safety is one of the most crucial features of quality care. However there is a growing 
culture of malpractice suits where patients seek legal redress for their grievances if the medical 
outcome is less than perfect (which is clearly a flawed expectation of the health care system). 
According to the Harvard Medical Malpractice Study, 0.13% of all hospitalizations in the USA 
will give rise to legal claims due to perceived or actual inappropriate or unsatisfactory outcomes 
and care [4]. Laboratory testing is not immune to this litigious approach when it is found to be 
responsible for the error. What matters to patients and family is not where the error occurred and 
who is responsible but that the error is detected before it causes any delay in care or outright 
harm [5]. Therefore this emphasizes the need for close scrutiny of the performance of the 
pathology laboratory across the total testing cycle. To achieve this, users of laboratory services 
must become partners to make laboratory testing safer and enhance patient safety which includes 
decisions on test ordering, patient preparation, and test interpretation [5]. 
 
Laboratory services may make up 5% of a hospital's budget but leverage 60-70% of the most 
important decisionson admittance, discharge, and medication in hospital practice [6]. In general 
practice this is significantly lower, in line with criticality of the patient population encountered. 
An Australian study showed in General Parctice the percent of encounters generating pathology 
test orders was 17.7% [7]. More recent publications estimate this levarge in a hospital practice to 
be up to 80% [8], and as high as 80-90% [9]. In some situations the pathology result is the 
principal factor in patient care decisions. Hence, healthcare systems are increasingly dependent 
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on reliable and prompt clinical laboratory data for patient care decisions. Furthermore the 
demand on pathology is increasingly to follow the patient, leading to growth in services where 
the patients are located. Point-of-care or near-patient testing (POCT) (blood or other body fluids) 
can provide faster data in order to meet clinical needs. The tests offered on POCT devices 
include: electrolytes (sodium, potassium, chloride, ionised calcium and magnesium), metabolites 
(glucose, lactate, urea, and creatinine), pH and gases (pO2, pCO2), oximetry (total haemoglobin 
including the different fractions, oxygen saturation, and total bilirubin), cardiac markers 
(troponin,  type natriuretic peptides), HbA1c, pregnancy test, activated clotting time etc.  In fact 
POCT accounts for approximately 34%  of the global in vitro diagnostic testing market (US$33.6 
billion), and was expected to grow from $5.5 billion in 2005 to as much as $7.5 billion in 2010 in 
the USA alone [10]. POCT is making the laboratory more visible and connected to the overall 
patient healthcare process as laboratory staff become involved in training of clinical staff and 
managing these POCT instruments.  
 
The role of the laboratory has been clearly outlined by the World Health Organisation (WHO): 
“The provision of timely and accurate laboratory results which are a cornerstone of effective 
diagnosis and treatment of patients” [11]. 
 
Pathology services in a large laboratory consist of several disciplines, namely chemical 
pathology (biochemistry), haematology, microbiology including serology, anatomical pathology 
including cytology, immunology and more recently molecular genetics.  Biochemistry is almost 
exclusively concerned with analysis of bodily fluids and mostly serum or plasma. Of all the 
disciplines biochemistry has the largest myriad of tests on offer, and it is not uncommon for a 
large referral laboratory to perform up to 500 different biochemical tests.    
  
 
1.1.1 Pathology errors and the three phases of the Pathology Testing Cycle 
The reliability of laboratory results depends heavily on accuracy, understood as a joint index of 
precision and trueness [12]. For the laboratory, accuracy can be defined as the true concentration 
of an analyte in an individual specimen. The total error comprises systematic (bias or accuracy) 
plus random error (imprecision). The exact error rate is difficult to ascertain as it depends on the 
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wide variety of definitions, the methods for identifying error frequency and nature and the type 
of healthcare facility [13]. The most recent publication estimated an error rate of 0.08% (1 
erroneous test result per 1223 test results) in a clinical biochemistry laboratory, where 81% of 
errors were pre-analytical, 10% analytical and 8% post analytical, and one was a service related 
error [14].  
 
Analysing error rates in more detail in a Stat (immediate) laboratory, it was estimated the 
distribution of the 160 total errors identified was 99 (61.9%) in the pre-analytical, 24 (15%) in 
the analytical, and 37 (23.1%) in the post analytical phase out of a total of 51746 analyses [15]. 
In three of these cases unacceptable results were obtained because of random errors due to 
pipetting difficulties on the analyser related to problems such as fibrin clots and insufficient 
sample volume aspirated. The authors were able to follow up the outcomes of the 160 (0.31%) 
laboratory errors and these are summarized in Table 1.   
 
Table 1. Laboratory errors and patient outcomes [15]. 
Error Number Percent of analyses (%) 
Total errors 160 0.31 
No effect 121 75.6 
Inappropriate Intensive Care Unit 
(ICU) admission 
1 0.6 
Inappropriate transfusion 2 1.3 
Further inappropriate investigation 9 5.6 
Laboratory tests repetition 27 16.9 
 
Studies in the last 30 years have also shown that clinicians ignore or overlook a lot of the 
abnormal routine test results [16, 17]. Some authors have even encouraged clinicians to ignore 
results if they are thought to be due to an error in the testing cycle or even to ignore some that are 
accurate findings but thought to be without clinical significance [18].  The exact error rate can be 
difficult to determine because often laboratory staff are reluctant to divulge data for fear of 
blame, individual failure and culpability associated with the events [19].  
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With POCT the error rate is even more difficult to determine as result capture in most frequently 
used systems (e.g. glucose meters) is dependent on transcription of results. This will only 
improve with adaptation of connectivity which allows electronic capture of results along with 
patient identifiers.  
 
 
The pathology testing cycle is divided into three phases: pre-analytical, analytical (or intra-
analytical) and post-analytical [20].  
 
Pre-analytical phase 
1.1 Clinician/Care Provider - Examine/Question Patient 
1.2 Decision/Test selection, ordering and providing clinical notes on request forms 
1.3 Phlebotomy  
- Patient identification including proper completion of request forms 
- Patient preparation (effects of prior meals, medication, activity, posture, time 
of day, stage in menstrual cycle, smoking, substance abuse, genetics and co-
morbidities, etc)  
- Sample collection (time of day, site- vein or capillary, IV, cannulas, skin 
cleanliness, tourniquet duration and influence, fist clenching or pumping, 
collection tube (serum or anticoagulant), collection technique – vacutainer, 
syringe suction and transfer, adequate and proper mixing of tubes, volume of 
blood collected, order of draw)  
- Sample labelling (patient full details, collection time date) 
- Sample packaging  
- Sample storage/transport (prolonged contact of cells, impact of temperature, 
mode of transport) 
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1.4 Laboratory 
- Sample preparation (centrifugation etc) 
- Sample accessioning  
- Sample aliquoting 
Analytical Phase 
 2.1. +/-Sample preparation/Sample suitability decision  
 2.2 Analysis 
 2.3 Review results/flags/clinical notes (real/artefactual interferences)  
 2.4 Repeat/Dilute etc 
 
Post-analytical 
 3.1 Quality Control checks 
3.2 Result review 
 3.3 Report formatting 
3.4 Validation 
 3.5 Value adding/interpretative commenting 
 3.6 Critical value reporting 
 3.7 Specimen storage 
3.8 Clinician/Care Provider result interpretation 
3.9 Clinical relevance 
3.10 Clinical response/action 
3.11 Patient follow-up  
   
1.1.2  Pre-analytical phase 
The phrase ‘garbage in garbage out’ most specifically applies to this phase [21], and it applies to 
all disciplines of pathology. Numerous publications have highlighted the fact that primary care 
physicians do not on average possess enough knowledge to optimally provide medical care when 
it comes to test selection [22], appropriate timing of tests, and making correct interpretations of 
results [23]. With the thousands of different laboratory tests currently available, and their ever 
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increasing range and complexity, it is inevitable that clinicians will sometimes lack the necessary 
knowledge and make errors. To aid clinicians and to improve test selection, laboratories and 
clinical disciplines have introduced diagnostic test algorithms [24]. The individual ordering the 
test and collecting the sample needs to recognize that the sample should be considered fragile 
and careful attention to detail is required for meaningful results [25]. The laboratory needs to be 
proactive in information dissemination, teaching and competency achievements (not just 
laboratory but phlebotomy and clinical staff). Laboratory professionals (pathologists and 
scientists) need to be available to provide advice on request or even when reviewing request slips 
or results and utilizing advancements in information technology to screen and aid clinicians in 
selecting the most appropriate laboratory tests.   
 
Overall, inappropriate quantity and quality of specimens account for over 60% of pre-analytical 
errors [26]. Problems related to specimen collection are the main cause of pre-analytical errors or 
variability: haemolysed samples 54%, insufficient volume 21%, incorrect sample 13%, and 
clotted 5% [27].  
 
1.1.3 Analytical phase 
Before a sample (plasma, serum or other body fluids) is loaded on an analyser or sampled by 
manual methods there may be checks that are performed: visual inspection (or in automation by 
detection system) of the sample for adequate volume, sample type, and sample integrity 
(presence of clots, bubbles, haemolysis, lipaemia, icteria, clarity in case inadequately 
centrifuged, plasma/cell ratio in case of intravenous fluid contamination etc). However, the 
identification of unsuitable specimens has always been a challenge for the laboratory, especially 
when this process is left to arbitrary criteria such as visual inspection [28]. The analytical sample 
quality is pivotal to accurate results.  
 
It is difficult to rely on request slips to assist in resolving unusual results as one study reports 
only 44% of pathology requests contained annotations in the narrative part of the notes [29], and 
some annotations were illegible.  
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The value determined for an analyte in a sample is influenced by many factors including: a) the 
standardization process; b) the analytical methodology (e.g. reagent problems); c) the analytical 
specificity; d) analyte interferences and e) matrix effects [30]. Other factors to consider that pose 
a challenge are variability of reference intervals (e.g. age, gender etc), calibrations, quality 
control, and reliability of published data [31]. All these factors may lead to interpretation bias 
[23].  
 
Errors in the analytical phase are probably of the greatest interest to laboratory professionals 
because they are most directly responsible for and connected to these mishaps [32]. Hence, 
efforts and resources are focused on achieving accurate results and eliminating errors in this 
phase.   
 
Informatics and computer science have changed laboratory practice as computers can be used to 
automatically test and eventually correct for analytical interferences, particularly haemolysis. 
This is most relevant in fully automated systems where operators do not visibly check samples. 
Additionally, an analytical flag, breaches of limit e.g. delta check, critical limits can be useful 
tools in identifying potential errors including interferences and incorrect sample type and 
preventing release of inappropriate results. Each error detection results in greater productivity 
coupled with lower costs.  
 
The analytic phase is far from being error-free with ongoing improvements constantly being 
implemented as will be pointed out in the sections below. Even though the errors that occur in 
this phase may be less frequent than pre-analytical errors if one accepts literature statistics [15], 
they can be clinically very significant, and deliver some embarrassing and harmful outcomes for 
patient well being, as well as financial and reputational impact on healthcare professionals and 
providers.  
 
1.1.4 Post-analytical phase 
This phase is considered by laboratory staff to be the ultimate quality check on the consistency 
and accuracy of both the pre-analytical and analytical phases. Developments in information 
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technology and automation provide the ability to increase tools for improved performance 
including the addition of interpretative comments. This phase depends on communication 
between the laboratory and clinician particularly with critical results, such as analyte values in 
situations that could be life threatening without treatment. In such cases turn-around-time 
becomes of paramount importance to ensure patient safety. Yet in one study, even when results 
were urgently requested, 45% of the results requested by Emergency Departments (EDs) were 
never accessed [15]. For reasons such as this, phoning directly and documenting critical results 
by laboratories is now becoming a common practice. Failure to notify caregivers of critical 
results may represent important patient safety vulnerability [33]. A simple system of repeating 
telephoned laboratory results has the potential to reduce the risk of medical errors and improve 
patient safety. For example Rensberg et al found of 472 outgoing telephone calls, 51 errors 
(10.8%) were detected [34]. Even when such a system is implemented errors can still occur. 
Barenfanger et al in a study involving three healthcare organisations required the receipient of 
critical results to repeat the results, and they found of the 822 results phoned 29 (3.5%) were 
erroneously recorded and the physicians had the highest error rate 6/95 (5%) [35]. An alternative 
way to ensure results are acted on in a timely fashion is use of web browsers where a clinician 
electronically signs off on each reviewed result. Such browsers can be hyperlinked to other 
knowledge resources behind them, including links into the laboratory handbook to give guidance 
on interpretations of results [29].  
 
1.1.5 The analytical sample 
Enormous effort has gone into improving sample quality (specifically plasma and serum), to 
produce a sample truly representative of the physico-pathological state of the patient that will at 
the end of the testing cycle as reflected accurately by the analyte(s) concentrations. This in turn 
is central to the accuracy of the subsequent cascade of patient care decisions.  
 
It is imperative that the in-vivo concentration of a constituent remains unchanged after 
withdrawal from the body fluid of a patient to obtain a valid medical laboratory result [36]. 
Preserving sample integrity is essential to ensure accurate results but there are other aspects to 
consider that may influence results. The clinical condition of the patient may produce analyte 
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concentrations that can cause analytical problems either with the analyte of interest (e.g. Hook 
effect) or other analytes (e.g. cross reacting, block reactions). Samples may contain additional or 
altered constituents that can influence analytical processes and accuracies of analyte 
determinations (e.g. herbal or other supplements, medications etc). Changes in sample content 
can also be induced by a number of factors e.g. sample type, storage, physical status, age, sex, 
etc. All these factors must be considered right from the beginning of the testing cycle through to 
determining reference intervals and interpreting results post-analytically before using 
biochemistry data for diagnosis or intervention.  
 
The ideal analytical sample, serum or plasma, needs to be cell and stroma free [37]. This is to 
ensure analyte concentrations are unaltered upon storage of (Chapter 2; Dimeski G, Solano C, 
Petroff MK, Hynd M. Centrifugation protocols: tests to determine optimal lithium heparin and 
citrate plasma sample quality. Ann Clin Biochem 2011;48:218-22.). If serum is the preferred 
sample for most assays, then it has to be completely free of fibrinogen and soluble fibrin, and 
hence is “fuel deprived” for latent clotting. Also it has to be produced in the shortest possible 
time to meet clinical expectations on turn-around time of test data. For plasma or whole blood, 
the anticoagulant of choice must be capable of preventing any clotting, should not alter 
analyte(s) concentrations or cross react with analytical procedures, and should not induce 
changes to sample integrity upon storage.  
 
1.1.7 Reference Intervals 
Meaningful interpretation of results in clinical chemistry by laboratory and clinical staff is 
dependent on use of appropriate reference intervals (RIs). RIs being guides or limits that are 
essential information to help distinguish healthy from diseased individuals, as well as to separate 
subgroups of patients with different pathological conditions, and assist in determining disease 
stages. This is important for accurately differentiating normal and pathological states. 
Laboratories may adopt RIs provided by the test manufacturer, peers or literature which may not 
be representative of the laboratory’s own population or may be based on old literature and 
different methodology. Age, gender, ethnicity, circadian, gestation and statistical analysis 
procedure are some of the main factors that can influence RIs. The majority of RIs cover 95% of 
the reference population of subjects, and classify the other 5% as abnormal. Additionally sample 
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type and quality will influence RIs, and the RIs need to be determined from samples that will be 
collected in the same way as routinely analysed samples.  
 
Sonntag surveyed 101 German laboratories for potassium reference interval concentrations and 
found they varied from 3.3-3.9 mmol/L at the low end to 4.5-5.6 mmol/L at the upper end, 
making it difficult to interpret the so-called normal value should a patient have the test 
performed at different pathology laboratories [38], as they move geographically or to different 
doctors. Another major influence on RI is standardization and this is predominantly a problem in 
immunoassays e.g. troponin I [39]. Hence the establishment of a common RI presents difficulties 
because of lack of assay standardization, local population differences, and disagreement on 
format of results, sample type etc.  
 
Performing thorough RI estimation is a resource intensive process and requires professional 
judgment, sufficient data and even then is beyond the resources of all but the largest laboratory 
services. There are also some RIs such as in paediatrics and pregnancy stages that are not 
possible to determine [40-42]. 
 
What also must be taken into consideration when reference intervals are determined is the 
influence of the sample type, and this can significantly affect upper and lower reference limits. 
For example potassium in serum is ~0.3 mmol/L higher than in lithium heparin plasma [43].  
 
 
1.1.7 Quality aspect of laboratories  
Unlike in other branches of medicine, laboratory medicine activities and processes particularly 
for biochemistry are in general well defined and controllable. The laboratories therefore can 
implement internal and external quality control schemes, education, certification, licensing, 
accreditation and recognition in the pursuit of accuracy, reliability and excellence [23]. This in 
turn is aimed at delivering accurate results on an ongoing basis.  
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Clinical chemistry has actively introduced systems to reduce analytical error beginning in the 
late 1940s with the College of American Pathologists (CAP) [44]. In Australia the equivalent 
body is the National Association of Testing Authorities (NATA), which was established in 1947. 
In Australia by 1984 legislation was implemented to require all laboratories to be accredited 
[45]. Equivalent bodies have sprouted across the world including the International Laboratory 
Accreditation Cooperation (ILAC) [46] to ensure high quality services are provided by 
laboratories.  
 
Assay interferences from blood collection tubes can present challenges to clinical laboratories 
which are not easily detected by the daily quality control or even by proficiency testing programs 
[47]. Detection of such errors due to poor sample quality or from tube additives may be detected if 
the test results are significantly altered, exceeding laboratory information check limits:  delta 
check (previous result check) and/or critical limits [20].  
 
1.1.8 Turn-around time (TAT) 
TAT is generally considered as the time it takes to complete a testing episode, from collection of 
the sample to reporting of results. TAT for a long time has been recognised as an indicator of the 
quality of laboratory services. This has multi-factorial impact: for critically ill patients, for the 
length of stay of patients, and for resource utilization. To clinicians, service quality encompasses 
the total test error (imprecision and inaccuracy), availability, cost, relevance and timeliness [48]. 
However, timeliness is one of the most important factors to the clinicians and this preference 
drives much of the proliferation of POCT [49]. Although clinicians consider result 
quality/reliability as the most important category of laboratory services, test TATS are persistent 
categories of dissatisfactions [50]. Whereas nurses were most satisfied with the accuracy of test 
results, one of the least satisfied services was with TAT along with laboratory management 
accessibility and responsiveness [51].  According to Valenstein, 80% of complaints laboratories 
receive are about TAT, even though there are differences amongst clinicians on what constitutes 
acceptable TAT [52]. It is estimated that 87% of dissatisfaction complaints originate from EDs 
[53]. For general chemistry (electrolytes and liver function tests) 60 minutes from collection to 
validation is the generally agreed acceptable TAT by laboratories for EDs and Intensive Care 
Units (ICUs) [54]. This is also the recommended TAT for troponins [55, 56]. For critical results, 
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it is expected they be communicated within 6 minutes post-analysis for inpatients and 14 minutes 
for outpatients [57]. When these expectations are considered, it is obvious that the time taken, for 
serum preparation is (30-60 minutes) simply unable to meet service demands for critically ill 
patients in a hospital environment. Improvements in TAT have been achieved by use of lithium 
heparin plasma, transporting specimens via pneumatic tube transport systems, centrifuging 
specimens at higher speeds and for shorter times, and laboratory automation. With serum, 
improvements have recently been achieved by use of new procoagulant compounds [58]. 
 
1.1.9 Automation 
Biochemical testing has undergone significant change as a result of technological advancements. 
The main drivers to introduce new technologies are pressure to reduce costs; to minimise errors 
and exposure to infectious samples; to overcome skilled staff shortages; to increase range of tests 
offered while maintaining quality and improving turn-around-time; and to achieve a higher 
throughput. Automation has changed the way work is done including job structures and the way 
people think about their work [59]. Automation systems are designed to eliminate dangerous and 
repetitious manual tasks. Fully automated systems (containing conveyer type lines incorporating 
centrifuges, de-cappers, aliquoters, re-cappers to refrigerated storage units) are becoming 
common equipment in large laboratories. Components of automation systems are capable of 
checking sample volume and for presence of clots and detection of inappropriate samples prior to 
sampling and analysis.  
 
One publication estimates that post-automation implementation; the reduction in labour costs 
was up to 50% in the preanalytical, labour-intensive phase [60]. Automation also allows staff to 
focus on abnormal samples and results which may be of a critical nature. With software 
advancements the quality of test results has been improved by algorithms for ordering and 
interpretation of tests. The introduction of autovalidation, computerized checks and addition of 
interpretative value-added data/comments in some laboratories has been reported to allow for 80-
85% of results to be reported without human intervention [61].  Laboratories relied heavily on 
knowledgeable personnel to help ensure the quality of reported results. With automation such 
knowledge in staff may be lost or not developed at all. New automation/information technology 
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has led to increased need for skills in data management and novel ways to develop 
improvements. 
 
Another major advantage of technology improvement is automated communication of test results 
which improves timeliness of notification, limits potential errors, and improves the likelihood of 
results reaching the clinical staff to provide important and timely decision support [62]. New 
automation/information technology has led to laboratory re-engineering which has increased the 
need for skills in systems control and support, for training in information technology and 
management techniques [63]. 
 
With automation linked to lower TATs, the pressure on hospital laboratories is to further reduce 
TAT along with improved quality of data (accuracy of results and added information), and to 
standardize on single sample type for most tests.   
 
1.2  Patients with Clinical Conditions and Induced Errors Leading to 
Analytical Interferences  
Interference occurs when a substance or process falsely alters an assay result. Interferences are 
the most common causes of errors in the analytical phase. As Marks points out, interfering 
substances continue to haunt the clinical laboratory as they are present in patient samples but not 
in the calibration standards or quality control material [64]. Interference effects may be variable 
depending on the nature of the analytes, the analytical technique and the instrument. Thus 
detailed knowledge of the analytical technique/instrument is essential for interference studies or 
detecting potential interferences, along with sound clinical knowledge. Analytical interferences 
can be difficult to identify and can produce serious errors. The most studied interferences are the 
serum indices: haemolysis, lipaemia and icteria.  
 
Although guidelines exist for interference testing [65], there is no mandatory requirement for 
instrument/method suppliers to perform or provide detailed and accurate interference studies or 
the results of such studies. Information that is provided by manufacturers on interferences varies 
from non-existent, inadequate, vague to complete with exact cut off limits, type of interference 
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etc.  Interference studies require laboratories to adopt an approach of shared decision-making. 
They should provide and receive support from diagnostic companies with interference testing 
findings and studies to minimise negative impact on patient outcomes. Laboratories have the 
range of samples for testing while diagnostic companies have the equipment and ability to 
redesign methods and lead to improvements. 
 
Analytical interference by haemolysis, bilirubin and lipaemia with laboratory assays is the most 
common concern in laboratory medicine [66], and a review of literature showed that they are the 
most studied interferences. 
 
 
A more extensive review on types of interference and interference testing is provided by these 
two publications:  
Dimeski G. Interference Testing. Clin Biochem Reviews 2008;29:S43. 
Dimeski G, Badrick T, St John A. Ion Selective Electrodes (ISEs) and Interferences - A Review. 
Clin Chim Acta;411:309-17. 
 
1.2.1 Haemolysis 
Haemolysis reflects red cell destruction, resulting in haemoglobin release in plasma or serum. 
Presence of haemolysis also usually means lysis of other blood cells (leucocytes and platelets) 
and resultant release of cellular content as well as remnants of cell membranes into the 
serum/plasma. Haemolysis is the most studied and most frequently encountered cause of 
interference in a chemical pathology laboratory. It can occur both in vitro and in vivo. In vitro 
haemolysis is reported to present in up to 3.3% of all samples [67]. The most common causes of 
haemolysis are mechanical factors: excessive suction when drawing blood via syringe [68], 
forcibly transferring blood from syringe into evacuated tube [69], drawing blood through a small 
needle or catheter [70, 71], exposing blood to freezing temperatures etc. Most haemolysed 
samples are collected by clinical staff (medical and nursing) rather than laboratory staff, with 
emergency departments being the single largest contributors [72]. With decentralization of 
phlebotomy services, the number of haemolysed samples will grow in the foreseeable future as 
specimen collection expertise is diluted.  
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A haemolysed sample is defined as having the presence of a free haemoglobin concentration of 
>0.3 g/L (300 mg/L). The upper reference limit for free haemoglobin is 20 mg/L in plasma and 
50 mg/L for serum, respectively [68]. Estimation of the effects of haemolysis in a study can be 
influenced by the haemolysate preparation technique. This is best illustrated by studying the 
effect of haemolysis on ammonium determination [73]. For most accurate estimates of the effects 
of haemolysis, studies should mimic the actual clinical setting processes.  
Currently there is no standardization between different analyser manufacturers’ methods for 
haemolysis estimation (sample diluents or wavelengths) or on the reporting of results. Some 
report quantitative, others semi-quantitative estimates of the haemoglobin in the sample. There is 
limited information on how haemolytic index (HI) is calculated, and the veil of proprietary 
information is often the response to enquiries, enhancing the “black box” image manufacturers 
have created for themselves. For example the Beckman analysers use a buffer as diluent, and 
monitor the absorbances at 340, 410, 470, 600 and 670 nm and solve a set of equations to 
compute the haemolytic, lipaemic and icteric indices. The reported results are semi-quantitative 
on a scale of 0 to10, where 10 is equivalent to 451-500 mg/dL of haemoglobin in the serum or 
plasma. The Roche Modular systems use saline as diluent and calculate the differences between 
absorbances at 570 and 600 nm, producing a quantitative value with no limits. The methods are 
only available on general chemistry analysers, and there are no immunoassay systems which 
measure haemoglobin. The HI is used by laboratories in decision making on whether a result 
may be reported or if annotation will accompany the result and the actual HI value is usually not 
reported to clinical units.  
The issue with haemolysis is that it affects a series of analytes leading to positive or negative 
bias depending on the analyser/method. The mechanisms of interference can be: a) additive 
because of greater concentrations of analytes in cells than in plasma (e.g. potassium (K+) ~23x, 
phosphate ~x7, folate ~30x greater concentration in red cells; lactate dehydrogenase (LD) 
present in all cells); b) spectral (haemoglobin absorbs at 415, 540 and 570 nm) leading to 
interference with alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), total and 
direct bilirubin; c) chemical (cross-reactivity) (e.g. errors in creatinine kinase (CK) due to red 
cell adenylate kinase); d) dilutional (gross haemolysis >6.0 g/L releasing cell fluid and content 
leading to false lower results e.g. sodium (Na+), chloride (Cl-)etc). The interference with 
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immunoassays is less frequent than with photometric assays. The release of proteolytic enzymes 
from cells, e.g. cathepsin E from red cells, may destroy small peptides such as insulin, glucagon, 
calcitonin, parathyroid hormone, adrenocorticotropic hormone (ACTH) and gastrin [74]. The 
most frequently affected immunoassay is troponin T (TnT). Sodi et al reported 6.4% of samples 
requested for TnT had gross haemolysis and were unsuitable for analysis [75]. In their study, 
they found the addition of pepstatin A inhibitor at 37ºC in haemolysed samples for over 48 hours 
effectively reduced TnT degradation but did not completely eliminate the effect which suggests 
there are other factors such as haemoglobin binding or masking of the epitopes preventing 
antibodies from recognizing TnT [75]. Snyder et al found on the Vitros ECi analysers that 
haemolysis increased results of some sandwich assays (prostate specific antigen and TnI), and 
decreased some competitive assays (vitamin B12, testosterone and cortisol analytes) [74]. The 
mechanism of interference is unknown but may be due to released compounds from the lysed 
cells which may cross-react with antibodies, bind to analyte and inhibit the antibody binding site, 
or suppress the reactions used in the detection method employed [74]. 
The World Health Organisation (WHO) recommends that a comment be reported with 
haemolysed samples “impaired by haemolysis” instead of analyte concentrations [36].  Re-
collection of samples or delay in reporting results is not always a viable proposition. In some 
cases patients will be in a critical condition, hence a reporting mechanism was devised for 
potassium, the most critically affected analyte [72]. In fact since that publication, interest in the 
effects of haemolysis has gained momentum and a number of other publications have appeared 
advocating and supporting the WHO approach [76-78]. 
 
1.2.2 Lipaemia 
Lipaemia describes the presence of high concentration of lipids in plasma or serum (it may not 
be easily detected in whole blood) resulting in the “milky”, turbid appearance. Lipaemia 
interferences become significant at >10 mmol/L depending on the method. For example 
Arambarri et al found in samples with elevated triglycerides concentrations >9.79 mmol/L, the 
ACL-3000 analyser (Instrumentation Laboratory, UK) failed to give any results [79]. From 
personal experience samples with triglycerides 15.0 mmol/L appear turbid and will affect some 
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tests on most if not all general chemistry platforms. Based on evidence from Princess Alexandra 
Hospital indicates the number of samples with gross lipaemia is reducing. This is due to earlier 
intervention by widespread use of statins to lower cholesterol, and other medication e.g. omega-3 
fatty acids along with lifestyle changes (weight loss, diet, exercise, reduction in alcohol intake) 
to reduce triglycerides [80]. 
 
A review of the literature shows that it is sparse on lipaemic studies yet lipaemia is consistently 
stated in publications as a major cause of interference. To my knowledge published data on the 
frequency of lipid interference is unavailable. Review of Chemical Pathology, Princess 
Alexandra Hospital lipid results from 2008 indicated that out of the 21300 samples with lipid 
analysis, only 180 had triglycerides >10.0 mmol/L and only 64 had triglycerides >25 mmol/L. 
The number of samples with gross lipaemia is reducing with widespread use of statins. The 
difficulty with lipaemic interference studies is obtaining sufficient native sample. Also lipaemic 
samples do not store well. Hence, lipid emulsions e.g. Intralipid, have been used to perform 
interference studies, particularly in the setting of lipaemic indices on instruments. Intralipid 
consists predominantly of small, relatively dense, phospholipid-rich liposomes and triglyceride-
rich artificial chylomicrons [81]. These lipid emulsions do not mimic native sample composition. 
General chemistry analysers are now all capable of providing a lipaemic index. Mostly it is a 
semi-quantitative estimate of the lipid level based on studies using lipid emulsions. Lipaemic 
index readings do not always correlate well and can be misleading in interpretation as to when a 
sample is too lipaemic to report any results. It is recommended that lipid interference studies be 
performed using native lipid samples to cover the wide ranging effects from the different lipids 
that are not present in commercially available lipid emulsions [82]. Grossly lipaemic samples are 
even more complicated. They often present with haemolysis (Figure 1) with increasing lipid 
concentration (thus the “strawberry milk appearance”), and this has been suggested to be linked 
to increased fragility of membrane structure [83].  
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Figure 1. Two examples (1 and 2) of samples with gross lipaemia: Example 3: Cup A - original 
sample; Cup B - high speed double centrifuged; Cup C- ultracentrifuged and lipid normalised. 
 
With grossly lipaemic samples lipid normalization techniques are required. The most effective 
technique is ultracentrifugation, which requires a specialized and expensive air pressure driven 
centrifuge. Lipid clearing agents e.g. Lipoclear which has been reported not to be suitable for 
some assays e.g. GGT, direct bilirubin, CKMB, cholesterol, HDL cholesterol and C-reactive 
protein (CRP) [76]. Lipids may be elevated because of pathological causes or medically induced 
as a result of patient treatment e.g. feeding or treating drug overdoses.  Lipid emulsions in recent 
times have been utilized in treating local anaesthetic intoxications [84].  
 
In general gross lipaemia produces negative bias with all photometric assays due to light 
scattering or absorption of the light rays by the lipids, including nephelometric, turbidimetric, 
and coagulation methods. Lipaemia affects indirect ion selective electrode methods due to 
volume displacement by lipid causing a decreased aqueous phase [85]. Additionally, lipids may 
prevent lipophilic analytes or reagents from binding, including antigen–antibody binding. They 
may also cause interference in assays for fat-soluble compounds such as steroids [86]. A good 
example of problems encountered with lipaemic samples due to therapeutic use of lipid 
emulsions is presented in the publication Dimeski G. A commentary on the effect of lipid 
emulsions on pathology tests. Br J Anaesth 2009;64:1033-1036. Additionally a procedure for 
obtaining a suitable sample for analysis by high speed centrifugation is outlined in Dimeski G, 
1 2 3 
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Jones B.  Lipaemic samples: Effective process for lipid reduction using high speed centrifugation 
compared with ultracentrifugation. Biochemia Medica 2011;21:87-92. 
 
1.2.3 Icteria 
Icteria or elevated bilirubin (yellow breakdown product of haem catabolism) is also capable of 
causing interference. Creatinine measured by some Jaffe methods is the most critical and 
significantly affected analyte, with assay values being decreased by increased bilirubin 
concentration. Although the exact mechanism of interference is unclear, some methods like the 
Roche rate-blanked method have been shown to be almost free of interference [87] and others 
continue to be affected (Dimeski G, McWhinney B, Jones B, Mason, R, Carter A. Extent of 
bilirubin interference in Beckman-Coulter creatinine methods. Ann Clin Biochem 2008;45:91-
92.)  
1.2.4 Immunoassays (IAs) 
Immunoassays (sandwich and competitive) are used to measure proteins, peptides, and smaller 
molecules including drugs without prior purification. This predisposes them to unique 
interference problems. Immunoassays have a significant role in disease diagnosis and for 
monitoring response to treatment, and without doubt they have transformed the clinical 
chemistry laboratory. A single antibody binding to an analyte of interest, or a one-site binding 
assay is rare; to increase specificity, assays involving three antibodies or three sites are becoming 
more common. Specificity is dependent not only on the binding properties of the antibodies, but 
on the composition of the sample antigen and its matrix, reagent composition, immunoassay 
format and analytical system. The reasons for the error rates being higher with immunoassays are 
multi-factorial. Firstly, due to the lack of standardization, and despite the analytical sensitivity, 
results between immunoassay methods may not be transferable. The absence of reference 
methods makes it difficult to ascertain an accurate error rate with immunoassays. Ismail et al 
reported that a patient with a wrong immunoassay result (thyroid stimulating hormone) went on 
to have 15 consultations, 77 laboratory tests, and one unnecessary pituitary computed 
tomography scan [88]. Despite these shortfalls, the versatility of IAs together with the ease of 
automation has thrust them into a leading role in almost all areas of the laboratory. The key 
advantages are antibody specificity and sensitivity. Interferences in immunoassays are 
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predominately due to endogenous factors. These can be heterophilic antibodies, poorly defined 
antibodies with a multiplicity of antigens. These include human anti-animal antibodies (HAAA), 
more specifically human anti-mouse antibodies (HAMA), and rheumatoid factor. In a very recent 
study Koshida et al found 34% of the patient samples studied were positive for either IgG or IgM 
HAMA [89]. It should be made clear that not all of these samples will give false results as 
analytical reagents contain blocking compounds e.g. immunoglobulins aimed to prevent HAMA 
from causing analytical accuracy problems. Thus only samples with very high concentrations of 
HAMA tend to cause problems. Another unique problem with immunoassays is the high-dose 
hook-effect which leads to false low or negative results in sandwich assays without a wash step 
between antibody additions. When the analyte concentration is at a very high concentration, the 
antibodies become saturated and the signal that would be generated by proper reaction between 
the two antibodies and the analyte starts to decrease. With further increase in the analyte 
concentration the signal will disappear, creating a fish hook effect instead of proportionate 
response to the analyte concentration increase. Typically analytes that can vary greatly in 
concentration may be affected e.g. human chorionic gonadotropin (hCG), myoglobin, prostate 
specific antigen (PSA), alpha-fetal protein (AFP) etc.  A good example of high-dose-hook-effect 
is presented in this poster publication Dimeski G, Lowe B, Ward G. A rare case of false 
negative urine hCG result with point-of-care kits (2010 AACB/AIMS Conference in Perth).  
 
Interferences in immunoassays sometimes can be difficult to identify even when repeated in 
another analytical platform. A solution that is often discussed is chemical analysis for specific 
proteins (chromatography, mass spectrometry) which is becoming more viable and routinely 
established. However, sensitivity seems an insurmountable problem for these methods in 
assaying many compounds.  
 
 
1.2.5 Presence of warfarin, heparin and other anticoagulants   
Blood collected in serum tubes for serum preparation can be affected by the presence of 
anticoagulants used as therapeutic agents and therefore present in patient blood samples. Blood 
samples may also contain anticoagulants from anticoagulant-containing solutions used to flush 
and prevent clotting of cannulas or taps, or from cross contamination from collection tubes. 
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These samples may clot in the recommended times, but often exhibit latent clotting or no clotting 
at all.  
 
Coagulation or the process of blood clotting to form aggregations of cross-linked fibrin or clots 
is a cascade of reactions in response to blood vessel injury as indicated in Figure 2.  Internal clot 
formation predisposes patients to increased rates of morbidity and mortality. These risks are 
minimised by use of anticoagulants (antithrombotic agents) as preventative and therapeutic 
compounds for thromboembolic disorders. The most commonly used therapeutic anticoagulants 
are warfarin and heparin. Newer and emerging anticoagulants include rivaroxaban, apixaban, 
ximelagatran/melagatrin (discontinued due to hepatic damage) [90] LY517717, YM150, DU-
176b, dabigatran, hirudin and many others [91]. Warfarin and heparin continue to be the 
anticoagulants of choice despite the fact they can cause bleeding if the concentration is too high. 
A major reason is the ease with which their effects can be reversed or neutralized if taken in 
excess (vitamin K for warfarin and protamine for heparin). Currently, parenteral agents 
(heparins) are used to prevent and treat acute thromboembolic disorders, often in hospital, while 
oral agents (warfarin) are used for long term anticoagulation [92]. A novel and as yet rarely used 
therapeutic anticoagulant is citrate to reduce bleeding in critically ill patients requiring dialysis 
[93-94]. 
   
The name warfarin stems from research funded and eventually patented by the Wincoscin 
Alumni Research Foundation. Warfarin is a coumarin which has become the most widely used 
anticoagulant in the world. It was first isolated from damp sweet clover hay infected by moulds 
such as Penicillium nigricans and Peniccilium jensi. In 1945 it found its first use as rodenticide 
[95]. Warfarin is orally administered, water soluble and has a high bioavailability [96]. It inhibits 
the synthesis of biologically active forms of the vitamin K-dependent clotting factors: II, VII, IX 
and X, as well as the regulatory factors protein C, protein S and protein Z [96]. Coumarins are 
vitamin K antagonists that produce their anticoagulant effect by inhibiting the cyclic 
interconversion of vitamin K and its 2,3 epoxide (vitamin K epoxide). Vitamin K is a cofactor 
for the post translational carboxylation of glutamate residues to -carboxyglutamates in the N-
terminal regions of vitamin K-dependent proteins, Figure 2. The -carboxyglutamate residues 
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form calcium binding sites which are required for biological activity of factors II, VII, IX, and X. 
Coumarins produce their anticoagulant effect by inhibiting the vitamin K conversion cycle, 
thereby causing hepatic production of partially carboxylated and decarboxylated proteins with 
reduced or absent procoagulant activity. In addition to their anticoagulant effect, the vitamin K 
antagonists inhibit carboxylation of the regulatory anticoagulant proteins C and S and therefore 
have the potential to exert a procoagulant effect [96]. One of the side effects of warfarin 
treatment is necrotic skin lesions which have been treated successfully with protein C 
concentrate [97].  
 
 
Warfarin is prescribed annually to 30 million Americans, with atrial fibrillation being the most 
common clinical condition [98]. Its clinical application received great impetus after its use 
following the myocardial infarction of President Dwight Eisenhower in 1955 [99].  In the UK it 
is estimated that at least 1% of the population and 8% of the over-80s are taking it regularly 
[100]. In Australia 250 000 patients are prescribed warfarin therapy annually [101], and this 
number is growing by approximately 9% per annum [102]. In fact, based on an Australian 
Statistics of Medicines 2007 report, out of the total of ~251 million prescriptions, ~2.9 million 
(1.16%) were for warfarin [103]. On the negative side, the limitations with warfarin are drug and 
food interactions that lead to a variable anticoagulant response which in turn leads to the 
requirement for frequent anticoagulant monitoring [96].  
 
Heparin is a naturally occurring anticoagulant present in mammalian species and first isolated in 
1916 from liver [104], the name being linked to its hepatic origin. However it has been isolated 
from lung and intestinal mucosa as well. Heparin is a highly acidic mucopolysaccharide at 
physiological pH. Hydroxyl groups on each of the monosaccharide residues may be sulfated 
giving rise to a polymer that is highly negatively charged. Its molecular weight ranges from 
5000-30000 with an average of 15000 (50 monosaccharide units). Heparin has been used 
therapeutically since the late 1930s [105]. Its major anticoagulant effect is due to a unique 
pentasaccharide sequence which has a high affinity for antithrombin III (ATIII) [106]. It then 
markedly increases the ability of ATIII to inactivate the coagulation enzymes thrombin (FIIa), 
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FXa and FIXa. The ATIII-heparin complex is a potent inhibitor of thrombin, which in turn 
prevents the formation of fibrin from fibrinogen (Figure 2). More recently Wajima et al proposed 
that the coagulation cascade is more accurately describe as a coagulation network because 
coagulation comprises a complex of series of interactions rather than the unidirectional chain of 
events implied by the classical cascade outline (Figure 3) [107].  
 
Heparin when present at high doses also catalysis the inactivation of thrombin by a second 
plasma cofactor, heparin co-factor II [106]. The inactivation of FXa is achieved by binding it to 
ATIII-heparin complex. Besides the unfractionated form, heparin is now also available as low 
molecular weight formulation (LMWH) (exoparin, dalteparin, tinzaparin, reviparin, etc). Both 
forms of heparin inhibit FXa and thrombin [106]. The LMWHs have largely replaced heparin 
due to greater convenience, and cost effectiveness with very little loss in efficacy [108, 109]. 
Heparin is not absorbed from the gastrointestinal tract and thus requires subcutaneous or 
intravenous injection; hence it is predominantly administered to inpatients. Its principal 
advantage is that its effects are immediate in contrast to warfarin which takes approximately 4 
days for full activity. Heparin has complicated pharmacokinetics and non linear dose 
anticoagulant response due to its ability to bind to plasma proteins (glycoprotein, platelet factor 
4, fibronectin, von Willibrand factor etc) and to cells (macrophages and endothelial) [106].  It 
has the potential to cause heparin-induced thrombocytopenia [111], which occurs in 0.5-5% of 
patients receiving heparin [108]. Additionally there is some evidence of long-term heparin 
treatment at high doses being associated with osteoporosis in some patients [112], and it can 
induce skin lesions [109]. Clinical conditions where it is most used as treatment are: post-acute 
coronary syndromes, unstable angina, cardiac surgery, pulmonary embolism, deep vein 
thrombosis, dialysis, specialized procedures such as adreno-venous sampling, as part of 
chemotherapy in cancer patients, patients undergoing surgery for hip fractures, hip/knee 
replacements, organ donors in transplants etc.  Amin and Ryan report that heparin treatment 
(unfractionated heparin) in inpatients was given to 12% of the total abdominal surgery 
population, and to 91% of the orthopaedic surgery patients [113].   
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 A proportion of patients stayed on low molecular weight heparin (32%), warfarin (31%), or 
other agents (28%). Some stayed on anticoagulants for up to 30 days post discharge with 31% 
receiving warfarin, 19% receiving LMWH (enoxaparin), and 5% receiving other anticoagulants 
[114]. For the other anticoagulants and active points with the coagulation cascade refer to Figure 
3. Recombinant hirudin which inhibits thrombin directly can be used as an alternative 
anticoagulant, particularly in patients with heparin-induced thrombocytopenia [115]. Other 
emerging anticoagulants are listed in Figure 3 [116]. 
 
In Australia it has been estimated that the overall prevalence of venous thromboembolism in all 
hospitalised patients is 2–3 per 1000 admissions [117]. Based on an Australian Statistics of 
Medicines 2007 report, out of total prescriptions of ~251 million, ~330 000 (0.13%) were for the 
heparin group [104]. Heparinisation of patients with high doses and then reversing them by 
protamine treatment permits some of the most complex, life saving cardiac and other surgical 
procedures to be completed with little risk from potential thromboembolitic complications.  
Protamine is a small strongly basic, positively charged protein which forms a complex with 
negatively charged heparin molecules, thus neutralizing the heparin effects.                       
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Figure 2. The Coagulation cascade [110].  
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Figure 3. The coagulation network as proposed by Wajima et al [107]. 
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Figure 4. A list of anticoagulants and action site in the coagulation pathway [116].  
 
 
1.3 Sample preparation for analysis 
 
1.3.1 Blood collection tubes  
Irrespective of the controls a laboratory implements, inaccurate results from plasma or serum 
samples of poor quality can be extremely difficult to identify. Sample quality is at the heart of 
the quality of service a biochemistry laboratory provides, both in terms of timeliness and 
accuracy. Blood collection tubes are not inert containers. Undesirable effects on test accuracy 
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can come from tube wall material, substances applied to rubber stoppers, surfactants on the tube 
wall, anticoagulants, separator gels, and clot activators.  
 
Rubber stoppers are internally coated with lubricant (silicone) to aid the removal of the stoppers 
from the evacuated tubes [118]. From personal observation exposing tubes to higher temperature can 
cause the silicone to form a droplet on top of the meniscus of the sample which can then be a potential 
source of interference.   Blood containers are now almost exclusively manufactured from plastic 
primarily for safety reasons: handling, transport, and storage to minimise exposure to 
biohazardous material during cleanup of breakages, etc. Surfactants are used to prevent adhesion 
of some components of the specimen to the tube wall and stopper, particularly proteins and cells 
which may than lyse; they are haemorepellent agents [46]. Some surfactants have been 
implicated in assay interferences [119, 120]. Other causes of interferences from tube contents 
(gel barriers, surfactants, or other additives) have been documented with CRP [121], free fatty 
acids [122], magnesium [123] and vitamin D [124].  
 
Gel barriers were introduced in the mid 1970s. They consist of an organic phase (resin), an 
inorganic powder and a network stabiliser [118].  The gel facilitates separation of serum from 
cellular constituents of blood during centrifugation thus limiting cellular activity affecting the 
serum concentrations of analytes of interest.  This improves analyte stability, primary tube 
sampling and storage, and reduces need for aliquot tubes. The specific gravity of the barrier gel 
is between that of cells and that of serum or plasma. The position of the gel in the tube after 
centrifugation is influenced by a number of variables (some of which are controlled by the tube 
manufacturer) specific gravity, yield stress, viscosity, density, tube material, centrifugation 
speed, temperature, acceleration and deceleration conditions, storage and patient specific factors 
such as heparin therapy, low haematocrit, increased plasma proteins [125]. The most commonly 
encountered problem is improper formation of the barrier due to alteration of its properties when 
tubes are stored at high temperatures [126].  Other gel formation problems that have been 
documented are in multiple myeloma patients with very high protein concentrations, >130 g/L 
[127], and bloods containing iodinated blood contrast media [128]. Faulty barrier formation can 
lead to additional costs for laboratories (probe replacements, downtime, and delay in analysis of 
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other samples) and patient implications (reporting of falsely low results because of low sample 
volume aspiration). 
 
With the introduction of plastic tubes, the addition of clot activators was necessary to ensure the 
blood clotting process is completed rapidly, minimizing latent clot formation in the separated 
serum. The commonly used clot activators are diatomaceous earth and particles of inorganic 
silicates [118, 128]. Silica particles are added with polyvinylpyrrolidone to aid the adherence of 
the silica particles to the tube walls and to facilitate rapid dissolution of silica in the blood 
specimen [46]. Even with the addition of these procoagulants recommended waiting times before 
centrifugation are 30 minutes for blood from healthy participants and 60 minutes or more for 
blood from patients on anticoagulants [118, 128]. Other procoagulants which have been tried are 
ellagic acid, thrombin and ground silica [129], thrombin [130], and thrombin plus snake venom 
batroxobin [131] for rapid serum generation.  
 
The anticoagulant of choice in producing plasma for just about all biochemical assays is heparin. 
Heparin salts are used as anticoagulants in blood collection devices to inhibit clotting of whole 
blood so as to allow production of plasma. The commonly used salts are lithium heparin and 
sodium heparin. Recommended heparin concentrations for venous blood collection tubes are 10-
30 USP units/mL blood or 12-30 IU/mL [38, 132]. A major advantage of plasma over serum is 
that blood samples collected in lithium-heparin tubes can be centrifuged immediately post-
collection.  Other anticoagulants used to produce plasma for a small number of analytes include 
ethylenediaminetetraacetic acid (EDTA) (used for ammonia, B-type natriuretic peptide, parathyroid 
hormone [133]), and sodium fluoride/potassium oxalate (used for glucose) [134].  
 
1.3.2  Syringes for collection of blood 
Syringes containing anticoagulants are common tools in patient testing to measure some of the 
most critical analytes and are almost exclusively used in POCT e.g. in blood gas analysers. The 
types of syringes used can be divided into two categories: reduced level of heparin or balanced 
heparin. The reduced level of heparin does not always eliminate clotting which in turn can lead 
to sampling problems, blockage of analysers, and clots coating electrode membranes. Heparin 
binds cations, particularly divalent cations (calcium - Ca2+ and magnesium - Mg2+), resulting in 
 60 
false low results. To minimise or overcome electrolyte-binding errors, balanced heparin is used 
in blood gas or “whole blood” syringes [135, 136]. Balancing is achieved by adding Ca2+ to the 
heparin formulation. This in turn renders the plasma prepared in syringes unsuitable for total 
calcium estimation. The recommended lithium heparin levels are < 15 IU/mL blood for heparin 
reduced syringes, or for calcium-titrated or balanced heparin 50 IU/mL blood or less [135, 136].   
 
1.3.3 Serum versus lithium heparin plasma 
Pathology laboratories, biochemistry laboratories in particular, currently use either serum or 
lithium heparin plasma for quantitative or qualitative determination of almost all analytes. 
Historically serum has been the specimen of choice, and it is predominantly used in private 
pathology laboratories where samples are collected in general practice or at dispersed collection 
centres, and there is time for them to clot completely before they reach the laboratory for 
analysis.  Plasma samples are used almost exclusively in major hospitals which deal with 
critically ill patients, for whom test results are often required urgently for immediate medical 
intervention.  
 
According to WHO, serum is the “undiluted, extracellular portion of blood after adequate 
coagulation is complete” whereas plasma is the “virtually cell-free supernatant of blood 
containing anticoagulant obtained after centrifugation” [36]. Both definitions indicate that there 
are likely to be imperfections in the quality of these sample types. Hence, it is understandable 
why there is a lack of consensus regarding the most appropriate specimen type for analysis of 
many biochemical analytes [43]. Many laboratories use serum and lithium heparin plasma 
interchangeably.   
 
It is well documented that there are significant differences in the levels of some analytes between 
serum and plasma, particularly potassium and total protein, and these require different reference 
intervals. For example plasma is the preferred medium for the determination of potassium 
concentration, although it is not ideal for many other biochemical analytes [137]. In contrast 
serum may produce more accurate potassium, LD, glucose and AST results in certain clinical 
conditions such as hyperleukocytosis (Chapter 2; Dimeski G, Bird R. Hyperleukocytosis: 
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pseudohyperkalaemia and other biochemical abnormalities in hyperleukocytosis. Clin Chem Lab 
Med 2009;47:880-1.). 
 
Under optimal clotting conditions serum is considered a cleaner specimen; it is fibrinogen-, 
fibrin and cell-free. It is a preferred matrix for many analytes but particularly for immunoassays, 
and for proteomic analysis [138]. The clotting times recommended by manufacturers are 30 
minutes for healthy patients and 60 minutes or longer for anticoagulated patients. Even under 
these conditions the blood specimens of some patients on high doses of anticoagulants or 
specimens collected from anticoagulated taps or cannulas may fail to clot completely (or at all), 
and the number of such patients in hospital environments is increasing (e.g. cardiac disease, renal 
dialysis, hip and knee replacements etc). The thrombin generated is insufficient to overcome the 
ATIII-heparin complex and catalyse the fibrinogen. Centrifugation of specimens prior to 
completion of coagulation can lead to latent clot formation and consequently increased frequency 
of intermittent failures, analytical errors and in the TATs of results. Additionally latent clot 
formation (Figure 4) can lead to risk of fibrin clot interference on automated analyzers, 
especially those with a common sample probe and no clot detection capacity [139]. An example 
of clot detection is use of pressure transducer to measure precise millivolt readings to detect 
pressure changes every 5 milliseconds during both the aspiration and dispensing of each sample. 
On board analysis detects bubbles and other abnormalities such as clots and abnormal viscosity 
[140]. Furthermore the presence of clots or fibrin strands in the specimen can lead to the 
aspiration of incorrect analytical sample volume, gradual deposition and build up on sample 
probes, in reaction pathways or chambers, lines as well as spectral and analyte binding 
interferences. At times problems caused by undetected clots have been falsely attributed to gel 
separators. Hence hospital based laboratories are increasingly using lithium heparin plasma as 
the preferred specimen type.  
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Figure 5. An example of a latent clot in a serum sample aliquoted from a primary tube.  
 
There are four major advantages of the use of lithium heparin plasma: a) it enables laboratories 
to achieve faster TATs; b) tubes are estimated to yield an extra 15-20% of specimen volume after 
centrifugation when compared with serum tubes of the same draw volume [36, 141], which may 
be advantageous in neonates and difficult-to-bleed patients; c) plasma is the preferred sample 
type for potassium analysis [137, 142]; and d) plasma has lower haemolysis levels [67]. 
However, lithium heparin plasma has a number of unfavorable characteristics: a) it contains 
some cells; b) the fibrinogen is intact which can cause interferences with assays if it precipitates 
(Figure 7); c) it is unsuitable for lithium analysis; d) heparin may cause problems such as 
precipitation of paraproteins [143]; e) it can lead to inaccurate quantification of albumin in 
bromcresol green methods [144]; f) intermittent interference has been reported with troponin T 
estimation even with the 4th generation reagent formulation [145]; g) the presence of fibrinogen 
in plasma can potentially mask the presence of paraprotein in electrophoretic patterns [146]; h) 
insufficient mixing of tubes immediately after collection can result in fibrin and microclot 
formation due to incomplete anti-coagulation, which in turn can lead to sampling inaccuracies 
such as with LD Figure 5 [37]; and i) differences have also been reported with other assays [142, 
147].  
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Figure 6. Example of lithium heparin plasma with microclots [37]. 
  
If platelets are present in the sample (more so in plasma than in serum), the release of ammonia 
from activation of platelets leads to falsely increased ammonia [148]. Heparin has been linked to 
negative interference with the ammonia estimation by one such method but not another [149]. 
Negative interference was observed when using heparin plasma on the Roche Hitachi 917 
method (general chemistry analysers) but not on the Dade Dimension RxL (general chemistry 
analyser) when compared with EDTA plasma which is considered the more suitable sample.  
 
Lithium heparin gel tubes will always present a small buffy coat layer on top of the gel at the 
bottom of the plasma after centrifugation. This layer, illustrated by the example in Figure 6, 
contains fibrin, cells and cell stroma, not just cells as indicated by WHO [36], and the amount of 
buffy coat varies from tube to tube. The rapid gel movement during centrifugation leaves some 
cells in the plasma. If the plasma specimen is mixed (e.g. during sub-sampling or handling), it 
will become turbid because of disturbance of the buffy coat, re-suspension of cell-containing 
material and fibrin, decreasing the specimen integrity.  
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Figure 7.  1) Example of a lithium heparin tube centrifuged with cells and cell stroma sitting on 
the surface of the gel barrier; 3) most of the clean plasma aliquoted; 2) the primary tube re-mixed 
to demonstrate the effect of cellular content. (A- plasma; B- buffy coat; C- gel barrier; and D-
cells).   
 
With storage, the cells in plasma can continue metabolic activity and alter concentration of a 
number of analytes e.g. bicarbonate, glucose, lactate. Alternatively, the cells can lyse or leak 
contents/analytes e.g. K+, inorganic phosphorus (Pi), LD, AST etc. Pouring off plasma directly 
from the primary tube into an aliquot tube may result in transfer of buffy coat layer components. 
 
It has also been suggested that individual molecules within pharmaceutical heparin preparations 
may have procoagulant activity particularly in the absence of antithrombin III [150]. Stimulation 
of platelet factor 4 (PL4), which is a protein stored in the alpha granules of platelets that is 
released during platelet aggregation, can neutralize heparin [151, 152]. PL4 may be released at 
the site of collection and into the sample or from platelets trapped in microclots which in turn 
1 2 3 
A 
B 
C 
D 
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can aid the formation of fibrin strands in the specimen. If all of these physico-chemical factors 
are present in the right balance, fibrin formation is likely to be enhanced in heparinized 
specimens. Other patient factors such as disease state and medication can both diminish the 
efficacy of heparin activity and lead to increased fibrin formation. Over time heparin activity in 
stored lithium heparin blood specimens is decreased, mainly due to PL4 activity. The formation 
of insoluble fibrin is enhanced when plasma is stored at low temperature [153] (Figure 7). In our 
laboratory up to 5% of the lithium heparin specimens stored for 2 days at 4ºC showed visible 
fibrin formation which would render them unsuitable for re-analysis. Such stored plasma 
specimens require aliquoting and re-centrifugation for re-testing or performing additional tests 
and due to the presence of small number of cells renders the plasma samples unsuitable for 
determination of some analytes such as K+ and glucose.  
 
With fully automated laboratory analytical systems incorporating cold storage units, re-testing 
and add-on or reflective testing become challenges with heparin plasma specimens. In contrast to 
reflex testing which is added automatically on the basis of algorithms, reflective testing is added 
by laboratory professionals and normally at a later time [154], by which time the sample integrity 
may be altered.  The re-use of lithium heparin plasma in automation systems with self-retrieval 
ability from refrigerated storage units is a significant problem as it may lead to inaccuracies in 
any assay and analyzer downtimes from samples with insoluble fibrin formation (Figure 5, 7). 
These systems are unable to sub-sample and re-centrifuge specimens. For accurate test results 
with such samples, manual sample handling is still necessary to ensure the analytical sample is of 
the highest quality. Automation of this nature will lead to less attention being focused on the 
individual sample.  
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Figure 8. Example of insoluble fibrin formation in a lithium heparin tube stored at 4°C for 
several days.  
 
The commonly measured analytes that do differ significantly in concentration between serum 
and plasma are: K+, Pi, LD, and total protein.  Plasma has higher viscosity and total protein by 
~4 g/L due to remaining fibrinogen (~5% of total protein), and other clotting factors. LD is also 
higher but lower K+ and Pi are lower. For example, Miles et al [142] also found significant 
differences in aldolase, angiotensin-converting enzyme and bile acids with the methods in use on 
their Roche Modular system.  As with the ammonia difference, the differences obtained with 
some analytes between the sample types may be method and analyser specific.  
 
Although guidelines (WHO, ISO, CLSI etc) exist for sample collection devices, storage, 
transport and centrifugation, there are no accepted criteria that define sample (serum or plasma) 
Fibrin mesh 
in plasma   
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quality.  This review has clearly indicated the need for such criteria. The requirement for the 
highest sample quality will only increase pressure with the increase in assay sensitivities, use of 
smaller sample volumes, increase in the number and range of analytes on automated analysers, 
greater degree of automation, and pressure on health care providers for patient care decisions to 
be made rapidly based on accurate test results.    
 
1.3.4  Alternative and new procoagulants to improve serum quality  
The focus on reducing laboratory errors is seen as a centerpiece to improved patient management 
since a significant proportion of medical decisions (far more so in a hospital practice the general 
practice) are based on pathology results. Attempts are made to reduce errors through increased 
vigilance, standardized protocols and rigid adherence to protocols, increased training of all staff 
involved in sample collection to result reporting, improvement with new methodologies, new 
analytical technologies, new assays and analytes, and the use of latest information technology 
including intelligence software etc. However it is often assumed that the quality of the serum 
samples obtained with collection tubes is the domain of tube or container manufacturers. 
Improvements are generally initiated by manufacturers in response to erroneous results that are 
observed and demonstrated to be tube component induced. It is then left to the tube manufacturer 
to provide improvements and overcome discrepancies.   
 
Based on Australian Statistics on Medicines (Australian Government, Department of Health and 
Aging) statistics, the increase in warfarin and heparin from 1998 to 2007 was from 0.81 to 1.15% 
and 0.08 to 0.13% respectively of total prescriptions [103]. Added to this is the introduction of 
other anticoagulation procedures e.g. citrate and newer anticoagulants e.g. rivaroxaban. Combine 
all this with contamination of samples “topping up of short samples” and from flushing of taps 
and cannulas with anticoagulants, the number of samples received form biochemical and other 
pathology testing that can be affected by anticoagulants is on the increase, particularly in the 
hospital population. 
 
If serum is the preferred sample type for most analytes, it needs to be produced rapidly from both 
normal and anticoagulated blood to be of greatest use in meeting TAT and quality demands.  It 
has been demonstrated that even the latest commercial tube, BD rapid serum tube (BD RST) 
 68 
from BD Diagnostics is unable to meet the need of hospitals for the entire patient population 
(Chapter 5; Dimeski G, Masci PP, Trabi M, Lavin MF, de Jersey J. Evaluation of the Becton-
Dickinson rapid serum tube: does it provide a suitable alternative to lithium heparin plasma 
tubes? Clin Chem Lab Med 2010;48:651-7.). Alternative clot activator sources are required to 
meet this need.  
 
There are some potent procoagulants that have been studied and could potentially be used to 
overcome the current problem with serum production. Snake venoms are complex mixtures 
containing many different biologically active proteins and peptides that comprise 90-95% of the 
dry weight of the venom [155]. These compounds induce different activities which include: 
neurotoxicity, coagulopathic (procoagulant and anticoagulant), fibrinolytic, haemolytic, and 
platelet activation [155, 156].  Fontana in the late 1700s was the first to observe the coagulant 
effects of snake venoms. When he injected viper venom into jugular veins of rabbits, the blood 
clotted and they died immediately [155]. Two centuries later, Russell’s viper venom activator 
was first studied as an activator of Factor X by MacFarlane and Barnett in 1934 [157]. One such 
clot activator, proteolytic enzyme, batroxobin obtained from the venom of Bothrops atrox has 
been patented for use in collection tubes [131]. There are many other snake venoms that contain 
prothrombin activators for the purpose of rapid clotting of the blood of their prey. Snake venom 
is the richest known source of procoagulant proteins. They have advantages as toxins since they 
are not easily inactivated, induce coagulation in the victim, and cause disseminated intravascular 
coagulopathy characterized by complete defibrinogenation [158].  These prothrombin activators 
are proteolytic enzymes which convert prothrombin present in blood to thrombin which in turn 
causes clotting.  
 
Prothrombin activators from snake venoms are classified into four groups on the basis of their 
cofactor requirement [158, 159]. More detail information on the prothrombin activators is 
provided in Chapter 3. 
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1.4 Research Aims  
 
In accordance with the thesis title “Improving outcomes of biochemical testing in the pathology 
laboratory”, research described in this thesis is as follows:    
 
Chapter 1. General Introduction  
The introduction provides a comprehensive literature review of the pathology testing cycle and 
the three phases with emphasis being on biochemistry and the common types of errors. The main 
focus is highlighting issues and deficiencies associated with sample quality and sample types 
most commonly used for biochemical analysis. It then leads to introducing a possible solution to 
some of these problems by proposing the use of snake venom procoagulants to produced 
improved serum quality in very rapid time. 
 
Chapter 2.  Evaluations of inaccuracies in biochemical analyses related to sample integrity  
The aim of the research performed here was to provide direct examples of how vital sample 
quality is including optimising centrifuge settings in providing accurate results and subsequent 
patient care with some of the most critical analytes measured in a biochemistry laboratory, 
troponin and K+.  
 
Chapter 3. Snake venom prothrombin activators as blood clotting reagents  
The aim was to evaluate the clotting effectiveness of snake venom prothrombin activators, using 
at least one from each of the four groups. The rate of thrombin generation from purified 
prothrombin and in plasma, catalysed by the venom prothrombin activators, was also 
determined.   
 
Chapter 4. Clotting of plasma and blood samples using snake venom prothrombin activators  
The aim was to determine the clotting ability of snake venom prothrombin activators using 
clotting time and Thromboelastography. Plasma and blood samples were: a) from healthy 
participants; b) citrate plasma spiked with heparin and rivaroxaban c) from anticoagulated 
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participants (warfarin, heparin and citrate); d) collected in anticoagulated tubes (citrate, heparin, 
EDTA); e) and low platelet counts.  
 
Chapter 5. Evaluation of the commercial thrombin containing tube (Becton Dickinson Rapid 
Serum Tube) to produce serum for biochemical analysis  
The aim was to evaluate the newly released commercial thrombin containing tube’s ability to 
generate serum from blood samples collected in a tertiary level hospital patient population.   
 
Chapter 6. Analysis of serum prepared using snake venom prothrombin activators – redefined 
criteria for serum quality 
The aim was to determine the ability of the snake venom prothrombin activators to produce 
highest quality serum suitable for biochemical analysis.  
 
Chapter 7. Outcomes and Future Directions 
The aim was to summarise the outcomes and indicate issues that may be suitable for future 
research and development resulting from studies in this thesis.   
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CHAPTER 2 
 
 
 
EVALUATION OF INACCURACIES 
IN BIOCHEMICAL ANALYSES 
RELATED TO SAMPLE 
INTEGRITY  
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Overview 
It is difficult to design biochemical assays that will be immune from all interferences and this 
goes beyond general chemistry and immunoassays, extending to the more sophisticated mass 
spectrometry. Although the analytical method or component of the assay may not be subjected to 
interferences, interferences may be present or introduced/induced in the pre-analytical 
component, or from the sample itself. The sample may contain unique factors which originate 
from exogenous or endogenous components due to patho-physiological causes or induced by 
improper or inappropriate treatment of the blood sample (transport, storage, tube additives etc). 
Highest sample quality is of paramount importance in minimising the contribution of interfering 
substances and to produce results that correctly reflect the patient in vivo levels. The influence of 
collection tube and collection tube components along with processes associated with collection 
tube handling can result in less than optimal sample quality (serum or plasma), factors, 
components or changes in the samples that can then influence test results. The errors can be 
further influenced by method design.  Poor sample quality can lead to intermittent and infrequent 
random errors which may or may not be detected by “intelligence, expert systems or rules” in 
information systems, quality control materials, or by laboratory and clinical staff.  
 
In line with the aims set out in this thesis, the following research on specific interferences has 
been completed and resulted in publications. The first two publications provide greater 
awareness and knowledge to both laboratory and clinical staff in differentiating real from 
artefactual results that are a direct result of poor sample quality. The third publications showed 
how changes in selected analytes can be used to optimized centrifuge settings to obtain highest 
sample quality, specifically lithium heparin plasma for biochemistry and citrate plasma for 
coagulation testing. Identifying causes and mechanisms of impact on results and subsequent 
corrective or preventative mechanisms with a feedback loop, followed by training and/or 
education, is imperative for improved patient outcomes and optional utilization of scarce 
resources. Increasing awareness of problems by laboratory and clinical staff is forcing 
manufacturers to respond and deliver improvements. 
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2.1 Falsely elevated troponin I results due to outliers indicate a lack of analytical 
robustness 
 
Ungerer JPJ, Pretorius CJ, Dimeski G, O’Rourke PK, Tyack SA. Falsely elevated troponin I 
results due to outliers indicate a lack of analytical robustness. Ann Clin Biochem 2010;47:242-
7.  
 
Troponins (TnI and TnT) are considered the most specific biochemical markers for cardio-
muscular damage. Clinicians monitor and respond promptly to any elevation in these proteins 
which are released after tissue damage such as in a myocardial infarct.  An elevated level will 
trigger clinical intervention as well as repeat analysis.  
 
False positive results can lead to inappropriate patient admission and treatment e.g. 
heparinisation. In contrast false negative results can lead to patients being sent home and 
improper or inadequate investigations being carried out, potentially exposing the patient to 
subsequent deterioration in health and adverse outcomes. Inaccuracies occur using both serum 
and lithium heparin plasma. A likely reason for result inaccuracies is an aggregation of non 
specific proteins, fibrin strands (refer to publication in Chapter 6) or precipitates binding the 
antibodies which can present in both serum and lithium heparin plasma. The analyser wash 
process may be incapable of removing these compounds or breaking the non-specific binding of 
antibodies. One of the limitations of the publication is the sample type was not classified to 
clearly demonstrate that the problem was not limited to one sample type. Thus Table 1 
demonstrates sample type, serum or plasma, can produce discrepant duplicates and clinically 
significant results. False positive troponin results are not limited to one tube manufacturer as 
demonstrated in the publication in Chapter 5 (evaluation of the BD RST tube). Robustness of 
troponin assays is going to become even more important as the new high sensitivity assays are 
becoming routinely utilized. Beckman themselves have such an assay under development. This 
study demonstrated re-centrifugation, improving sample integrity was a factor in reducing the 
error rate and error extent even in an assay that lacks robustness.  
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Table 1. Samples with AccuTnI results exceeding recommended change criteria in a 
month were in total 881 samples were analysed (May 2009, PAH). 
 
Sample Analyser Serum S 
Plasma P 
Result 1
g/L 
Auto Repeat 
or Result 2
g/L 
Repeat 2
g/L 
Repeat 3
g/L 
515 DxI800 P 0.051 0.633 0.049 0.039 
422 DxI800 P 0.008 0.047 0.009 0.006 
704 Access 2 S 0.676 1.339 0.845 0.829 
87 DxI800 S 0.036 0.099   
8 DxI800 S 0.069 0.178 0.074 0.060 
876 Access 2 P 0.055 0.095   
2 DxI800 S 0.046 0.021   
152 DxI800 P 0.080 0.020 0.024 0.028 
523 DxI800 S 0.072 0.009 0.007 0.024 
142 DxI800 S 0.362 0.044   
10 DxI800 P 0.054 0.006   
485 DxI800 P 5.692 0.326 0.194 0.052 
 
 
This publication is evidence of analytical method requiring improvement in design, and sample 
quality contribution to errors. 
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2.2 Pseudohyperkalaemia and other biochemical abnormalities in hyperleukocytosis 
 
Dimeski G, Bird R. Hyperleukocytosis: Pseudohyperkalaemia and other biochemical 
abnormalities in hyperleukocytosis. Clin Chem Lab Med 2009;47:880-1.  
 
The publication provides an excellent example of lack of awareness by both laboratory and 
clinical staff of cell damage in blood samples from fragile leukocytosis patients and its impact on 
analytes. To date published reports with fragile leukocytosis have been on the K+ effect. In such 
samples there is a very large buffy coat layer on top of the gel barrier consisting almost entirely 
of these fragile leukocytes. Besides direct mechanical stress, these cells spontaneously rupture 
upon standing and release their content, hence the elevated LD in the hand delivered plasma 
tube, tube C in the table of the manuscript. Although lithium heparin whole blood provides an 
alternative methodology for POCT K+ estimation, there is no alternative to the use of serum 
sample to obtain accurate LD and AST results. Serum from properly clotted blood samples from 
such patients does not present with the buffy coat layer on top of the gel barrier that can alter 
concentrations of analytes on storage. Additionally, exposure of such samples to higher 
temperatures can lead to rapid glucose lowering, due to consumption by leukocytes. This 
manuscript demonstrates the artefactual elevation in K+ can lead to potentially fatal induced 
hypokalaemia as result of K+ lowering treatments being initiated. 
 
Almost exact same findings have been reported subsequently by Guiheneuf et al, falsely elevated 
K+, LD and AST in lithium heparin plasma but not in serum sample in two cases with T-cell 
lymphopblastic leukaemia [1].  
 
 
1. Guiheneuf R, Vuillaume I, Mangalaboyi J, Launay D, Berthon C, Maury JC, Maboudou P, 
Rousseaux J. Pneumatic transport is critical for leukaemic patients with major 
leukocytosis: what precautions to measure lactate dehydrogenase, potassium and aspartate 
aminotransferase? Ann Clin Biochem 2010;47:94-6.
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2.3. Centrifugation protocols: Tests to determine optimal lithium heparin and citrate 
plasma sample quality 
 
 Dimeski G, Solano C, Petroff MK, Hynd M. Centrifugation protocols: Tests to determine optimal 
lithium heparin and citrate plasma sample quality. Ann Clin Biochem 2011;48:218-22. 
 
Currently there are no recommandations or guidelines that outline what tests are to be used in 
determining optimal centrifugation protocols to produce highest quality lithium heparin plasma 
or citrate plasma. The findings in the manuscript clearly indicate that irrespective of the 
centrifugation settings chosen, lithium heparin plasma in a lot of respects does not produce the 
same quality sample as fully clotted serum. Lithium heparin plasma may be comparable to serum 
immediately after centrifugation provided it has been handled appropriately, and the cell layer 
above the gel barrier is not disturbed. As the data indicated the presence of the buffy coat layer 
above the gel barrier (containing cells, cell stroma and cellular content) can lead to changes, 
inaccuracies in concentration of a number of analytes. The study showed lithium heparin plasma 
irrespective of the centrifugation settings did not provide the same stability as serum samples.  
The ability to produce serum rapidly would alleviate the need to use lithium heparin plasma for 
just about all biochemical testing and meet the laboratory need of high quality sample that is able 
to retain analyte stability and deliver on TAT expectations for critical results. The rest of the 
thesis research will concentrate on generating serum by snake venom procoagulants using blood 
samples containing the range of commonly encountered therapeutic and blood collection tubes 
anticoagulants. 
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CHAPTER 3 
 
SNAKE VENOM PROTHROMBIN 
ACTIVATORS AS BLOOD 
CLOTTING REAGENTS 
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3.1 Introduction 
The conversion of prothrombin into the serine protease thrombin is one of the central reactions 
of the blood coagulation cascade, coming at the confluence of the intrinsic and extrinsic streams. 
Prothrombin activation is by Factor Xa (FXa). Prothrombin (72 kDa) is primarily synthesized in 
the liver and its concentration in blood is 1-2 M [1, 2, 3]. Koldas and Uras using an ELISA 
method estimated it to be 117±43 mg/L (1.6 ±0.5 M) in plasma [4].  -Thrombin (36 kDa) is 
considered to be the key enzyme, the ultimate and final coagulation protease produced in the 
coagulation cascade, responsible for thrombus formation by converting fibrinogen into fibrin. It 
is also able to activate platelets, Factors V, VIII and XI and thus accelerates its own generation 
by positive feedback. Converting fibrinogen to fibrin resulting in clot formation is the endpoint 
of a complex series of proteolytic reactions [5]. Clot structure is influenced by the amount of 
thrombin formed. Clots that are produced by low thrombin concentrations are composed of thick 
fibrin fibers that are loosely woven; there are fewer individual fibers for a given amount of 
fibrinogen. These clots are more susceptible to fibrinolysis than clots produced by high thrombin 
concentrations that are composed of tightly packed thin fibrin fibers with more individual fibers 
per fibrinogen hydrolysed [6]. 
 
FX (59 kDa), like many other blood coagulation proteins, is synthesized in the liver. Its plasma 
concentration is 0.17M (10g/mL of plasma) [7, 8]. The FXa conversion of prothrombin to 
thrombin is greately enhanced by accessory components: calcium ions, negatively charged 
phospholipids (provided in vivo by activated platelets) and by the non-enzymatic protein 
cofactor, FVa. The combination of FXa with the accessory components constitutes the 
prothrombinase complex. These accessory components stimulate prothrombin activation in a 
multiplicate manner, resulting in a considerable decrease in Km for prothrombin (mainly by the 
phospholipids) and a correspondingly large increase in the velocity of the reaction [9, 10]. Thus 
Factor Va functions both as a receptor for FXa and as a positive effector of FXa catalytic 
efficiency. It is the key to efficient conversion of prothrombin to thrombin [1, 11] but by itself 
has no procoagulant activity [12]. The concentration of FV (330 kDa) in plasma is about 20 nM  
(6.6 g/mL of plasma) [8,13], and an additional pool of ~20% of the total FV in whole blood is 
stored in the -granules of platelets [8]. Thrombin converts FV to FVa, and FVa accelerates 
FXa-catalysed prothrombin activation more than 1,000-fold. Under physiological conditions the 
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cofactor activity of FVa in prothrombin activation is down-regulated by activated protein C, a 
serine protease which cleaves FVa to inactive peptides [14]. Calcium is required to bind 
prothrombin and other vitamin K dependent proteins (FVII, FIX, FX, protein C, protein S) to 
membranes containing acidic phospholipids [15]. Calcium also shortens the onset of clotting and 
produces thicker fibrin fibers than those generated when thrombin is added in the absence of 
calcium [16]. It is interesting to note that the concentration of prothrombinase complex cannot 
exceed the maximum plasma concentration of FVa (about 20 nM), which is approximately ten 
times lower than the concentration of FX (170 nM). 
 
Another cation that influences thrombin activity is sodium. The B chain of -thrombin contains a 
sodium ion binding site. Occupancy of this binding site determines whether thrombin acts as a 
procoagulant or anticoagulant. In the presence of Na+, the ”fast” conformation of thrombin is 
present (“fast thrombin”) which recognises fibrinogen as substrate. In the absence of Na+, the 
“slow” state of thrombin is present (“slow thrombin”) which acts as an anticoagulant by 
activating protein C [17, 18]. Activated protein C degrades FVa and thus limits coagulation. 
Therefore, in vitro studies need to include sodium in solutions whereas Na+ is always present in 
blood and plasma samples.     
 
The two pathways for the conversion of human prothrombin to thrombin by FXa are shown in 
Figure 1 [19]. If the initial cleavage is at Arg320, meizothrombin is formed as an intermediate 
product. Meizothrombin has a brief life span, undergoing autolytic cleavage to form 
meizothrombin des-F1 and then -thrombin [20]. Meizothrombin has five to seven time greater 
ability to induce vascular constriction to than -thrombin [21]. In the absence of FVa, the initial 
cleavage by the phospholipid bound FXa is at R271, producing prethrombin-2 as the intermediate 
product which has no enzymatic activity. This is then converted to -thrombin.  
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Figure 1. Pathways of Factor Xa activation of prothrombin. Formation of -thrombin from 
its precursor, prothrombin, by FXa requires peptide bond cleavages at Arg271 and Arg320 [19].  
Fibrinogen (340 kDa) is composed of two A, two B and two  polypeptide chains that are 
associated noncovalently as well as by disulfide bonds [22, 23]. Its plasma concentration is 2-4 
g/L, 6-12 M [24]. The -thrombin cleavage of the A chain at Arg16 releases fibrinopeptide A 
(FPA) and generates fibrin I. The -thrombin cleavage of the B chain at Arg14 releases 
fibrinopeptide B (FPB), forming fibrin II [25].  The FPA and FPB undergo polymerisation by 
FXIIIa to form the insoluble cross-linked fibrin network. A number of variables can influence 
the structure of a fibrin clot, including the local pH, ionic strength [26], concentrations of 
calcium [16], fibrinogen [27], and thrombin present during gelation. The concentration of 
thrombin present at the time of gelation has the most influence on fibrin clot structure as 
discussed above [24] while fibrinogen concentration has the most influence on clot strength [28].   
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As well as its formation, the inactivation of the mammalian prothrombinase complex must be 
tightly regulated to ensure correct levels of -thrombin are present. The prothrombinase complex 
is inactivated by two systems. Firstly the antithrombin III-heparin complex is a potent inactivator 
of both FXa and -thrombin [29]. Antithrombin III (58 kDa) circulates in plasma at a 
concentration of 150 g/mL, ~3 M [7, 30]. Physiologically ATIII circulates in a form that has a 
low inhibitory activity, and the inhibitory activity is enhanced at least 1000-times in the presence 
of heparin and other heparin-like glycosaminoglycans, such as heparan sulphate [31]. The second 
system for prothrombinase inactivation is the -thrombin-dependent activation of protein C 
which then cleaves FVa, preventing its binding to FXa and prothrombin [32].  
 
Snake venom prothrombin activators (also known as prothrombinases) are powerful 
procoagulants which are present at high concentrations in some snake venoms [33]. For example 
the prothrombin activator from Pseudonaja textilis venom has been observed to cause death in 
rats within a few minutes of intravenous injection at a 23 g/kg body weight dose [34]. Later 
studies showed 8 g of purified prothrombin activator from P. textilis, (called PtPA), given 
intravenously to rats (250-400 g), caused acute disseminated intravascular coagulation and 
subsequent death in less than one minute [35]. Chester and Crawford were the first to report that 
Australian snake venoms are able to clot blood from warfarinised patients [36]. PtPA was shown 
to coagulate citrated, FV and FX deficient plasmas, and to convert purified human prothrombin 
to thrombin. It was also found to efficiently convert descarboxyprothrombin (present in warfarin 
treated patients instead of normal prothrombin) to -thrombin. It was also shown that heparin up 
to 100 IU/mL had no effect on the activity of PtPA in hydrolyzing the FXa chromogenic 
substrate S-2222 [34].    
 
The four groups of snake venom prothrombin activators are shown in Figure 2.  
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Figure 2. Modification of the Kini [37] schematic representation of structures of the four groups 
of prothrombin activators from snake venoms. In the Group C diagram “?” indicates that the 
details of bonding between FVa and FXa components are unknown.   
FVa component FXa component 
FXa component 
Ca++ dependent component 
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They are grouped based on structural characteristics, functional properties and co-factor 
requirements for prothrombin activation [38]. Groups A and B prothrombin activators are zinc 
metalloproteinases. Functionally they resemble human FXa in converting prothrombin to -
thrombin but structurally they are unrelated to mammalian coagulation factors which are serine 
proteinases [39]. Group A activators activate prothrombin without the requirement of cofactors 
such as calcium, phospholipids or FVa and they are resistant to the natural coagulation inhibitors, 
such as heparin and antithrombin III [40, 41]. They are found in several viper venoms e.g. ecarin 
(Echis carinatus) [42, 43] and Bothrops species e.g. berythractivase (Bothrops erythromelas) 
[43]. Ecarin molecules contain three domains; the metalloproteinase domain having a zinc-
chelating sequence [44]. Zinc is essential for the catalytic activity of ecarin and carinactivase.  
 
Group B activators require calcium but not phospholipids or FVa for their optimum activity. 
Examples are carinactivases also isolated from Echis carinatus venom [42] and multactivase 
isolated from Echis multisquamatus venom [45]. They too are not inhibited by heparin or 
antithrombin III. The carinactivases have a subunit that has metalloprotease activity and is 
homologous to ecarin but also contain a calcium binding regulatory subunit. Unlike ecarin, 
carinactivases do not bind the prothrombin derivatives, prothrombin-1 and 
descarboxyprothrombin [40]. 
 
The prothrombin activators of Groups C and D are serine proteinases. Group C prothrombin 
activators are structurally and functionally similar to the transient mammalian prothrombinase 
complex FXa-FVa [39]. Group D prothrombin activators are homologous to the mammalian FXa 
alone. Kini has reported that the Group C and D prothrombinases hydrolyze the macromolecular 
substrate prothrombin about 10 times faster than mammalian FXa [37].  
 
The Group C prothrombin activators are found in the venoms of Australian brown snake and 
taipan species, such as Pseudonaja textilis (Eastern Brown), Oxyuranus scutellatus (Coastal 
Taipan) and Oxyuranus microlepidotus (Inland taipan) [41]. They were first purified and 
characterized from O. scutellatus in 1980 [45], and from P. textilis in 1987 [46] and are 
designated as OsPA and PtPA respectively. Their clotting activity is enhanced by calcium and 
phospholipids but not by FVa. They contain their own FVa like cofactor in complex with an FXa 
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like proteinase [47, 48]. The FV/FVa from the venom of P. textilis has been shown to be 
structurally much smaller than human FV, lacking the B domain. Unlike human FV which 
requires proteolytic activation, recombinant P. textilis FV/FVa is fully (constitutively) active as a 
single polypeptide chain [12].  It functions in the absence of negatively charged phospholipids 
and is resistant to activated protein C [12, 49], making it resistant to regulation by the 
haemostatic system. Taipan and brown snake venoms are among the most toxic in the world, 
their strong procoagulant capability inducing disseminated intravascular coagulopathy as one of 
the symptoms [50]. Dried P. textilis venom contains prothrombin activator at a level of ~40% of 
the total dry weight of the venom [48, 51]. Rao and Kini report the yield of purified prothrombin 
activator was 16-20% of the crude venom [39]. The closely related species, O. scutellatus 
(coastal taipan) and O. microlepidotus (inland taipan) have 10-20% prothrombinase complex in 
the venom [33]. The high concentrations in venom and the high activities mean that trace 
amounts of venom reaching the blood stream have major clotting effects. 
 
The Group D prothrombin activators are also found in Australian elapid snake venoms, notecarin 
from Notechis scutatus, trocarin from Tropidechis carinatus, and hopsarin from Hoplocephalus 
stephansi [38]. Their activity is greatly enhanced by human or bovine FVa, calcium ions and 
phospholipids [38]. The Group D FXa like proteases form a tight 1:1 complex with mammalian 
FVa [12, 39, 52].  
 
The FXa component of PtPA has been isolated after dissociation of the complex and shown to 
cleave prothrombin at the same site as human FXa but five times better. Unlike human FXa it is 
calcium independent and it is estimated to be 50-70 times more potent than bovine thrombin in 
clotting of human plasma [53]. The Group D prothrombin activators (FXa like molecules) are 
slightly smaller than Group C FXa molecules, and are 80-97% identical in sequence to the FXa 
components of the Group C prothrombin activators [48]. These may be better than Group C 
FXas at forming a complex with mammalian FVa as they have evolved to bind to it. It has been 
shown that human FVa can substitute to same extent for the FVa in the taipan and brown snake 
venom if the FVa was first separated from its native cofactor [54].   
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It has been hypothesized that snake venoms containing prothrombin activators generate large 
quantities of thrombin in blood or plasma thus resulting in rapid clotting. To support this it has 
been shown by Dr Paul Masci (from this research group) that freshly reconstituted prothrombin 
activator containing snake venoms were able to clot re-calcified citrate plasma (using a Clotek 
analyser) down to a concentration of 500 pg/mL in less than 300 seconds (unpublished data), 
Figure 3.   
 
 
 
Figure 3. Clotting times of re-calcified citrate plasma with various venoms’ concentrations (Pt - 
P. textilis, Os - O. scutellatus, Om - O. microlepidotus, Ns - N. scutatus and Ec - E. carinatus). 
Re-calcified citrate plasma takes > 10 minutes to clot in the absence of added procoagulant.  
 
 
 
The aims of the experiments reported in this chapter were to study thrombin formation by snake 
venom prothrombin activators from each of the four groups. The prothrombin activators selected 
were: Group A - ecarin; Group B - carinactivase - 1 and carinactivase - 2; Group C - OsPA and 
PtPA; and Group D - notecarin. They were first purified using literature procedures then 
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characterised using sodium dodecyl sulfate polyacrylamide gels electrophoresis (SDS-PAGE) 
and specific clotting activity. This was followed by estimation of the rate of thrombin generation 
from prothrombin in both buffer and plasma. Finally the prothrombin activators were tested for 
their ability to clot FV and FX deficient plasmas. 
 
  
3.2 Materials and Methods 
 
3.2.1 Equipment 
Spectrophotometric measurements were made with a Hitachi U-2800 spectrophotometer (Hitachi 
High Technologies, Tokyo, Japan).   
 
The chromatography equipment used for purification of the prothrombin activators was:  
- a Gilson Miniplus II peristaltic pump (Gilson, France) using black to purple chamber 
set at the required flow rates;  
- an Altex 152 dual wave UV detector set at two attenuations of 280 nm (Altex, 
Berkeley, CA, USA); 
- a LKB 7000 ULTRORAC fraction collector (LKB Instruments, Bromma, Sweden) using 
a time-base fraction collection. 
Concentration of eluted fractions was performed using YM membranes in an Amicon stirred cell 
concentrator Model No. 405 (Amicon, Millipore, MA, USA).  
 
The absorbance of a protein mixture (taking the average molar extinction as 10) can be directly 
related to the concentration of the protein(s) by measuring the absorbance at 280 nm [55, 56]. 
The protein concentration was estimated by diluting the eluted prothrombin activator solution 
10-fold in Hepes buffer (Hepes buffer pH 7.4, 150 mM NaCl, 2 mM CaCl2, and 0.05% surfactant 
p20) and then measuring the absorbance at 280 nm. It was assumed that a 1 mg/mL solution of 
the protein would have an A280 of 1. The absorbance value was multiplied x10 to give the 
mg/mL protein concentration of the pooled stock solution.  
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3.2.2 Purification of snake venom prothrombin activators  
Dried E. carinatus venom was obtained from Sigma #V8250 500 mg (St Louis, Missouri, USA). 
Dried P. textilis, O. scutellatus and N. scutatus venoms were obtained from Venom Supplies 
(Tanunda, South Australia, Australia). 
 
3.2.2.1 Group A (ecarin) and B (carinactivase 1 and 2) 
The purification of ecarin and carinactivases-1 and 2 from E. carinatus venom (1 g) was carried 
out using the two step procedure of Yamada et al [40]. The prothrombin activator activity of the 
eluted fractions was identified in a citrate plasma clotting assay using a Clotek analyser (Hyland 
Laboratories, CA, USA) in the presence of calcium (30 mM) to identify carinactivase 1 and 2, 
and in the absence of added calcium to identify ecarin.  Pooled fractions of the three 
prothrombinase activitors contained 9.6 mg of ecarin, 6.5 mg of CA-1, and 1.8 mg of CA-2 
respectively. The stock ecarin, CA-1, and CA-2 solutions were 1.15 mg/mL (19.2 M), 1.33 
mg/mL (22.1 M), and 0.34 mg/mL (5.6 M) respectively and were stored at -20ºC in distilled 
water.  
 
3.2.2.2 Group C (PtPA and OsPA) 
The purification of PtPA from the venom P. textilis (1 g) and OsPA from venom of O. 
scuttelatus (1 g) was performed by the method described by Masci et al [35]. Pooled fractions of 
the PtPA and OsPA contained 294 mg and 128 mg respectively. The stock OsPA and PtPA 
solutions were 1.09 mg/mL (4.3 M) and 4.8 mg/mL (19.2 M) respectively. They were stored 
at -20ºC in 50 % glycerol.  
 
3.2.2.3 Group D (notecarin)  
The purification of notecarin from the venom of N. scutatus (1 g) was performed by the method 
described by Tans et al. [57]. Pooled fractions of the notecarin contained 115 mg.  The stock 
notecarin solution was 1.07 mg/mL (17.9 M) and was stored at -20ºC in 50 % glycerol.   
 
These preparations and stock solutions were used in all experiments involving the prothrombin 
activators except if otherwise stated. Clotting activities of the prothrombin activators are shown 
in Table 1 and 2 of Results Section.    
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3.2.2.4 Molar concentrations of prothrombin activators stock solutions 
The molar concentrations were calculated from the protein concentrations (in mg/mL) using the 
following molecular weights: ecarin, 55 000 [40, 58], CA-1 and CA-2, 60 000 [40] PtPA, 250 
000 [12, 32, 47, 59], OsPA, 250 000 [54], and notecarin, 60 000 [52, 57]  
 
 
3.2.3 Electrophoresis studies  
  
3.2.3.1 Characterisation of purified snake venom prothrombin activators by SDS-PAGE  
SDS-PAGE was used to estimate the molecular masses of the polypeptides present in the six 
purified prothrombin activators, human thrombin and prothrombin in the presence (reduced) and 
absence (non-reduced) of -mercaptoethanol using the protocol described by Laemlli [60]. SDS-
PAGE was also used to give an indication of the level of purity (homogeneity) of the six 
prothrombin activator preparations.  
The stock solution of the prothrombin was 17.8 mg/mL (#HCP-0200; Haematology Technology 
Incorporated, Essex Junction, VT, USA). The stock thrombin solution was 10 mg/mL (#HCT-
0020; Haematology Technology Incorporated, Essex Junction, VT, USA). The protein marker 
used was Precision Plus Protein, Kaleidoscope Standards (#161-0375, Bio Rad, Hercules, CA, 
USA) 
The 8% SDS-PAGE resolving gel (20 mL) composition was:                                                            
- 9 mL of deionised water                                                                                                                 
- 5.3 mL of 30% acrylamide (6.68 mL) [30% Acrylamaide/Bis Solution 37.5:1 (2.6%) #161-
0158 Bio Rad]                                                                                                                                  
- 5.0 mL of 1.5 M Tris –HCl pH 8.8 buffer                                                                                   
- 200 L of 10 % SDS  [#200-142, Progen Industries, Australia]                                                         
- 200 L of 10% ammonium persulfate (APS) [#161-0700, BioRad, USA]                                                    
- 12 L of TEMED [#T9281-25 mL, Sigma].  
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The stacking gel (8.0 mL) composition was:                                                                                            
- 5.5 mL of deionised water                                                                                                               
- 1.3 mL of 30% acrylamide                                                                                                                                
- 1.0 mL of 0.5 M Tris–HCl pH 6.8 buffer                                                                                            
- 80 L of 10% SDS (75 uL)                                                                                                                        
- 80 L of 10% APS                                                                                                                               
- 8 L of TEMED   
The sample loading buffer (3x) composition was:                                                                                                              
Non-reduced                                                                                                                                                     
– 2.4 mL of 1.0 M mM Tris-HCl, pH 6.8,                                                                                                               
- 0.005g (0.05% w/v) of bromophenol blue,                                                                                               
- 3.0 mL of 50% glycerol,                                                                                                                 - 
- 3.0 mL of 10% SDS.    
Reduced                                                                                                                                                        
– 2.4 mL of 1.0 M Tris-HCl, pH 6.8,                                                                                                               
- 0.005g (0.05% w/v) of bromophenol blue,                                                                                               
- 3.0 mL of 50% glycerol,                                                                                                                 - 
- 3.0 mL of 10% SDS,                                                                                                                                   
- 0.5 mL (5%) -mercaptoethanol (#44143, BDH, UK).  
The samples were incubated for 5 minutes at 100ºC in a water bath. 
The SDS-PAGE stock running buffer (10x) composition was:                                                                                               
- 30.3 g Tris (#T6066-5kg, Sigma),                                                                                                              
- 144 g glycine (electrophoretic grade) (#G-4392, Sigma),                                                                       
- 10 g SDS (#200-0142, Progen Industries),                                                                                                  
- and made up to 1 L.  
The gel running buffer (1x) was 100 mL of 10x stock made up to 1 L. 
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The non-reduced (NR) and reduced (R) sample buffer volumes were 10 L. The following 
sample volumes and amounts were mixed with sample buffers: 10 L of prothrombin (9 g) or 
thrombin (10 g) then 10 and 20 L respectively were loaded on the gel; 20 L of ecarin (96 
g), PtPA (80 g) or OsPA (17 g) then 25 L loaded on the gel from each preparation; 15 L of 
CA-1 (100 g) then 25 L loaded on the gel; and 20 L of CA-2 (34 g) then 30 L loaded on 
the gel. The samples were mixed and then incubated for 10 minutes at 100ºC before being loaded 
on the gel. 
The gels were run at 100 V using a Mini-Protein II Cell PAGE apparatus (Bio-Rad, USA) until 
the dye-front reached the bottom of the gel. The gels containing the activators were stained with 
Coommassie Brilliant Blue G (#B-0770, Sigma, St Louis, Missouri, USA) (0.25% w/v 
Coommassie Brilliant Blue G, 45% methanol, 10% acetic acid). Excess stain was removed by 
destainer (45% methanol, 45% water and 10% acetic acid).    
 
3.2.3.2 Specific activity of purified solutions of prothrombin activators 
 
The aim of this experiment was to determine the specific activity of the purified prothrombin 
activator solutions and of thrombin. The activity was measured by plasma clotting studies using 
a Clotek analyser at 37ºC. This analyser uses a sample tube containing a magnetic ball which 
oscillates vertically when the tube is inserted into the machine. The magnetic steel ball is held in 
position by a magnetic field while the tube oscillates. The sample, buffer, ± calcium and 
procoagulant are added and the timer is triggered. Thrombin converts fibrinogen into clottable 
fibrin, and the time required to form the detectable clot is the clotting time.  At clot formation the 
steel ball is removed from the magnetic suspension field and the light path, causing the light 
beam to strike the photocell and stop the timer [61]. The normal pooled citrate plasma (Greiner 
Vacuette citrate tube #454327, 3.2% or 0.109 mol/L sodium citrate), citrate plasma having 
coagulation profile – prothrombin time, activated partial thromboplastin time, platelet count, 
fibrinogen level within reference intervals, was obtained from the Haematology Department, 
Pathology Queensland, Princess Alexandra Hospital (PAH). All citrate samples were centrifuged 
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in a swing-out bucket rotor centrifuge for 10 minutes at 3000g and 20ºC (Hereaus 1-RS, 
Germany). 
 
The Clotek tube contained 100 L of normal pooled citrate plasma, 100 L of Tris Buffer  
(150 mM Tris HCl, 150 mM NaCl, pH 7.4), 50 L 0.2 M CaCl2, and 50 L of each PA at a  
concentration range of 0.001 to 100 nM 
 
3.2.3.3 Prothrombin to thrombin conversion by prothrombin activators  
In this experiment the aim was to determine the ability of the PAs to convert prothrombin to 
thrombin in a fixed period of five minutes. This was  performed using SDS-PAGE nUView 
Precast Mini Gels (#NB10-420, 4-20%) with running buffer Tris-Glycine (#BG-143) and Sample 
buffer (#BG-145) ( NuSEP, Australia) under non-reducing and reducing (5% -mercaptoethanol 
#44143, BDH, UK) conditions.  
 
The stock solution of the prothrombin was 17.8 mg/mL (#HCP-0200; Haematology Technology 
Incorporated, Essex Junction, VT, USA) and it was diluted 1/50 with distilled water to provide a 
working solution of 0.36 mg/mL, giving a final concentration in the tube (20/100) of 72 g/mL.  
For loading on the gel the 0.36 mg/L working prothrombin solution was used. The prothrombin 
activators were diluted with distilled water to provide working concentrations of 6 nM, which 
gave a final concentration in the tube of (20/100) 1.2 nM. The stock thrombin solution was 10 
mg/mL (#HCT-0020; Haematology Technology Incorporated, Essex Junction, VT, USA) and 
was diluted (1/30) with distilled water containing 0.01% Tween 20 to minimise adherence to 
walls of plastic containers, providing a working thrombin solution of 0.33 mg/L which was used 
to load on the gel. The buffer was 20 mM Hepes buffer pH 7.4, 150 mM NaCl, 2 mM CaCl2, and 
0.05% surfactant p20.
 
 
For the SDS-PAGE analysis of the prothrombin to thrombin conversion the volumes of the 
compounds used were: 60 L of Hepes buffer, 20 L of prothrombin (72 g/mL or 0.99 M), 
and 50 L of the 6 prothrombin activators (1.2 nM).  
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After five minutes incubation at 23ºC a 40 L aliquot was transferred into equivalent volume of 
non-reducing or reducing sample buffer.  The samples were then incubated for 10 minutes at 
100ºC in a heating block. Aliquot of 25 L of each PA, thrombin and prothrombin, and 12 L of 
the prestained molecular weight marker (#SM0671 Page Ruler Prestained Protein Ladder, 
Fermentas, Hanover, MD, USA) were loaded on the gels. The gels were run at 100 V using a 
Mini-Protein II Cell PAGE apparatus (Bio-Rad, USA) until the dye-front reached the bottom of 
the gel. The gels containing the activators were stained with Coomassie Brilliant Blue G (#B-
0770, Sigma, St Louis, Missouri, USA) (0.25% w/v Coomassie Brilliant Blue G, 45% methanol, 
10% acetic acid). Excess stain was removed by destainer (45% methanol, 45% water and 10% 
acetic acid). 
 
3.2.4 Kinetics studies of thrombin formation by prothrombin activators   
The thrombin substrate was S-2238 (#820324 Chromogeinix IL Lexington MA, USA), stock 25 
mg (626 Da) dissolved in 15 mL, 2.67 mM. Prothrombin activators (nominally 600 nM stock 
solutions) were prepared in distilled water and then further dilutions were prepared to provide a 
cuvette concentration range of 0.006-6 nM. The buffer used was 20 mM Hepes, 150 mM NaCl, 5 
mM CaCl2, 0.05% surfactant p20, pH 7.4. Spectrophotometric settings were 405 nM, with read 
time of 1800 seconds and readings at 5 second intervals. Absorbance readings were converted to 
p-nitroanaline (pNA) concentrations using a molar absorbance of 9600 M-1 [62].  
 
3.2.4.1 Quantitation of the amount of thrombin generated by prothrombin activators in a 
fixed time period 
The experiment was designed to determine the amount of thrombin that is generated from 
prothrombin by each of the prothrombin activators at 0.6 nM concentration.   
 
Prior to the activation study a standard curve of thrombin concentration was obtained. At 
different thrombin concentrations, the absorbance of the pNA generated by thrombin hydrolysis 
of the chromogenic substrate S-2238 was continuously monitored at 405 nm over 180 seconds. 
The slope of the absorbance plot between 130 and 180 seconds (average ~155 seconds) at 
different thrombin concentrations were used to construct a standard curve. The standards curve 
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was determined using 50 L of S-2238 substrate (134 M), 50 L of different thrombin 
concentrations (range of 0.25-30 nM) and 900 L of Hepes buffer.   
 
For the prothrombin activators the cuvette contained 50 L of prothrombin (247 nM), 10 L (0.6 
nM) of the different prothrombin activators, 100 L (267 M) S-2238 substrate to minimise 
rapid substrate depletion and 840 L of Hepes buffer, pH 7.4. The reaction was monitored over 
180 seconds and the reaction slope for each of the six PAs was determined at 155 seconds 
(average slope from 130-180 seconds). The amount of thrombin generated from prothrombin by 
each PA was calculated using the standard curve.  
 
3.2.4.2 Evaluation of thrombin generation from prothrombin by the different prothrombin 
activators by analysis of progress curves 
The experiment in the previous section gave a single point estimate of the concentration of 
thrombin generated in 155 seconds. Kinetic analysis of the progress curves should allow more 
precise estimates of the rate of thrombin generation.  
  
For this study it was necessary to evaluate kcat for S-2238 and thrombin. The cuvette contained 
50 L of S-2238 substrate (134 M, 50 L of thrombin at different concentrations (range 0.25-
150 nM) and 900 L of Hepes buffer, pH 7.4. For the prothrombin activators the cuvette 
contained 50 L of prothrombin (247 nM), 10 L of the different prothrombin activators, 100 L 
(267 M) S-2238 substrate and 840 L of Hepes buffer. The progress curve for each prothrombin 
activator was determined at three different concentrations ranging from 0.006-6 nM.  The kinetic 
parameters of the prothrombin activators were then obtained from the fit to the thrombin 
standard curve, using the estimated thrombin kcat value. 
 
The data were analysed using DynaFit 4.04.64 Enzyme Kinetic Data Analysis Software (BioKin 
Ltd, Watertown, MA, USA) [63] with the assistance of Dr Lambro Johnson. 
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3.2.4.3 Estimation of the amount of thrombin generated by PtPA and OsPA in normal 
citrate plasma that remained after clotting for five minutes in the clot free component 
 
The experiment was designed to provide an estimate of the amount of thrombin that is generated 
(and remains active) by different concentrations of PtPA and OsPA in plasma after five minutes 
clotting, in the presence and absence of heparin. The same experiment was performed using BD 
RST as the source of thrombin. 
 
For the first part of the study, normal citrate plasma was prepared from a healthy participant 
(author). The 10 tubes of blood collected were immediately centrifuged and the citrate plasma 
pooled. For the remaining part of the study normal pooled citrate plasma (< 24 hours old) was 
obtained from the Haeamotology Department, Pathology Queensland, PAH.   
 
The thrombin substrate was S-2238 stock (25 mg, 626 Da) dissolved in 15 mL, 2.67 mM 
(#820324 Chromogeinix IL Lexington MA, USA). The heparin used was 5000 IU/5 mL (1000 
IU/mL), (Sodium heparin, Pfizer, NZ). The heparin concentration was as per published 
information, 190.9 IU=1 mg; (1IU =0.0053 mg), ~12000 Da [64]. The buffer used was 20 mM 
Hepes buffer; 150 mM NaCl; pH 7.4; 0.05% surfactant p20.  
 
For the plasma incubation the tubes (ST/PC 500 #72.690.001, Micro tubes 1.5 mL, Sarsteadt, 
Germany) contained 0.5 mL of citrate plasma, 50 L of 0.5 M CaCl2, and 5-40 L thrombin or 
the PAs plus 20 L of heparin to provide concentrations of 2, 10 and 20 IU (860, 4300, and 8600 
nM). Tubes were incubated for five minutes at 23ºC. Immediatley after five minutes, the clot 
was ringed using two wood applicator sticks, removed and discarded.  From the clot free 
component of the sample, a 20 L aliquot was used for thrombin estimation.  
 
The spectrophotometer cuvette contained 930 L of Hepes buffer, 50 L of S-2238 (134 nM) 
and 20 L of the clear serum. The absorbance change was monitored at 405 nM for five minutes. 
The concentration of thrombin was estimated from the initial rate of S-2238 hydrolysis using the 
standard curve prepared in the previous experiment. 
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3.2.5 Ability of prothrombin activators to clot FV- and FX- deficient plasmas                          
The six PAs were tested for their ability to clot commercial FV deficient plasma (#0008466150) 
or FX deficient plasma (#0008466350) (Instrumentation Laboratory, Lexington, MA, USA) 
using the Clotek analyser. The Clotek tube contained 100 L of FV or FX deficient plasma, 100 
L of Tris Buffer (150 mM Tris HCl, 150 mM NaCl, pH 7.4), 50 µL 0.2 M CaCl2 and 50 L of 
procoagulant.  
 
3.3 Results and Discussion 
3.3.1 Electrophoresis studies 
3.3.1.1 Characterisation of purified snake venom prothrombin activators by SDS-PAGE  
SDS-PAGE was used to assess the homogeneity and estimate the molecular weights of the 
polypeptide chains in the fractions of the six purified PAs, human thrombin and prothrombin in 
the presence (R) and absence (NR) of -mercaptoethanol using the protocol described by Laemlli 
[60]. The results are shown in Figure 4 and can be interpreted as follows: 
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Figure 4. SDS-PAGE of the six PAs, prothrombin and thrombin. A; NR- non reduced B: R- 
reduced SDS-PAGE gels: 1 - prothrombin, 2 - thrombin, 3 - ecarin, 4 - CA-1, 5 - CA-2, 6 - PtPA, 
7 – OsPA, Lane -8 notecarin, M - marker.  
 
1. Prothrombin in the NR and R gels showed a single band at ~ 75 kDa consistent with its 
molecular mass of 72 kDa [65], and a minor band at ~37 kDa which is possibly thrombin. 
With the reduced gel only a single band was observed at ~75 kDa.   
2. Thrombin in the NR gel showed a dominant band at 37 kDa coinciding with its molecular 
mass of 36 kDa and in the R gel a band at 33 kDa which coincides with the B chain (31 
kDa) which is covalently linked by disulphide bond to the A chain (6 kDa) [66], the A 
chain was too small to be shown in the R gel.    
3. The ecarin preparation showed the strongest band in the 55-65 kDa region in both gels, as 
expected and reported by Morita and Iwanaga who showed it is a single band of 56 kDa 
[67]. Nishida showed it to be a band at70-72 kDa which they state it is the precursor of 
the active form of ecarin but the apparent mass was higher than calculated for the entire 
sequence [44]. Perhaps the 75 kDa band in the NR gel was a precursor form. Rosing and 
Tans 1992 state the molecular mass is between 55-63 kDa [58] which is consistent with 
the findings here. However the preparation was far from homogenous, as indicated by the 
variety of other bands shown in the gel.  
4. The CA-1 gels showed very strong bands at 50-65 kDa and one minor band at ~20 kDa in 
both gels as expected and reported by Yamada [40]. CA-1 appears to be a somewhat 
cleaner preparation than ecarin, although still containing a number of contaminants.  
5. The CA-2 gels showed that the CA-2 preparation was heterogenous making identification 
of the bands difficult. Yamada states CA-2 is almost identical in structure and 
enzymological features to CA-1 [40], and it also contains a calcium binding subunit.   
6. PtPA in the NR gel showed 6 bands at 210, 130, 55, 40, 25 and 15 kDa while in the R gel 
it showed 7 bands at 100, 65, 55, 40, 30, 20 and 15 kDa which is consistent with the 
findings by Rao and Kini [39]. Rao and Kini report the following bands in the NR gel: 
125, 100, 65, 52, 40, 30, and 17, and the R gel showed 6 bands at 100, 65, 52, 40, 30 and 
17 kDa. Flight et al showed there were up to 6 distinctive bands with different intensity 
in freshly purified PtPA from brown snakes originating from different geographical areas, 
with the 220 kDa band corresponding to the FVa subunit and 53 kDA corresponding to 
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the FXa subunit [47]. Crouch showed the NR gel having bands at 200, 150, doublet at 55-
65, 47 and 36 kDa while the R gel showed bands at 115, 85, 60, 47, 37, 30 and 15 kDa 
[59].  
7. OsPA in the NR gel showed 7 bands at 250, 160, 100, 60, 50, 40, and 15 kDa while the R 
gel also showed 7 bands at 100, 80, 65, 60, 40, 30 and 15 kDa.  
 
PtPA and OsPA are complexes of two distinct proteins, FXa and FVa. Therefore, in a 
non-reducing gel the theoretical expectation would be for a band at about 210-220 kDa 
representing the intact FVa molecule [12, 47], plus a band at about 53-60 kDa 
representing the FXa component [59]. In a reducing gel, the FVa would be expected to be 
unchanged but the FXa component would dissociate into a heavy chain of 40 kDA, and a 
light chain of 32 kDa [59]. This study and others have observed a greater number of 
bands. Bos et al [12] under reducing conditions showed recombinant pt-rFVa had three 
bands, 180, 110, and 90 while the pt-FXa had three bands at 37, 27 and 18 kDa. 
However, the various polypeptides shown by SDS-PAGE appear to remain together in 
the complex under native conditions since preparations in which the FVA has been 
cleaved in several places retain full activity [12]. Characterisation of the several bands in 
the SDS-PAGE of PtPA and OsPA could be achieved by N-terminal sequencing after 
elution from the gel and this is an experiment planned for future research.  
8. The notecarin in the NR gel showed bands at 45 and 22 kDa while the R gel showed 
major bands at 37, 30, 22 and 15 kDa as expected and reported by Tans [57, 68], and this 
was in line with the structure in Figure 3 (heavy and light chains). It indicated it was 
likely to be the purest of the six PAs.  
 
The six preparations were used in the remaining experiments in this chapter and in some 
experiments in Chapter 4 and 6. Further development of purification procedures and 
identification of observed bands on SDS-PAGE is required to fully define the prothrombin 
activator structures and to determine accurate concentrations.  It seems likely that some partial 
proteolytic degradation of the prothrombin activators occurs in venom over longer term storage.  
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3.3.1.2 Specific activity of purified solutions of prothrombin activators 
 
It was necessary to define the specific clotting activities of the six preparations, especially 
because of the heterogeneity revealed by SDS-PAGE.  In determining the specific activities of 
the prothrombin activator preparations, the thrombin specific activity was used as a guide. 
Thrombin specific activity is normally expressed in National Institutes of Health (NIH) units. 
One NIH unit is defined as the amount of enzyme that clots 1% fibrinogen solution or plasma 
with identical reactivity in 15 seconds, at 37ºC, pH7.3 and sodium concentration of 0.154 M 
[69]. For human thrombin clotting times in the range of 15-25 seconds are used for determining 
activity at 37ºC, and one NIH thrombin unit is equivalent to 0.324 ± 0.073 g [70]. Therefore, 
highly purified human thrombin has a specific activity of 3086 NIH units/ mg protein. The BD 
RST tube (4 mL fill volume) contains 15 NIH units or 4.86 g of of bovine thrombin [71]. Based 
on the molecular weight of thrombin 36 000 [72], the concentration of thrombin in the BD RST 
tube equates to 1.215 g/mL, 3.75 NIH units/mL (33.7 nM) if the tube was filled with 4 mL of 
blood.  
 
Clotting times with different concentrations of the prothrombin activators were determined and 
the results are shown in Table 1.  
 
Table 1. Clotting times at 37ºC with normal pooled citrate plasma and the different prothrombin 
activators and thrombin at different concentrations with calcium. 
With added Ca2+ (sec) Prothrombin Activator 
concentration  (nM)  Ecarin CA-1 CA-2 PtPA OsPA Notecarin Thrombin  
100 43.0 108 65.8 3.5 5.7 42.4 4.3 
50 56.0 145 85.0 4.6 6.5 52.8 6.7 
30 69.0 181 167 4.9 7.9 57.5 10.5 
10 105 >300 >300 12.5 12.5 68.5 32.8 
3 208 >300 >300 20.1 18.3 99.8 92.3 
1 >300 >300 >300 61 30.0 144 >300 
0.1 >300 >300 >300 120 108 284 ND 
0.01 >300 >300 >300 212 >300 >300 ND 
0.001 >300 >300 >300 >300 >300 >300 ND 
ND - not determined 
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The optimum thrombin reaction is at 37ºC, and the thrombin reaction at room temperature was 
estimated to decrease to ~75% [73]. If we define a unit of clotting activity as the amount of PA 
required to give a clotting time of 100 seconds, the specific activity of the six PA preparations 
can be calculated. The relative clotting activities of each PA preparation and thrombin are shown 
in Table 2.   
 
The data from this experiment showed 3 nM thrombin gave a clotting time of approximately 100 
seconds. This represents one activity unit under these conditions. The relative activity units of 
the six PAs were calculated by dividing the concentration of the thrombin by the PA 
concentration that produced a clotting time close to 100 seconds. The results are shown in Table 
2.   
 
Table 2. Estimated activity units for each PA in terms of thrombin. 
 PA PA concentration (nM) giving 
clotting time close to 100 s (from 
Table 1) 
Relative activity ([thrombin], / [PA], 
Column 1) giving clotting time close to 100 
s  
Ecarin 10 0.3 
CA-1 100 0.03 
CA-2 50 0.06 
OsPA 0.1 30 
PtPA 0.1 30 
Notecarin 3 1 
 
The relative activity units showed the Group C (PtPA and OsPA) PAs were 30 times more active 
when compared with thrombin in producing approximately the same clotting time of 100 
seconds under these conditions. What must also be kept in mind is that these values are based on 
these preparations which are not pure as shown in the SDS-PAGE.  
 
3.3.1.3 Prothrombin to thrombin conversion by prothrombin activators  
The ability of the six purified PAs to convert purified prothrombin to thrombin in five minutes 
was evaluated. The results are shown in Figure 5. 
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Figure 5. SDS-PAGE of prothrombin to thrombin conversion by the different PAs after 5 minute 
incubation at 23ºC.  A non- reduced, B is reduced. M – marker with molecular mass in kDa; 
Lane 1- prothrombin; Lane 2 - ecarin; Lane 3 – CA-1; Lane 4 – CA-2; Lane 5 – PtPA; Lane 6 – 
OsPA; Lane 7 – notecarin; and Lane 8 - thrombin.  
 
The R and NR gels showed that only the Group C PAs had converted prothrombin to thrombin 
after five minutes incubation at 23ºC with concentration of 1.2 nM. It was anticipated some of 
the intermediates or thrombin precursors may have been present as the prothrombin was in the 
progress of conversion. The thrombin generated was of equal mass to human -thrombin, 37 kDa 
which is produced by human FXa [74]. The above results showed that the other four PAs had 
converted very little if any of the prothrombin to thrombin. The NR and R gels indicated only a 
single prothrombin band while thrombin showed a small amount of fragments 1 and 2 being 
further separated below the thrombin band.  The findings with PtPA are in line what was found 
in an extended time course study performed with PtPA and notecarin by Dr Geoff Birrell from 
this research group (data unpublished) Figure 6. This study showed that at four minutes most of 
the prothrombin was converted by PtPA to thrombin and thrombin precursors, and by ~10 
minutes there were no precursors. The study by Dr Birrell with notecarin showed that conversion 
of prothrombin to thrombin was much slower than with PtPA, Figure 7. The gel data indicated 
PtPA was able to convert similar amounts of prothrombin to thrombin in four minutes whereas 
150 minutes was required for notecarin to achieve approximately the same conversion. Dr Birrell 
also carried out N-terminal sequencing of the bands to identify them, and confirmed (Figure 8) 
that the prothrombin to thrombin conversion followed pathway B as shown in Figure 1.  
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Figure 6. Time course of prothrombin (10 g) to thrombin conversion by PtPA: Lane 1- 0 time, 
Lane 2 – 30 secs, Lane 3-1 mins, Lane 4-2 mins, Lane 5-4 mins, Lane 6-6 mins, Lane 7-8 mins, 
Lane 8-10 mins, Lane 9-15 mins, Lane 10-20 mins, Lane 11-25 mins, Lane 12-30 mins, Lane 13-
45 mins, Lane 14 150 minutes and Lane 15-Marker. (Prothrombin 72 kDa, Thrombin 36 kDa). 
 
  
Figure 7. Time course of prothrombin (10 g) to thrombin conversion by notecarin: Lane 1- 0 
time, Lane 2 – 30 secs, Lane 3 - 1 mins, Lane 4 - 2 mins, Lane 5 - 4 mins, Lane 6 - 6 mins, Lane 
7 - 8 mins, Lane 8 - 10 mins, Lane 9 - 15 mins, Lane 10 - 20 mins, Lane 11 - 25 mins, Lane 12 - 
30 mins, Lane 13 - 45 mins, Lane 14 - 150 minutes and Lane 15 - Marker. (Prothrombin 72 kDa, 
Thrombin 36 kDa). 
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Figure 8. N-terminal sequencing of bands from the prothrombin to thrombin conversion (10 g 
of prothrombin):   Lane 1 - 1 min; Lane 2 - 10 mins, Lane 3 - 2 hours, Lane 4 – 30 secs, Lane 5 – 
5 mins, Lane 7 – 2 hours. 
 
 
 
3.3.2 Kinetics studies of thrombin formation by prothrombin activators  
3.3.2.1 Quantitation of the amount of thrombin generated by prothrombin activators in a 
fixed time period 
A standard curve of rate of S-2238 hydrolysis at different thrombin concentrations was 
determined by measuring the pNA generated by the thrombin hydrolysis of the chromogenic 
substrate S-2238 at 405 nm, Figures 9 and 10. The formation of thrombin from prothrombin 
catalysed by the PAs, was then determined using the same substrate, Figure 11.  
 
The initial concentration of thrombin was zero or close to zero, as expected from the purity of the 
prothrombin and indicated by the zero or close to zero slopes of the progress curves at zero time 
(Figure 11). The rate of pNA formation increased as prothrombin was converted to active 
thrombin by the PAs. The concentration of thrombin at any time was proportional to the slope of 
the curve at that time point. Table 3 shows the calculated amounts of thrombin produced by each 
prothrombin activator over 155 seconds.  
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Figure 9. The absorbance at 405 nM of the pNA generated from S-2238 by different thrombin 
concentrations over 155 seconds.  
 
 
 
 
Figure 10. Standard curve derived from the slopes of the progress curves in Figure 9 and 
thrombin concentrations. 
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Figure 11. Progress curves for S-2238 hydrolysis by thrombin generated by 0.6 nM 
concentration by the different prothrombin activators.   
 
Table 3. The concentration of thrombin generated by 0.6 nM concentration of the different 
prothrombin activators over 155 seconds calculated from the standard curve in Figure 8.  
 
Prothrombin Activator  
(0.6 nM) 
Calculated slope 
(A405/s)  
Concentration of 
thrombin generated 
(nM) in 155 seconds 
Ecarin 0.00085 1.7 
CA-1 0.00007 0.2 
CA-2 0.0005 1.0 
PtPA 0.0094 20.1 
OsPA 0.0077 16.5 
Notecarin 0.0001 0.1 
 
The SDS-PAGE analysis demonstrated that the purified PA solutions differed in the 
concentrations of contaminants or impurities. This needs to be considered when comparing 
effectiveness of these PA preparations in generating thrombin.  
The concentration of thrombin generated was highest by PtPA followed by OsPA which 
translated to 20.1 and 16.1 nM of the original prothrombin (247 nM) being converted to 
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thrombin in 155 seconds. At five minutes it was estimated the amount of thrombin that would be 
generated by the 0.6 nM concentration would be 38.9 and 31.9 nM for PtPA and OsPA 
respectively. Provided the progress curves were linear, increasing the PA concentration to 6 nM 
the projected thrombin concentrations would be 389 and 319 nM for PtPA and OsPA 
respectively (assuming a high initial prothrombin concentration, as found in plasma). It would 
require < 3 nM of PtPA or OsPA to generate the concentration of thrombin in the BD RST tube. 
Therefore (1.0-1.5 g)/4 mL of PtPA or OsPA in 4 mL blood collection tube is likely to provide 
complete clotting in a normal blood sample in 155 seconds.  The third most efficient PA 
preparation by a significant margin, ~10 times lower was ecarin. The least amount was generated 
by CA-1 and notecarin. Notecarin requires calcium phospholipid and FVa for high activity, none 
of which was present in this experiment. The added advantage of the PAs is they would continue 
to produce thrombin with time as long as prothrombin was present.  
 
3.3.2.2 Evaluation of thrombin generation from prothrombin by the different prothrombin 
activators by analysis of progress curves 
As indicated in the previous experiment the quantitation of thrombin activity generated by the 
PAs was important to provide an indication as to the potential minimum concentration that 
would be suitable for incorporation in blood collection tubes to produce serum.  This experiment 
was performed in the same way as the previous experiment. However, the progress curves were 
used to demonstrate the rate of thrombin generated by the PAs from prothrombin and were 
evaluated according to the kinetic scheme.   
Activator + Prothrombin           Activator + Thrombin + Propetide          : ka   
Thrombin + S-2238                    Thrombin·S-2238                              : kf kr 
 Thrombin·S-2238                      Thrombin + pNA + Peptide product    : kcat   
 
In this scheme ka is the second order rate constant for the formation of thrombin, S-2238 is a 
thrombin specific peptide nitroanilide substrate, kf and kr are the forward and reverse rate 
constants for the formation of the Michaelis complex and kcat is the catalytic rate constant for 
thrombin cleavage of  S-2238 to pNA and peptide product.  The complexity of this model 
precludes simultaneous estimation of all its parameters from the limited progress curve data. 
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However, for the comparative purposes of the present study the parameter of primary interest, 
the apparent activator rate constant ka, can be determined by substituting known or assumed 
values for the other parameters of the model.  To this end literature values [75] for the thrombin 
kinetic constants (kcat = 61.3 s-1 and Km = 1.65 mM) were used with a calculated value of kr = 
kf.Km – kcat, assuming diffusion limited formation of the Michaelis complex (kf = 109 s-1M-1).  
The DynaFit program automatically derives the simultaneous equations from this model and 
solves them by a simultaneous non-linear regression fit of the experimental progress curve data 
to the model.   
 
The suitability for purpose of this analytical approach was first tested by fitting the reduced 
model (absence of prothrombin activator) by measuring thrombin activity with its specific 
chromogenic substrate, S-2238. 
Thrombin + S-2238                    Thrombin·S-2238                                    : kf kr 
Thrombin·S-2238                      Thrombin + pNA + Peptide                       : kcat   
 
The experimental pNA progress curves generated by known concentrations of thrombin from S-
2238 (Figure 12), were calculated using the literature values above for kf, kr and kcat.  The 
agreement between the experimental and fitted values for the thrombin concentrations (Table 4) 
validated this analytical approach, and the substitution of the literature values for the thrombin-S-
2238 rate constants in the model for determining the apparent rate constants for the activators 
(ka). 
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Figure 12.  Progress curve data (symbols) of pNA production from S-2238 by a range of 
thrombin concentrations (0.25 to 15 nM) fitted to the above model (red lines) by the DynaFit 
program using the specified literature values of the rate constants to give best fit estimates of the 
thrombin concentrations (Table 4). 
 
Table 4.  Comparison of experimental (initial) thrombin concentrations with the fitted estimates 
derived from the reduced model by the DynaFit program. 
 
Set Experimental 
Thrombin  
concentration 
(nM) 
Fitted 
Thrombin 
concentration 
(nM) 
CV % 
1 0.25 0.33  0.5 
2 0.75 0.96  0.2 
3 1.5 1.73  0.1 
4 2.5 2.93  0.1 
5 7.5 7.48  0.2 
6 15 14.7  0.3 
 
The results showed there was a good agreement between the experimental thrombin 
concentrations and those calculated by the DynaFit program (r2 0.999), and gave ka values for 
prothrombin activation by each of the six PAs. 
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In control experiments, there was no reaction between the different PAs and the thrombin 
substrate, S-2238 nor was there any reaction between the prothrombin solution and S-2238. The 
activation rate constants confirmed that the Group C PAs (PtPA and OsPA) were most potent in 
converting prothrombin to thrombin. In fact they generated 20 times more thrombin than ecarin 
and CA-2, more than 200 times than CA-1 and approximately 1000 times more than notecarin. 
As the experiment used PA preparations that were of different levels of purity these differences 
need to be interpreted with caution. Notecarin is an FXa only molecule. Without FVa to form a 
prothrombinase complex the prothrombin activation was very slow. The notecarin findings were 
in line with published findings, since prothrombin activation by FXa alone is an inefficient 
process [8, 76]. The experimental curves for each of the PAs and the estimated activation rate 
constants are shown in Figure 13.  The rates of thrombin generated were estimated from the 
experimental curves in Figure 13, and the activation rate constants calculated, Table 5.  
Table 5. Summary of the different prothrombin activators estimated activation rate constants and 
the thrombin generation rate.  
 
Activator Activation Rate Constant 
ka (s-1 M-1) 
Thrombin Generation Rate 
(nmol thrombin mL-1  min-1 mol-1 prothrombin 
mol-1 activator) 
PtPA 6.72 + 0.12 x 105 40.3 
OsPA 6.36 + 0.19 x 105 33.9 
Ecarin  4.61 + 0.06 x 104 2.76 
CA-1 3.94 + 0.12 x 103 0.24 
CA-2 3.18 + 0.06 x 104 1.91 
Notecarin 7.14 + 0.02 x 102 0.043 
 131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
 
 
 
 
 
 
 
 
 
Figure 13. Experimental curves at three concentrations of the PAs with the best curves (red 
lines) calculated by the DynaFit program. 
 
PtPA OsPA 
CA-1 Ecarin 
CA-2 Notecarin 
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3.3.2.3 Estimation of the amount of thrombin generated by PtPA and OsPA in normal 
citrate plasma that remained in the clot free component after clotting for five 
minutes with and without heparin 
OsPA and PtPA were shown by the earlier experiments to generate large amounts of thrombin, 
suggesting they may be useful procoagulants in blood collection tubes for serum preparation.  
This experiment provided an estimate of the amount of thrombin that remained in the clot free 
component of citrate plasma treated by different concentrations of the PAs, PtPA and OsPA. 
This thrombin remnant would be responsible for latent clots if fibrinogen was not completely 
consumed before the sample was centrifuged. Aliquots of OsPA and PtPA were added to citrate 
plasma. After five minutes, clots were removed and aliquots of plasma added to S-2238 in Hepes 
buffer to measure thrombin activity. The BD RST tube with different fill volumes was also 
evaluated to compare its amount of thrombin with that generated by prothrombin activators. The 
evaluation was also performed in the presence of different heparin concentrations (Sodium 
heparin, #PF_02112105, 5000 IU/5 mL, Pfizer, NZ). Figure 14 shows progress curves for S-
2238 hydrolysis.  
 
The initial slope of the reaction using the time range of 0-50 seconds was determined and the 
concentration of thrombin calculated from the standard curve in Figure 10. In control 
experiments, there was no reaction between the different PAs and the thrombin substrate, S-2238 
nor was there any reaction by heparin, and negligible reaction between the re-calcified citrate 
plasma and S-2238. Re-calcified plasma alone took ~37 minutes to clot at 23ºC.  
 
Clot formation at all concentrations of each PA was rapid; in less than one minute, a very solid 
clot formed and no latent clotting was observed up to 48 hours. This indicated that the fibrinogen 
in the sample was completely removed by all three concentrations of PtPA and OsPA in the five 
minutes incubation period. The amount of thrombin in the reaction mixtures was calculated and 
is shown in Table 6. 
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Figure 14. S-2238 hydrolysis by thrombin generated by three different PtPA and OsPA 
concentrations over a five minute period in normal citrate plasma. 
 
 
Table 6. The estimated thrombin concentrations post five minutes incubation with different 
PtPA and OsPA concentrations in the clot free component of citrate plasma from a normal 
participant. 
 
Estimated thrombin concentration 
(nM) in the clot free mixture (serum) 
Prothrombin activator 
concentration (nM) 
PtPA OsPA 
1.2 1.00 0.87 
1.2 0.87 0.70 
6.1 2.03 1.21 
6.1 1.94 1.30 
12.3 3.19 3.45 
12.3 3.49 3.45 
              
 
The results indicated that the amount of thrombin remaining in the clear component was low 
compared with the concentrations of thrombin formed from 247 nM of pure prothrombin at 155 
seconds by OsPA and PtPA (16.5 nM and 20.1 nM respectively. It is likely that most of the 
thrombin was removed during the clot removal as it would be entrapped in the fibrin clot mesh 
which is in line on what has been reported in literature [77, 78]. This experiment did not achieve 
its original objective (seeking to determine how much thrombin was generated in plasma by the 
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PA’s) but it did provide interesting information about the residual thrombin acitivity in serum 
after clot removal.  
 
The second experiment used normal pooled citrate plasma spiked with three different heparin 
concentrations. The results are shown in Figure 15 and Table 7.  
 
    
 
Figure 15. Reaction curves with different heparin concentrations using 1.5 nM of PtPA and 
OsPA. 
 
 
As expected, the sample without heparin clotted instantly, forming a very strong solid clot which 
was rather difficult to crush with the wood applicators. The samples containing 2 and 10 IU 
heparin clotted within two minutes and showed no latent clotting after 24 hours. The clots were 
less solid in these samples. The samples with 20 IU heparin clotted in three minutes and 
produced visually much weaker clots (more like those observed in the BD RST tube or with pure 
thrombin). The serum with 20 IU heparin formed a latent clot within five minutes of removal of 
the first clot, which indicated that not all the fibrinogen was removed. Even though heparin-
ATIII complex in plasma inhibits both human FX and thrombin [29] it was unable to prevent the 
PtPA and OsPA PAs from catalysing prothrombin to thrombin although the reaction was clearly 
slowed down at the higher heparin concentrations. Heparin may not affect the PtPA and OsPA 
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FXa as much as human FXa. The amount of thrombin generated must be sufficient to enable the 
clotting to go to completion as it did with both the 2 and 10 IU of heparin. Comparing the 
progress curves with zero and 2 IU of heparin it is clear that even 2 IU of heparin led to major 
decrease in thrombin activity remaining after five minutes. The thrombin generated to clot the 
plasma in the five minutes clotting time with the 20 IU of heparin was insufficient, and this led 
to latent clotting. To overcome latent clotting in samples containing very high heparin (e.g. 20 IU 
concentration) both higher PtPA or OsPA concentrations and longer clotting time must be 
considered in order for the amount of thrombin generated to overwhelm the ATIII-heparin 
complex and completely catalyse fibrinogen conversion to fibrin in the sample. The progress 
curves in the samples with 10 and 20 IU of heparin suggest there may have been thrombin 
precipitation in the buffer solution, resulting in light scattering. Clot strength will be studied in 
Chapter 4. 
 
Table 7. Estimated thrombin concentration after five minutes incubation of citrate plasma with 
1.5 nM PtPA and OsPA concentrations, with and without added heparin.  in the clot free 
component of citrate plasma from a pooled normal plasma. 
 
Estimated thrombin concentration  (nM) in the clot free aliquot in 
samples with different heparin concentration (IU/mL) 
PtPA and OsPA (1.5 nM) 
0 2  10 20 
PtPA 0.44 <0.1 2.03 3.10 
OsPA 0.36 <0.1 2.58 2.73 
 
The results indicated the amount of thrombin remaining in the clear component was low 
compared with the concentrations of thrombin formed from 247 nM of pure prothrombin at 155 
seconds by OsPA (16.5 nM) and PtPA (20.1 nM) respectively. It was likely most of the thrombin 
was removed during the clot removal as it would be entrapped in the clot fibrin mesh. Unlike the 
heparin free sample and the sample containing 2 IU of heparin, the plasma samples with the 10 
and 20 IU of heparin produced much looser clots. Th nature of the progress scurves with 10 and 
20 IU of heparin were unlikely to provide accurate thrombin concentrations.   
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Four different volumes (1, 2, 3 and 4 mL) of citrate plasma were added to BD RST tubes. After 
mechanical removal of the clots, the thrombin activities of aliquots of the solutions were 
measured. Results are shown in Figure 16, and the estimated thrombin in the clot free component 
is shown in Table 8.  
 
 
 
 
Figure 16. S-2238 hydrolysis by thrombin present in four different volumes of plasma in the BD 
RST tube over five minute period in normal citrated plasma. 
 
All four samples clotted within two minutes and there were no latent clotting for up to 24 hours. 
However the clot strength was visually lower than that observed in the citrate plasma samples 
containing PtPA and OsPA. 
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Table 8. The estimated thrombin after five minute incubation with different volumes of normal 
citrate plasma added to the BD RST tube.   
Volume of citrate 
plasma (mL) in BD 
RST tube 
Original thrombin concentration 
(nM) in BD RST tube  
Estimated thrombin (nM) in 
the clot free aliquot 
1.0 135 4.26 
2.0 67.5 1.41 
3.0 45 0.49 
4.0 33.8 0.31 
 
The results in Table 9 showed that the thrombin concentration remaining in the clot free 
component was very low compared with the thrombin specified as being present in the tube. This 
suggested the large majority of the thrombin was removed bound to fibrin in the clot. This result 
was consistent with results observed using OsPA and PtPA as procoagulants (Table 6 and 7). 
 
The experiment was repeated using citrate plasma spiked with 2, 10 or 20 IU of heparin. 
Progress curves of the residual thrombin activity after clot removal are shown in Figure 17, and 
estimates of thrombin concentration are shown in Table 9. None of the samples produced 
complete clotting in the presence of any of the three heparin concentrations. The strongest clot 
(although loose by comparison to the solid clots in the absence of heparin) as expected was 
observed with the samples containing 2 IU heparin and 1 mL of plasma. The clots formed were 
by far the weakest in the tube filled with 4 mL of citrate plasma containing 20 IU heparin. The 
clot was very loosely formed and only present in a very small part of the sample which suggested 
this was formed before the ATIII-heparin complex bound the thrombin. All tubes containing 
heparin showed latent clotting after five minutes.  The progress curve shapes with the heparin 
containing plasma were similar to the curves observed with PtPA and OsPA. Only the tubes 
using 2 IU of heparin in 1 mL or 4 mL gave linear plots and therefore reliable estimates of 
thrombin concentration. Simply the amount of thrombin in the tube was sufficient to provide 
complete clotting in plasma samples from healthy patients but not those with heparin.  
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Figure 17. Reaction curves with different heparin concentrations using 1 and 4 mL of citrate 
plasma in BD RST tube.  
 
 
Table 9. The estimated thrombin post five minutes incubation with different volumes of citrate 
plasma added to the BD RST tube in the clot free component of citrate plasma from a normal 
participant. 
 
Thrombin concentration (nM) in the clot free 
aliquot in samples with different heparin 
concentration (IU/mL) 
Volume of 
Citrate Plasma 
(mL) in BD 
RST Tube 
Original Thrombin 
Concentration (nM) in 
BD RST Tube 
0 2  10 20 
1 135 4.26 0.22 2.07 2.72 
4 33.7 0.31 <0.1 1.47 1.56 
 
Th nature of the progress scurves with 10 and 20 IU of heparin were unlikely to provide accurate 
thrombin concentrations.   
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3.3.3 Ability of venom prothrombin activators to clot FV- and FX- deficient plasmas 
This experiment was used to show whether any of the prothrombin activators depend on 
mammalian FV or FX for their plasma clotting activity. Clotting times for normal plasma and the 
two deficient plasmas are shown in Table 10.  
Table 10. The clotting results of the different prothrombin activators and thrombin with FV and 
FX-deficient plasmas compared to normal pooled citrated plasma.   
 
 Clotting Time (s) 
Procoagulant (30 nM) Normal pooled 
citrated plasma  
FV deficient plasma FX deficient plasma  
Ecarin 66.8 74.8 77.5 
CA-1 184 >300 >300 
CA-1 (100nM) ND 216 218 
CA-2 133 159 159 
OsPA 13.3 12.7 12.7 
PtPA 9.0 7.4 7.6 
Notecarin 47.5 >300 71.9 
Thrombin  13.8 44.6 50.2 
ND – not determined 
 
The results may be summarised as follows: 
• Ecarin results showed only a small increase in clotting time which was expected because 
the primary generation of thrombin is FVa and FXa independent. 
• CA-1 results showed that the clotting time increased significantly, almost doubled which 
was not expected as it depends on calcium but not on FVa or FXa. 
• CA-2 results showed that a small increase in clotting time which was expected because 
the primary generation of thrombin is FVa and FXa independent. 
• OsPA and PtPA results showed no change (if anything slightly decreased clotting time), 
and this was expected as they do not require human FVa or FXa. 
• Notecarin results showed that it did not clot the FVa deficient plasma in five minutes, this 
was expected since notecarin is dependent on human FVa, as it is a FXa like molecule 
and can form a hybrid prothrombinase complex. The absence of FXa increased the 
clotting time to a smaller extent. 
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• Thrombin results showed that clotting time was significantly increased, > 3 times longer 
in the plasma without FV or FXa. This increase suggests that in clotting of normal plasma 
additional plasma is formed by thrombin activation of FV, resulting in new 
prothrombinase complex.  
 
 
3.4  General Discussion
 
The prothrombinase complex either human, snake venom or hybrid combination of snake FXa 
(Group D) and human FV plays a pivotal role in coagulation of mammalian blood. Thrombin is 
the essential enzyme product of the blood coagulation enzymatic cascade. Rapid generation of 
large amount of thrombin is critical in achieving rapid and complete clotting of blood. The aims 
of the work were to determine which group of snake venom PAs was most suitable to further 
evaluate with the end outcome being the production of high quality serum in the shortest possible 
time. A second aim was to determine how much thrombin could be generated by a given 
concentration of prothrombin activator. 
 
The SDS-PAGE studies confirmed that the PA preparations contained the polypeptide chains 
(represented by bands on the gels) expected from the literature, but they also contained 
additional polypeptide, partial proteolytic degradation of PA components to the presence of 
impurities in the solutions or both. For identification of the various polypeptides, N-terminal 
sequencing of the SDS-PAGE bands would be required. The specific activities of the PAs in the 
plasma clotting assay provided a clear indication that the Group C PAs offered greatest potential. 
The prothrombin to thrombin conversion study (using purified prothrombin in buffer) by SDS-
PAGE demonstrated that these PAs were the most effective and efficient in converting most of 
the prothrombin to -thrombin. The large amount of thrombin generated in such a short time is 
the prerequisite for complete degradation of the fibrinogen in blood and plasma samples. 
Estimation of fibrinogen would be a useful marker for checking if the serum has fully clotted 
and, fibrinogen was fully consumed (see Chapter 6).  The high yields of 0.294 g and 0.128 g of 
PtPA and OsPA respectively from 1 g of dried venom indicates these venoms being a feasible 
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supply source as tube procoagulants. All these attributes indicated they could fulfill the main aim 
of this thesis, producing highest quality serum in the shortest possible time. It is easy to see why 
these snakes equipped with such potent prothrombinase complex are ranked as the deadliest 
snakes in the world [79], disabling pray in only a few minutes.  
 
The kinetic activity studies using S-2238 hydrolysis showed the amount of thrombin formed by 
the different PAs. The ka values re-affirmed the potential of the Group C PAs, with PtPA being 
slightly more effective than OsPA.  
 
The studies on residual thrombin in sera formed with PtPA, OsPA and thrombin (from the BD 
RST tube) after clot removal showed that it was not a good indication of the amount of thrombin 
formed. The experiments in the presence or absence of heparin were valuable in demonstrating if 
clotting was completed and provided an indication on the amount of Group C PAs that would be 
required (>1.5 nM, to clot samples containing high heparin (> 10 IU of heparin) concentrations. 
This concentration would be required to overcome the inhibitory ability of the ATIII-heparin 
complex which forms a strong 1:1 complex with thrombin [80]. The ATIII-heparin complex 
inhibits most of the serine proteases generated in the blood coagulation cascade, Chapter 1, 
Figure 2. In fact the thrombin inhibition by ATIII is accelerated by approximately four orders of 
magnitude in the presence of heparin of at least 18 residues (as used in the experiments in this 
study) and this binding is reversible [81]. Heparin itself has anti-FXa activity and its 
anticoagulant effect appears to increase disproportionately in intensity and duration as the dose is 
increased [82]. Results using thrombin from BD RST tubes indicated that the amount of 
thrombin added along with other compounds to aid the rapid clotting process was insufficient to 
clot samples containing  2 IU heparin. 
 
Results with the commercial plasmas deficient in FV or FX indicated that the Group C PAs 
(PtPA and OsPA) were independent of these two coagulation factors for their clotting efficiency. 
Whereas the Group A and B activators and thrombin itself were significantly aided by the 
presence of these factors in plasma. These experiments clearly confirmed that the Group D PA, 
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notecarin in the absence of mammalian FVa would be ineffective in these patients to produce 
suitable serum in a timely manner.   
Although FV deficiency is not very common, it is said to have prevalence in the general 
population of 1 in 1,000,000 in the homozygous form [83, 84]. Additionally in any major tissue 
injury human FVa is rapidly recruited at the injured tissue sites in an attempt to form a clot, plug 
thus in such clinical situations human FVa may be in low supply in circulating blood.  
 
Inherited FX deficiency is a rare autosomal recessive bleeding disorder that is estimated to occur 
in 1:500,000 - 1,000,000 individuals [85], and more common in countries like Iran, 1:200,000 
[86]. Acquired deficiency occurs in up to 5% of patients with amyloidosis as a result of 
adsorption into amyloid fibrils in the spleen [87]. FX deficiency has also been reported with 
cancer, infections and in burns [88]. The liver is the major organ for production of coagulation 
factors; hence it plays a major role in the mechanism of blood coagulation and homeostasis. 
Patients with liver disease may have severe coagulopathies, especially in severe liver disease. 
For example Koldas and Uras found prothrombin concentration to be 50% lower in patients with 
cirrhosis when compared with normal volunteers [4]. Thus low levels or absence of FV and FX 
will make notecarin and thrombin less effective as clotting agents for such samples. Decrease in 
prothrombin concentration is less likely to affect final clotting because its concentration is so 
high.  
 
It would be extremely rare that prothrombin would be at low enough concentration that sufficient 
thrombin could not be generated. However if prothrombin is low fibrinogen is likely to be low as 
well, as it too is synthesized in the liver. Patients with low prothrombin, chronic liver diseases 
[4] and high heparin doses present the greatest challenge. Prothrombin deficiency is amongst the 
rarest inherited coagulation disorders, with a prevalence of approximately 1:2,000,000, and no 
living patient with undetectable plasma prothrombin has been reported to date [89, 90]. It may be 
necessary to supplement these activators with additives for tubes to be used with such patients 
e.g. protamine, the heparin antidote.   
 
Although the purified prothrombin activators used in this study were not homogenous, very low 
concentrations were required to generate high quality serum. The true concentrations would be 
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somewhat less than the calculated concentrations used here, making the efficiencies even higher.  
The focus from here on will be on a more comprehensive evaluation of the Group C PAs testing 
their suitability as procoagulants as well as the BD RST tube and human thrombin with human 
plasma and whole blood (in Chapter 4). The BD RST tube will be extensively evaluated in 
Chapter 5 as alternative in a tertiary level hospital using normal and anticoagulated patient blood 
samples. Finally, in Chapter 6, selected PAs will be evaluated for their ability to rapidly produce 
rapidly high quality serum.  
 
  
3.5 Conclusion 
The study confirmed that at least some of the snake venom PAs were suitable procoagulants to 
further evaluate for serum generation in blood collection tubes. The Group C prothrombin 
activators, PtPA and OsPA offer a novel approach to generate rapid and high quality serum in a 
very short time. The great strength of these activators was not only that very small amounts were 
required (for normal and heparin anticoagulated samples) but also that they utilised the blood 
prothrombin which is present at a high concentration (~120 mg/L).  
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CHAPTER 4 
 
 
 
 
CLOTTING OF PLASMA AND 
BLOOD SAMPLES USING SNAKE 
VENOM PROTHROMBIN  
ACTIVATORS 
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4.1 Introduction 
In the previous chapter it was demonstrated that snake venom prothrombin activators efficiently 
generate thrombin from purified prothrombin and they clotted plasma very efficiently. The 
current procoagulants used in blood collection tubes to produce serum fail to meet laboratory 
needs to produce high quality serum from all patient samples, specifically from the growing 
number of anticoagulated patients (i.e. heparinised). To address this problem, BD launched a 
premium clotting tube in 2009, the BD RST tube which uses bovine thrombin (15 NIH) as the 
clotting accelerator [1]. This tube aims to clot blood samples rapidly, including anticoagulated 
samples within 5 minutes. Further evaluation of the BD RST tube is provided in this chapter and 
Chapter 5.   
Anticoagulation therapy is very effective for primary and secondary prevention of 
thromboembolic events. However, anticoagulation can lead to incomplete or delayed clotting of 
blood samples used to produce serum for biochemistry testing. Laboratories using serum as the 
sample of choice for biochemical testing regularly encounter latent clotting in samples collected 
from anticoagulated patients (patients on warfarin, heparin, citrate etc) or due to contamination 
from anticoagulant-containing blood tubes e.g. topping up in short collections, draw back when 
syringes are used to transfer blood into blood collection tubes, or flushing of taps with 
anticoagulants and not discarding the first few milliliters of blood containing the anticoagulant. 
The most recently published study estimates EDTA contamination was present in 0.46% of 
samples submitted for routine biochemical analysis [2]. 
Warfarin is the oral anticoagulant of choice. Warfarin affects the vitamin K dependent factors, II, 
VII, IX and X [3] by inhibiting the -carboxylation of serine protease zymogens. For example 
prothrombin contains 10 residues of -carboxyglutamic acid [4], which are required for efficient 
conversion to thrombin by the human prothrombinase complex.    
Blood from patients on warfarin therapy is monitored closely and regularly (daily or every 
second day) in the early stage when anticoagulation treatment commences or when there is a 
changeover form heparin to warfarin. It is necessary to adjust the dose of warfarin to bring the 
International Normalised Ratio (INR) into the therapeutic range of 2-3 units. In the early stages it 
is not unusual to observe INR that exceed 5 units. Blood samples from patients with INR of 5 or 
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higher present with incomplete clotting or latent clotting problems in serum samples. 
Additionally, warfarin levels may vary with patients’ (or carers’) ability to self-medicate and 
monitor levels. Over-anticoagulation may lead to major bleeding, which includes intracranial 
haemorrhage and bleeding leading to death or hospitalisation, and has been reported to occur in 
1.2%–8.1% of patients during each year of long-term warfarin therapy [5, 6].  
Heparin is the intravenous or subcutaneous anticoagulant of choice and is mostly administered in 
a hospital environment. Heparin exerts its anticoagulant effect primarily through interaction with 
ATIII to form a complex which is a potent inhibitor of thrombin and FXa. High molecular 
weight heparin is more effective in inhibiting thrombin whereas low molecular weight heparins 
are more effective in inhibiting FXa [7, 8].  Kidney dialysis patients regularly receive high doses 
of heparin. They can receive in excess of 10000 IU of heparin during the dialysis. In general they 
receive a bolus which could be 22-46 IU/kg and continuous top up to maintain suitable 
anticoagulation right up to 30 minutes prior to stopping dialysis [9]. The other large group of 
patients on higher doses of heparin is cardiac patients (myocardial infarct patients) to prevent 
coronary rethrombosis and undesirable outcomes.  The usual dose of heparin is an intravenous 
bolus infusion (5,000 IU) when commencing alteplase, continuing for 48 hours at an initial rate 
of 1,000 IU/h, titrated to maintain a target APTT ratio of 1.5-2.0 [10]. There are many other 
clinical situations where patients receive heparin infusion including those that undergo 
catheterization for sampling such as inferior petrosal sinus sampling, parathyroid hormone 
sampling etc.  
Cardiac surgery patients receive the highest doses of heparin, 300 IU/kg when they are put on 
cardiopulmonary bypass [11]. The other patients that receive these levels of heparin are organ 
donors prior to organ harvesting [12]. Additionally cardiac patients are haemodiluted during the 
surgery to ensure blood flows more easily through the extracorporeal circuit. This means all the 
coagulation components (fibrinogen, platelets etc) are at low concentrations. In fact fibrinogen is 
usually <2.5 g/L in these patients during the surgical procedure. As well they receive other 
medication that may diminish coagulation factor efficacy. The heparin is used to prevent blood 
clotting on contact with the surface of the extracorporeal circuit. The patients are also 
hypothermic (normally the operation is performed at a body temperature ~33ºC) which is 
induced to reduce neuronal damage but leads to functional platelet impairment that is 
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proportional to the degree of hypothermia. The number of platelets and their function are also 
altered by cellular trauma induced by oxygenators, roller pumps and pump suction devices [11, 
12].  
Despite its potent anticoagulation effects, there are limitations associated with heparin, including 
a relatively short half-life (high molecular weight 30-90 minutes, low molecular weight 3-6 hrs) 
after IV injection, unpredictable pharmacokinetics with subcutaneous administration, 
hypersensitivity, and heparin-induced thrombocytopenia (HIT) [13]. HIT develops in 1-3% of 
cardiac surgery patients and ~5% of orthopaedic patients [14]. Furthermore the efficacy of 
heparin may be reduced when ATIII activity is low (<60%) [14]. Acquired ATIII deficiency is 
observed in 1-20% of patients presenting for cardiac surgery and is particularly common in 
individuals receiving preoperative heparin therapy. This is because heparin increases the rate of 
ATIII turnover [14, 15]. Thus alternative anticoagulants need to be used in such patients. These 
includes other new thrombin inhibiting anticoagulants (e.g. desirudin), FXa inhibitors (e.g. 
rivaroxaban), and the divalent cation chelator, citrate. 
 
Rivaroxaban is an oral anticoagulant taken once daily. It binds selectively to the active site of 
FXa regardless of whether FXa is free or bound within the prothrombinase complex [16]. It is 
rapidly absorbed and achieves maximum plasma anticoagulant effect within 1-4 hours [17]. It 
inhibits FXa in a competitive and reversible manner [18]. It was introduced to prevent venous 
thromboembolism in adult patients undergoing elective hip or knee replacement surgery several 
years ago. It is in advanced clinical trials for the treatment of thromboembolic disorders, deep 
vein thrombosis and atrial fibrillation. Unlike warfarin, it does not appear there will be stringent 
requirements for frequent monitoring, nor are dietary restrictions necessary [19].  
 
 
Citrate is becoming an alternative anticoagulant to heparin in critically ill patients at risk of 
bleeding and requiring dialysis [20, 21]. This anticoagulation procedure tends to be confined to 
specialized clinical units, such as intensive care, where the ability to monitor ionized calcium is 
essential as citrate chelates divalent cations, most specifically calcium, which in turn requires 
regular replenishment. 
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For a procoagulant present in a blood collection tube to be able to produce high quality serum 
rapidly from all patient samples, it must be able to coagulate blood containing the various 
anticoagulants discussed above at therapeutic concentrations. In this chapter the snake venom 
PAs studied in Chapter 3 have been evaluated as suitable procoagulants along with human 
thrombin alone and bovine thrombin in the BD RST tube. Evaluation was performed on both 
plasma (using the Clotek analyser) to obtain the plasma clotting time (approximately equating to 
prothrombin time), and whole blood using a thromboelastograph (TEG) analyser. 
Thrombelastography technology is utilized to evaluate the viscoelastic properties of blood 
samples during the coagulation process, and provides a graphical representation from the onset 
of fibrin formation through platelet aggregation to fibrinolysis. This technology is used to 
provide comprehensive clinical assessment of coagulation instead of evaluating only discrete 
portions of the coagulation cascade. It is used in assessment of bleeding and thrombotic 
conditions, for monitoring of haemostasis of coagulation and to guide management of blood 
transfusion needs during major surgical interventions, foremost in liver transplant, cardiovascular 
surgery, and to a lesser extent in trauma, neurosurgery, postpartum haemorrhage etc [22-25].  
TEG results can assist with decisions on which and how much of a blood product to transfuse, 
and reduce the need for transfusions and risks from immune-reactivity [26]. It has been 
demonstrated that the TEG data provide a better indicator of hypercoagulable state after injury 
than prothrombin time or activated partial thromboplastin time [27], providing details on clot 
formation and strength etc. Very recently Lang et al using a rotational thromboelastometry 
(ROTEM) have shown that clot strength increases in a fibrinogen concentration dependent 
manner independent of platelet count as demonstrated in Figure 1 [28]. Other studies using 
ROTEM have shown that fibrinogen concentrate can improve clotting in thrombocytopaenia [29] 
and it is used in treatment of excessive bleeding during surgery [30].     
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TEG studies have been performed using fresh native or anticoagulated whole blood and re-
calcified citrated plasma. However fresh native whole blood has been shown to produce most 
reliable TEG results provided it is analysed within a short time, < 6 minutes post venous 
collection [22, 31]. Camerzind et al recommend citrated blood should be stored at least one hour 
and a maximum eight hours for accurate results [22].  
 
 
TEG analysis has been used as a direct test for early recognition of snake envenomation in 
children, and as an indication of the severity of the condition [32].  Dambisya used TEG to study 
how snake venom affected coagulation using the venom from Calloselasma rhodostoma 
(Malaysian pit viper) [33]. The same author also studied the anticoagulant ability of Pseudechis 
australis (King Brown snake) venom, which was shown to prolong clot formation in a dose 
dependent relationship [34]. In this study TEG was used to characterise clot formation by the 
snake venom procoagulants with the various blood and plasma sample types.  
Figure 1. The relationship between 
platelets and fibrinogen during 
blood clotting. Panel A, normal 
clot firmness is generated by 
normal levels of platelet (open 
circles) and fibrin(ogen) (black 
lines); Panel B, reduced clot 
firmness is observed when platelet 
and fibrin(ogen) levels are 
reduced; Panel C, clot firmness is 
restored by increased fibrin 
interaction in the presence of fewer 
platelets [28]. 
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Clotting effectiveness has been evaluated at a range of concentrations of the different snake 
venom procoagulants with various samples from healthy volunteers and from patients being 
treated with different anticoagulants (warfarin, heparin, and citrate), and samples spiked with 
heparin, and rivaroxaban. Evaluation also involved samples collected in blood collection tubes 
with different anticoagulants (lithium heparin, citrate, and EDTA), and from patients with low 
platelet counts. The most important criteria for these compounds as procoagulants are the speed 
and completeness of clotting. Being able to completely clot blood in < 5 minutes from healthy 
and anticoagulated patients would provide biochemical laboratories the ability to standardise on 
serum as the preferred sample type for all patients and in all laboratories with equivalent turn-
around times to lithium heparin plasma. 
 
4.2 Materials and Methods 
4.2.1 Clotek Analyser 
For the Clotek analyser (Hyland, USA), refer to Chapter 3.   
 
4.2.2 Thromboelastograph Analyser 
Thromboelastography studies were performed using a Thrombelastograph® 5000 (TEG®, 
Haemscope Corporation, Niles, IL, USA) with TEG Analytical Software version 4. The main 
parameters of clot formation that are measured on the TEG (Figure 2) are:  
R - (r) reaction time (s): time from the start of the analysis until the TEG tracing amplitude 
reaches 2 mm, indicating detectable clot formation. It may be prolonged as a result of 
coagulation factor deficiencies or due to anticoagulation (heparin) therapy or severe 
hypofibrinogenaemia.  A small R value may be present in hypercoagulability syndromes (Figure 
3). 
K – time (s): time from the start of the clot formation to the time the curve reaches amplitude of 
20 mm (indicates the clot formation kinetics). It is a measure of the speed to reach a specific 
level of clot strength or viscoelasticity, as a result of fibrin build-up and cross-linking. It is 
affected by concentration of fibrinogen and platelets, and sometimes referred to as the 
coagulation time.   
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MA - maximum amplitude (mm): maximum strength of the clot. It is a direct measure of the 
highest point on the TEG curve and represents clot strength. The MA is dependent on platelet 
concentration and function. A low MA may indicate reduced platelet function, and platelet 
concentrates may be appropriate.  
TMA – time (s): time from start of the analysis until MA is reached. 
α  (degree) - the angle between the baseline and the tangent to the TEG trace through the starting 
point of coagulation. A reduced α angle may indicate shortage of fibrinogen.   
Ly30 – measures the fibrinolysis during the first 30 minutes after MA. 
The R time, MA and TMA will be used in describing clot formation. 
  
The sample volume is 340 L. The cup is heated to 37ºC. A stationary pin attached to a wire 
which can monitor movements, is immersed in the sample. The pin oscillates 4º45’ in either 
direction, back and forth every 4.5 s. Clot formation influences the oscillation of the pin, and 
these dynamic changes are captured in a plot or curve or trace generated.  
 
 
Figure 2. Example of a TEG trace with labelled clotting 
parameters.  
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Figure 3. TEG tracings: A- normal trace with parameters; B-hyper and hypocoagulable tracings 
[35].  
 
4.2.3 Blood and plasma samples 
The study was performed at the PAH, Brisbane, Australia with appropriate ethics approval from 
the hospital and The University of Queensland, and with informed consent from volunteers.  
 
Haematology Department at the PAH, Pathology Queensland was the predominant source of 
citrate blood or plasma collected in Greiner citrate tubes, 3.2% (Cat No 454327, Greiner, 
Austria). Normal samples were selected based on having coagulation parameters within 
reference intervals. Citrate plasma from warfarin medicated patients (confirmed by the clinical 
unit) was defined by the coagulation profile, INR specifically. No patient identity was required 
beyond this point; the samples were arbitrarily numbered for the study. Blood samples from 
healthy participants were obtained in Greiner citrate, EDTA and lithium heparin tubes.  
 
Blood samples for native blood studies were collected from a healthy participant (author) in a 
plain syringe (Terumo 10 mL #CE0197) via a 21G butterfly needle inserted in the antecubital 
vein, and then transferred within 60-90 seconds into the appropriate commercial serum tubes 
which were filled to the fill mark and mixed for 30 seconds by inversion 10 times.  
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 EDTA and lithium heparin blood and plasma were obtained from a healthy participant (author) 
in Greiner tubes (EDTA 1.5-2.2 mg/mL # 454023; lithium heparin #456083 containing 90 IU 
heparin). Fully heparinised blood samples were obtained from participants undergoing cardiac 
surgery and, after going on cardiopulmonary bypass, from a bypass port. The samples were 
collected 30 minutes after heparinisation in 50 mL plain syringes (BD Plastipak REF #300866). 
The syringes were delivered to the laboratory within 15 minutes post collection.  
 
All samples were centrifuged in a swing-out bucket rotor centrifuge for 10 minutes at 3000g and 
20ºC (Hereaus 1-RS, Germany). 
 
4.2.4 Prothrombin activator preparations 
The stock prothrombin activator solutions as prepared in Chapter 3 were: 
- Ecarin - 1.15 mg/mL (19.2 M); 
- CA-1 – 1.33 mg/mL (22.1 M); 
- CA-2 – 0.34 mg/mL (5.6 M); 
- OsPA – 1.09 mg/mL (4.3 M); 
- PtPA - 4.8 mg/mL (19.2 M); and 
- Notecarin – 1.07 mg/mL (17.9 M). 
 
The working solutions were prepared in distilled water. For their respective clotting activities 
refer to Table 2, Chapter3. The buffer used for the plasma clotting studies was 150 mM Tris HCl, 
150 mM NaCl, pH 7.4. The calcium solution was 0.2 M CaCl2. 
 
 
4.3   Results and Discussion 
4.3.1 Clotting of normal pooled citrate blood and plasma 
This experiment was intended to provide the concentration ranges that would be required for each  
PA to clot normal pooled citrate plasma in a suitable time and then whole blood, as a guide to  
optimise the concentration for further studies. The Clotek tube contained 100 L of normal pooled  
citrate plasma, 100 L of Tris Buffer (150 mM Tris HCl, 150 mM NaCl, pH 7.4), 50 L 0.2 M  
CaCl2, and 50 L of procoagulant. The TEG cup contained 20 L  
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0.2 M CaCl2, 60 L PA and 260 L pooled citrate blood. The clotting results for each  
procoagulant with the normal pooled citrate plasma (with and without re-calcification) are  
shown in Table 1.  
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Table 1. Clotting times with normal pooled citrate plasma and the different PAs and thrombin at different concentrations with and 
without calcium. 
With added Ca2+ (sec)  Without added Ca2+ (sec)   Prothrombin 
Activator 
conc (nM)  
Ecarin CA-1 CA-2 PtPA OsPA Notecarin Thrombin Ecarin CA-1 CA-2 PtPA OsPA Notecarin Thrombin  
100 43.0 108 65.8 3.5 5.7 42.4 4.3 94.0 >300 216 3.9 7.3 51.7 5.6 
50 56.0 145 85.0 4.6 6.5 52.8 6.7 129 >300 >300 5.0 8.2 67.6 9.2 
30 69.0 181 167 4.9 7.9 57.5 10.5 167 >300 >300 6.1 8.9 76.7 14.6 
10 105 >300 >300 12.5 12.5 68.5 32.8 >300 >300 >300 9.0 14.0 115 43.6 
3 208 >300 >300 20.1 18.3 99.8 92.3 >300 >300 >300 15.5 21.5 250 145 
1 >300 >300 >300 61 30.0 144 >300 >300 >300 >300 24.6 34.5 >300 >300 
0.1 >300 >300 >300 120 108 284 ND >300 >300 >300 93.0 152 >300 ND 
0.01 >300 >300 >300 212 >300 >300 ND >300 >300 >300 >300 >300 >300 ND 
0.001 >300 >300 >300 >300 >300 >300 ND >300 >300 >300 >300 >300 >300 ND 
 
ND – not determined 
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Although citrate plasma is not completely calcium depleted, the total calcium concentration in 
normal citrate plasma is ~1.3 mmol/L and the ionised calcium concentration is unmeasurable (< 
0.25 mmol/L) on a blood gas analyser (Siemens Rapidlab 1265, Siemens, UK). Citrate binds 
calcium and free calcium is not readily available to be used for clot formation. Calcium is part of 
the prothrombinase complex and is essential for efficient prothrombin to thrombin conversion. 
Citrate binds more than calcium: it also binds magnesium, zinc and other divalent metal ions. 
The amount of citrate present in the blood collection tube, 0.109 mol/L is more than sufficient to 
chelate all the metal ions in the sample. The results showed that ecarin, the Group A PA, in the 
presence of added calcium was more than twice as effective in clotting the plasma. The Group B 
PAs, CA-1 and CA-2 activity decreased ~4-fold by the absence of calcium, confirming that 
calcium was required for effective clotting activity. Notecarin, the Group D PA was stimulated 
by the presence of added calcium, and the requirement for calcium was most evident with the 
decrease in the notecarin concentration. The addition of calcium increased its effectiveness by 
~30%. Thrombin itself was affected to a smaller degree by the absence of the added calcium. 
Thrombin generates additional thrombin from prothrombin in the sample via the coagulation 
cascade catalysed by the plasma prothrombinase which requires calcium. Thus the decreased 
clotting time with added calcium reflects the extent of additional thrombin formed. The data 
showed that the Group C PAs (PtPA and OsPA) were the most efficient in clotting the normal 
pooled citrate plasma both in the presence or absence of added calcium. In fact the absence of 
calcium made minimal difference to the clotting ability of these two procoagulants.  
 
With and without the presence of added calcium the two Group C PAs required ~0.1 nM 
concentration to achieve clotting in < 5 minutes. The lowest concentration range achieving a 
clotting time of < 5 minutes (300 seconds) for each PA was then selected to perform the whole 
blood clotting studies as shown in Figure 4 and Table 2. The clotting time showed 3 nM 
concentration of thrombin produced approximately the same clotting time as 0.1 nM 
concentrations of OsPA or PtPA, making them 30 times more efficient.  
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Table 2. Results of the TEG clotting study with normal pooled re-calcified citrate blood with the 
different PAs.  
Procoagulant (nM) R (min) MA (mm) TMA (min) 
Ecarin     
32 (black) 1.2 60.5 18.2 
9 (green) 2.2 61.6 20.1 
3.2 (pink) 3.4 59.0 21.6 
0.9 (brown) 6.5 59.5 29.7 
Carinactivase - 1     
50 (black) 3.3 69.1 21.7 
32 (green) 4.6 68.5 27.1 
9 (pink) 6.2 63.9 31.4 
3.2 (brown) 7.4 64.9 30.3 
Carinactivase - 2  
50 (black) 1.8 64.9 19.9 
32 (green) 2.1 68.2 20.0 
9 (pink) 3.3 67.8 19.7 
3.2 (brown) 4.6 68.0 23.6 
OsPA  
0.9 (black) 0.7 63.7 18.4 
0.09 (green) 2.9 61.8 20.5 
0.009 (pink) 4.2 63.5 22.5 
0.0009 (brown) 6.2 59.3 24.8 
PtPA  
0.9 (black) 1.5 62.4 22.1 
0.09 (green) 2.6 63.1 23.6 
0.009 (pink) 3.9 63.9 24.8 
0.0009 (brown) 5.8 53.4 28.1 
Notecarin  
3.2 (black) 1.2 62.1 20.2 
0.9 (green) 1.8 63.7 18.3 
0.09 (pink) 3.7 63.2 20.3 
0.009 (brown) 7.3 59.0 26.3 
Thrombin  
32 (black) 2.3 65.2 22.8 
9 (green) 3.5 64.0 23.8 
3.2 (pink) 5.5 62.4 27.6 
BD RST    
24 (green)    
6 (black)    
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Figure 4. TEG traces of normal pooled re-calcified citrate blood with the different PAs. The 
colour code showing concentrations of PA is given in Table 2.  
 
 
 
The results of the TEG studies further support the plasma clotting findings that the Group C PAs 
(PtPA and OsPA) were the most effective in clotting the normal pooled re-calcified citrated 
whole blood. For example 9 pM PtPA and OsPA achieved an R time of < 5 minutes, and the 
maximum clot strength as confirmed by the MA results. The second most effective was 
notecarin, the Group D PA which was able to produce the desired R time and maximum clot 
strength with a minimum concentration between 0.09 and 0.009 nM. Notecarin generates snall 
amount of thrombin which in turn produces active FVa from the plasma, leading to the formation 
of the hybrid prothrombinase complex. This was followed by ecarin, the Group A PA which was 
able to achieve the desired R time and maximum clot strength with a minimum concentration 
Notecarin  
Thrombin 
PtPA  OsPA  
Ecarin  CA - 1  CA - 2  
BD RST  
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between 0.9 and 3.2 nM. The least effective were the Group B PAs, CA-1 and CA-2 which 
required between  9 and  3 nM concentrations respectively to achieve R times of < 5 minutes 
and maximum clot strength. The required minimum thrombin concentration to achieve the 
desired R time and maximum clot strength was  3 nM compared with < 0.01 nM of OsPA or 
PtPA. This 30-fold greater efficiency of OsPA and PtPA over thrombin, also found in plasma 
clotting (Table 1) is consistent with the production of many thrombin molecules from 
prothrombin for each molecule of PA. 
 
4.3.2 Clotting of blood and plasma in Greiner lithium heparin tubes from a healthy 
participant  
Samples collected in lithium heparin tubes are likely to be the most heparinised samples a 
laboratory will receive, particularly if the tubes are filled below the recommended fill volume. 
This experiment was to provide a guide to the minimum concentration required of the PAs to 
clot samples that may be received from heparin anticoagulated patients and produce high quality 
serum. Greiner lithium heparin tubes were filled to the recommended fill mark, giving a heparin 
concentration of 18 IU/mL and these tubes were centrifuged by standard protocols to give 
lithium heparin plasma. The Clotek tubes contained 100 L of lithium heparin plasma, 100 L of 
Tris Buffer (150 mM Tris HCl, 150 mM NaCl, pH 7.4) and 50 L of procoagulant. The TEG 
cups contained 60 L PA and 260 L of the participant blood collected in a Greiner lithium 
heparin tube.    
 
For the BD RST tube, deionised water was added to two tubes (BD RST1- 1 mL; BD RST2 - 4 
mL), allowed to mix on a roller for 30 minutes to dissolve the thrombin and the content was used 
as with the other procoagulants.   
 
The clotting results of each procoagulant with the lithium heparin plasma are shown in Table 3, 
and the lithium heparin whole blood results are shown in Figure 5 and Table 4 respectively.  
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Table 3. Clotting study with lithium heparin plasma collected in Greiner Lithium Heparin Tube.     
Clotting Time (s) Prothrombin 
Activator 
conc (nM)  
Ecarin CA-1 CA-2 PtPA OsPA Notecarin Thrombin 
120 69.0 >300 100.1 7.5 15.6 47.8 >300 
60 122.6 >300 180.3 10.7 18.1 62.7 >300 
36 175.2  270.6 13.1 21.0 82.4 >300 
12 >300  >300 32.7 37.1 269.3  
4 >300  >300 78.5 102.1 >300  
1 >300  >300 207.8 >300 >300  
0.1 >300  >300 >300 >300   
0.01 >300  >300 >300 >300   
        
 
The first experiment was designed to show the effectiveness of the venom PAs in clotting 
heparinised plasma from blood collection tubes. The minimum concentrations to achieve a 
clotting time of < 5 minutes were: ecarin ~36 nM, CA-1 > 120 nM, CA-2 ~36 nM, OsPA 1-4 
nM, PtPA ~1 nM, notecarin ~12 nM and thrombin > 120 nM. The BD RST tube content was 
tested as well with 6 and 25 nM thrombin. It should be noted these concentrations are 
considerably lower than those present in BD RST tubes after addition of 4 mL of blood (135 
nM). Both concentrations produced clotting times > 5 minutes. The results showed the Group C 
PAs (PtPA and OsPA) were easily the most effective in clotting the lithium heparin plasma 
obtained from blood of a healthy participant collected in Greiner lithium heparin tubes, requiring 
between 0.1 and 1 nM PtPA and between 1 and 4 nM OsPA respectively to achieve clotting in < 
5 minutes. 
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Table 4. Results of the TEG clotting study with blood collected in Greiner lithium heparin tube 
from a healthy participant.  
Procoagulant (nM) R (min) MA (mm) TMA (min) 
Ecarin  
56 (black) 9.9 18.8 37.8 
32 (green) 13.8 18.6 39.8 
Carinactivase - 1  
100 (black)  35.6* ND ND 
50 (green) 34.8* ND ND 
Carinactivase - 2  
56 (black) 10.4 23.0 37.8 
34 (green) 18.0 18.5 47.5 
OsPA (nM) 
56 (magenta) 1.9 37.6 24.7 
34 (pink) 2.3 36.5 26.1 
9 (green) 2.9 29.8 25.2 
3 (black) 10.3 6.2 20.0 
PtPA 
56 (magenta) 2.3 33.5 26.6 
34 (brown) 2.3 39.8 27.2 
9 (green) 2.8 31.3 25.7 
3 (black) 6.8 14.7 25.8 
Notecarin  
56 (black) 2.5 34.1 30.7 
32 (green) 7.9 18.0 28.4 
BD RST  
25 (black) 35.6* ND ND 
6   (green) 35.8* ND ND 
Re-calcified citrate blood  
Run 1 6.3 61.2 30.1 
Run 2  6.5 61.5 27.1 
*stopped measurement; ND – not determined    
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Figure 5. TEG traces of blood collected in Greiner lithium heparin tubes, (18 IU heparin per mL 
of blood) with the different PAs. The citrate sample was collected for the comparison of the MA 
values.  The colour code showing concentrations of PAs is given in Table 4. 
 
 
Ecarin  
CA-1 
CA-2 
OsPA PtPA 
Notecarin  
BD RST 
Re-calcified 
citrate blood 
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This experiment with lithium heparin whole blood showed that some of the PAs were capable of 
clotting the heparinised blood while other PAs were unable to clot the blood even at the highest 
concentration range tested in the experiment. The results support the lithium heparin plasma 
findings that the Group C PAs (PtPA and OsPA) were the most effective in clotting the blood 
collected in Greiner lithium heparin tubes, requiring  9 nM for OsPA and PtPA to achieve R 
time within five minutes. However, the MAs were < 40, significantly lower than the MAs (~61) 
achieved in the re-calcified citrate blood. It is probable that the ATIII-heparin complex inhibited 
most of the thrombin formed, and subsequently prevented strong clot formation e.g. by limiting 
activation by Factor XIII. Decreased thrombin concentration has been shown to produce weaker 
clots [36]. The next best PA was notecarin, while ecarin and CA-2 achieved partial clotting at 
higher concentrations. The thrombin concentrations of 6 and 25 nM from the BD RST tubes 
failed to clot the blood at all. The Group C PAs (OsPA and PtPA) were able to produce a much 
larger burst of thrombin to overwhelm the ATIII-heparin complex that inhibits both thrombin 
and FXa and subsequently the clotting process.  
 
 
4.3.3 Clotting of normal pooled citrate plasma spiked with different concentrations of 
heparin   
This experiment was performed to determine the required concentrations of the different PAs to 
clot plasma spiked with heparin at different concentrations to mimic levels likely to be found in 
plasma from heparinised patients.  
 
Normal pooled citrate plasma had its total calcium adjusted to 2.71 mmol/L and then aliquots of 
sodium heparin (Sodium heparin, #PF_02112105, 5000 IU/5 mL, Pfizer, NZ) were added to give 
final heparin concentrations in the Clotek tube of 0.8, 2.0, 10 and 20 IU/mL which are the range 
that may be encountered in patient blood samples. Additionally 1 mL aliquots of the citrate 
plasma were dispensed in Greiner lithium heparin tubes, and then mixed on a roller for 15 
minutes to give a lithium heparin concentration of 90 IU/mL. The Clotek tubes contained 100 L 
of sodium or lithium heparin plasma, 100 L of Tris Buffer (150 mM Tris HCl, 150 mM NaCl, 
pH 7.4) and 50 L of procoagulant.  
 
The clotting results from each PA with the heparin spiked plasma samples are shown in Table 5.  
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Table 5. Clotting of normal pooled citrate plasma spiked with heparin or dispensed in Greiner 
lithium heparin tubes.   
Heparin  
(IU/mL) 
Thrombin (nM)/Clotting Time (sec) 
 100 60 30 10 
0 5.1 7.0 13.5 24.7 
0.8 23.2 >300 >300 >300 
2.0 >300 >300 >300 >300 
10 >300 >300 >300 >300 
20 >300 >300 >300 >300 
90 (Greiner 
Li Hep tube) 
>300 >300 >300 >300 
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Table 5 continued. Clotting of normal pooled citrated plasma spiked with heparin or dispensed in Greiner lithium heparin tubes.   
PtPA (nM)/Clotting Time (sec) OsPA(nM)//Clotting Time (sec) Notecarin (nM)/Clotting 
Time (sec) 
Heparin  
(IU/mL) 
120 
nM 
 
60 
nM 
36 
nM 
30 
nM 
20 
nM 
12 
nM 
120 
nM 
 
60 
nM 
36 
nM 
30 
nM 
20 
nM 
12 
nM 
120 
nM 
 
60 
nM 
36 
nM 
12 
nM 
0 3.3 4.3 5.2 5.5 6.4 10.1 6.9 7.2 8.3 8.6 8.9 9.4 44.3 55.1 61.6 87.0 
0.8 3.5 5.3 7.4 7.6 10.4 14.0 9.1 10.8 12.9 13.7 16.4 21.7 49.8 65.0 78.3 126 
2.0 6.2 9.8 12.7 15.7 16.6 26.5 13.8 15.2 17.6 19.1 22.6 27.9 57.0 92.2 129 262 
10 25.3 39.1 46.1 60.2 72.3 142 27.3 35.2 49.2 56.5 86.1 270 >300 >300 >300 >300 
20 38.0 47.2 68.2 80.6 232 >300 93.9 120 >300 >300 >300 >300 >300 >300 >300 >300 
90 (Greiner Li 
Hep tube)  
17.4 27.7 53.7 69.5 228 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 
 
 
Ecarin (nM)/Clotting Time (secs) CA-1(nM)//Clotting Time (secs) CA-2 (nM)/Clotting Time (secs) Heparin  
(IU/mL) 120 nM 
 
60 nM 36 nM 12 nM 120 nM 
 
60 nM 36 nM 12 nM 120 nM 
 
60 nM 36 nM 12 nM 
0 28.5 40.0 49.3 92.3 170 258 >300 >300 80.6 120 168 267 
0.8 30.1 41.3 51.8 109 215 297 >300 >300 87.8 126 181 >300 
2.0 33.1 50.9 70.7 156.6 >300 >300 >300 >300 130 230 >300 >300 
10 75.7 142 269 >300 >300 >300 >300 >300 >300 >300 >300 >300 
20 140 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 
90 (Greiner Li 
Hep tube)  
>300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 >300 
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As was shown in the previous experiment the presence of heparin presents a major challenge for 
PAs in ensuring blood is completely clotted. This experiment showed the relative effectiveness 
of the PAs in clotting of heparinised plasma. As in the previous experiment the data showed 
PtPA and OsPA were the most effective PAs in overcoming the anticoagulant effect of heparin. 
PtPA required the lowest concentration (12-20 nM) to clot plasma containing the highest heparin 
concentrations that may be encountered in patient samples. The results also showed that heparin 
prolonged clotting by all of the PAs, as expected since they function by generating thrombin 
which is known to be inactivated by heparin-ATIII. One interesting finding was that PtPA was 
able to effectively clot the heparinised plasma from the Greiner lithium heparin tube in < 5 
minutes with all but the lowest PtPA concentration of 12 nM even though the heparin 
concentration was 90 IU/mL compared with the spiked sample containing 20 IU/mL heparin. It 
is possible that clotting by PtPA was aided by the surfactant contained in the Greiner lithium 
heparin tube. OsPA required > 36 nM and ecarin > 60 nM to be able to clot the plasma 
containing 20 IU of heparin, and both were unable to clot the heparinised plasma from the 
Greiner lithium heparin tube in < 5 minutes respectively. CA-2 and notecarin were unable to clot 
the plasma containing  10 IU of heparin while the CA-1 was unable to clot the plasma 
containing > 0.8 IU of heparin in the pre-requisite time of < 5 minutes even when the 
concentration was 120 nM. The thrombin study showed that a thrombin concentration of 100 nM 
was needed to clot the sample spiked with the lowest heparin concentration, 0.8 IU/mL. Thus 
when considering the BD RST tube which contains 135 to 34 nM bovine thrombin (1 to 4 mL fill 
volume) it is unlikely to clot samples containing heparin >2 IU/mL in the prerequisite time of 
five minutes. This confirmed the findings in Chapter 3 that thrombin and other additives present 
in the BD RST tube are unable to clot even moderately heparinised samples. 
 
4.3.4 Clotting of blood and plasma obtained from a “fully heparinised” cardiac surgery 
participant  
The highest concentration of heparin given intravenously is in complex surgical procedures such 
as cardiac surgery. This experiment was designed to determine whether the selected PA 
concentrations were able to clot “fully heparinised” cardiac surgery patient blood and produce 
high quality serum.  The participant had received 37000 IU of heparin and the sample was 
collected ~30 minutes post heparin infusion, equating to ~9.3 IU of heparin per mL of plasma.  If 
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samples are collected for biochemistry during the maximum heparinisation period the results 
usually need to be provided in the shortest possible time. This will preferably require the clotting 
to be completed by the procoagulant by the time these serum samples arrive in the laboratory, 
usually < 10 minutes. The heparin given to patients is sodium heparin while in blood collection 
tubes or syringes it is lithium heparin. The maximum amount of heparin infused in such patients 
is ~45000 IU. These patients are also haemodiluted i.e. there is an increase in blood plasma 
volume to ~ 4 L, giving a heparin concentration of ~10 IU per mL of plasma.   
 
For plasma clotting, the Clotek tube contained 100 L of cardiac participant plasma, 100 L of 
Tris Buffer (150 mM Tris HCl, 150 mM NaCl, pH 7.4) and 50 L of procoagulant.  
 
For the whole blood clotting, the TEG cup contained 60 L of PA and 260 L of the participant 
blood. Being fully heparinised the blood did not clot on its own. For the BDRST-1  experiment, 
the content of two BD RST tubes were dissolved with 1 and 4 mL of distilled water respectively, 
and 60 L of the solution obtained was used in the TEG cup as the procoagulant. For the 
BDRST-2 experiment the tubes were filled with 1 and 4 mL of blood respectively, the tubes 
were inverted 10 times (~30 secs) and 340 L of the blood was transferred to the TEG cup. The 
clotting results for each PA with the patient’s plasma are shown in Table 6, and the whole blood 
results are shown in Figure 6 and Table 7 respectively.  
Table 6. Clotting times in seconds of plasma from a “fully heparinised” cardiac surgery 
participant with the different PAs and thrombin at different concentrations.  
Clotting time (s) Procoagulant 
Conc (nM) PtPA OsPA Ecarin CA-1 CA-2 Notecarin Thrombin BDST 
120 10.0 ND 64.8 175 66.5 ND >300 >300 (27 
nM) 
60 14.8 18.7 89.7 >300 95.1 68.6 >300 >300 (6 nM) 
36 15.9 27.3 >300 >300 124 84 >300 ND 
12 36.3 35.5 >300 >300 >300 163 ND ND 
6 65.9 ND ND ND ND ND ND ND 
4 301.6 100 >300 >300 >300 179 ND ND 
3 ND 123 ND ND ND ND ND ND 
1 ND >300 ND ND ND >300 ND ND 
ND – not determined 
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This experiment showed the concentration of each PA required to clot the plasma in the 
prerequisite time of < 5 minutes. The minimum PA concentration giving clotting time < 5 
minutes were: PtPA 3 nM, OsPA 1 nM, notecarin 1 nM, CA-2 12 nM, ecarin 36 nM,  CA-1 60 
nM, and thrombin >120 nM. The only surprising finding was that notecarin efficacy was 
comparable to the Group C PAs. The reason for this may well be FVa found in platelets was 
available to form the hybrid prothrombinase complex with notecarin FXa. Even at 120 nM, 
thrombin was unable to clot the fully heparinised plasma, nor was the thrombin in the BD RST 
tube at 0.22 or 0.91 g.      
 
The concentrations determined to achieve the pre-requisite R time of < 5 minutes and maximum 
clot strength from these results for the different PAs were: PtPA 6 nM, OsPA 3 nM, notecarin > 
11 nM (more likely to be closer to 34 nM), ecarin > 11-34 nM (more likely to be closer to 34 
nM), CA-2 12-34 nM, and CA-1 57-112 nM. Notecarin produced clots with higher MAs than the 
Group A and B PAs. It could be due to decreased thrombin formed. The strongest clots formed 
as indicated by the MA were with PtPA and OsPA, and the weakest with the CA-1 and CA-2 
prothrombin activators. The TEG study re-affirms the PtPA and OsPA were the PAs of choice 
for clotting of fully heparinised patient blood samples. 
 
The thrombin in the BD RST tubes (BDRST-2 experiment with 135 nM of thrombin) produced 
incomplete clotting and weak clots as indicated by the MA. Such samples are very likely to form 
latent clotting in the serum post centrifugation.  
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Table 7. Results of the TEG clotting study with blood from a “fully heparinised” cardiac surgery 
participant.  
Procoagulant (nM) R (min) MA (mm) TMA (min) 
Ecarin  
56 (black) 2.3 47.6 19.4 
34 (green) 3.7 49.0 25.1 
11 (pink) 16.6 35.2* 53.3* 
3 (brown) 28.8* ND ND 
Carinactivase - 1  
112 (green)  5.3 36.9 23.7 
56 (black) 9.8 33.1* 37.7* 
Carinactivase - 2  
56 (pink) 2.8 38.1 25.8 
34 (green) 3.3 36.9 24.3 
11 (black) 8.9 30.7* 38.5* 
OsPA (nM) 
56 (black) 0.2 64.2 18.6 
3 (green) 2.9 61.4 25.8 
2.3 (brown)  4.2 54.8 28.4 
2 (pink) 11.0 29.4* 37.9* 
PtPA 
56 (black) 0.4 62.9 20.1 
6 (pink) 4.4 60.9 27.9 
3 (green) 9.7 42.8* 48.6* 
2 (brown) 28.7* ND ND 
Notecarin  
56 (black) 0.8 51.9 23.3 
34 (green) 1.1 51.0 19.6 
11 (pink) 2.2 46.6 22.2 
3 (brown) 7.2 39.5 33.6 
BD RST - 1  
25  (black) 18.9* ND ND 
6 (green) 19.3* ND ND 
BD RST - 2  
135 (black) 0.4 9.9 13.3 
34 (4 mL) (green) 0.3 12.7 8.1 
*stopped measurement; ND – not determined    
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Figure 6. TEG traces of blood from a “fully heparinised” cardiac surgery participant with the 
different PAs. The colour code showing concentrations of PAs is given in Table 7. 
CA-2  CA-1 
Notecarin  
Ecarin  
BDRST-1 
OsPA  PtPA  
BDRST-2 
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4.3.5 Clotting of normal pooled citrated plasma spiked with Rivaroxaban  
This experiment was done to examine the effect of one of the new FXa inhibitor anticoagulants 
Rivaroxaban on the clotting ability of the procoagulants.   
 
One Rivaroxaban tablet (10 mg, Mol Wt 435, Xarelto, Bayer Schering Pharm, Germany) was 
crushed in 5 mL deionised water (2 mg/mL), allowed to mix for 30 minutes, and then centrifuged 
to remove undissolved particles. The typical therapeutic dose given is 10-40 mg once daily. For a 
70 kg person (~3000 mL plasma) the total amount is 0.14-0.57 mg/kg, 0.0033-0.013 mg/mL of 
plasma. The concentrations prepared and tested in the Clotek tube were: 0.0033, 0.0083, 0.017, 
0.033, and 0.17 mg/mL. 
The Clotek tubes contained 50 L of Tris Buffer (150 mM Tris HCl, 150 mM NaCl, pH 7.4), 50 
L 0.2 mM CaCl2, 100 L normal pooled citrate plasma, 50 L of Tris buffer or anticoagulant of 
different concentration, and 50 L of PA (30 nM to be able to compare activity of all PAs).   
 
Table 8. Clotting times in seconds with normal pooled citrate plasma and Rivaroxaban.  
Procoagulant 
(30 nM) 
Rivaroxaban concentration 
(mg/mL) 
 0 0.003 0.008 0.017 0.033 0.17 
PtPA 4.8 5.8 6.2 7.7 8.8 12.0 
OsPA 8.6 8.6 8.8 8.8 9.3 16.9 
Ecarin 42.6 50.7 51.6 53.9 58.9 83.9 
Notecarin 41.7 42.7 44.9 46.2 47.6 67.3 
CA-1 128 133 152 176 194 258 
CA-2 60.9 61.1 62.8 66.1 70.6 98.0 
Thrombin 7.1 7.0 7.3 7.4 8.0 9.8 
BDRST  
23 nM 
5.1 5.3 5.2 5.8 5.7 7.7 
 
The data showed that Rivaroxaban had minimal effect on the PAs in the concentration range 
0.0033-0.013 mg/mL of plasma that may be encountered in patients. This suggested that 
Rivaroxaban does not inhibit the snake venom PAs, although OsPA, PtPA and notecarin all 
depend on a FXa-like protease for their activity. However, at higher concentrations, the drug had 
a significant inhibitory effect on clotting in the presence of each of the procoagulants. This may 
be due to inhibition of FXa produced from human FX in the plasma by the thrombin generated 
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by the procoagulants. This suggestion is further supported by the observation that clotting by the 
“non-FXa-like” PAs, ecarin and carinactivases was also affected by high concentrations of 
Rivaroxaban.   The data showed thrombin formation and clotting was unaffected.  
 
4.3.6 Clotting of citrated blood and plasma obtained from warfarin medicated 
participants  
As warfarin is the most commonly used anticoagulant it was important to determine if warfarin 
therapy affects the ability of the venom PAs to clot samples from patients medicated with 
warfarin.  For the plasma clotting studies plasma samples with different descarboxyprothrombin 
levels based on the INR were selected and tested with the different procoagulants. INR is 
calculated from the patient prothrombin clotting time (PT patient), laboratory normal 
prothrombin clotting time (PT normal) and the International Sensitivity Index (ISI) value for the 
analytical system, (INR= (PT patient/PTnormal) ISI [37]. 
 
For the whole blood clotting study a warfarin medicated participant taking four milligrams 
warfarin per day was recruited. The study was only performed with PtPA and OsPA due to 
availability of limited blood sample volume.   
The coagulation profile of the warfarin medicated patient, measured on a FUTURA Coagulation 
Analyser (Instrumentation Laboratory, Lexington MA, USA), was as follows:  
Coagulation Test Result Reference Interval  Units 
PT   27.4  9-13  seconds 
INR   2.61  0.9-1.2  
aPTT   36.15  24-39  seconds  
Fibrinogen (derived) 5.2  1.7-4.5  g/L 
 
The Clotek tubes contained 100 L of citrate plasma, 100 L of Tris Buffer (150 mM Tris HCl, 
150 mM NaCl, pH 7.4), 50 L of 0.2 M CaCl2, and 50 L of procoagulant (30 nM to be able to 
compare activity of all PAs). The TEG cup contained 20 µL of 0.2 M CaCl2, 10 L of the PtPA 
or OsPA and 310 L of citrate blood from the warfarin-medicated patient.  
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The results of the citrate plasma clotting study are shown in Table 9. The results of the citrate 
whole blood clotting study are shown in Figure 7 and Table 10. 
 
Table 9. Clotting times with re-calcified citrate plasma from warfarin medicated patients.  
Experiment A - snake venom PAs. 
Sample INR  Procoagulant 
30 nM 1.1 1.2 1.5 2.0 2.9 6.4 7.6  
PtPA 5.0 5.7 6.7 6.1 7.0 9.8 10.5  
OsPA 9.0 9.1 12.6 16.8 17.2 17.2 19.3  
Notecarin 69.4 67.1 68.6 66.6 71.0 91.0 121  
Ecarin 72.2 63.4 63.4 69.4 85.6 114 111  
CA – 1 231 198 232 229 >300 >300 >300  
CA – 2 115 103 115 109 149.2 242 240  
 
 
Experiment B – PtPA and Thrombin   
 
Sample INR  Procoagulant 
30 nM 1.1 1.7 2.3 2.8 5.8 6.4 
PtPA 7.4 8.1 8.1 8.3 11.1 13.3 
Thrombin 13.4 13.7 14.7 14.0 14.7 16.3 
 
Warfarin leads to decreased levels of normal (carboxylated) FX and prothrombin, with increased 
levels of their descarboxy precursors. Prothrombin and descarboxyprothrombin are the substrates 
targeted by the PAs. The decrease in prothrombin means less thrombin was generated by the 
PAs, hence the prolonged clotting times being observed. Increase in the only variable, 
(prothrombin clotting time) in the INR estimation equation will lead to increased INR results. 
Thrombin itself is not affected by warfarin therapy thus the clotting time with thrombin was not 
affected. The results in this experiment showed the CA-1 was the only PA unable to clot plasma 
samples with INR  2.9.  The results showed PtPA and OsPA were the most effective 
procoagulants with plasma from patients taking warfarin. 
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Table 10. TEG studies with citrate blood collected in a citrate Greiner tube from a warfarinised 
participant with added PtPA and OsPA.  
Participant on Warfarin  
PtPA or OsPA conc in 
TEG cup (nM) 
R 
(min) 
MA 
(mm) 
TMA 
(min) 
Control (re-calcified blood 
alone) (green for PtPA and 
black for OsPA) 
0 
12.2 50.4 35.5 
PtPA treated  (A)     
 56 (pink) 0.4 53.1 20.6 
 5.6 (black) 0.8 59.6 18.8 
 0.56 (brown) 9.4 54.3 31.5 
 0.056 (blue) 10.3 51.4 32.9 
OsPA treated (B)     
 23.5 (green) 0.6 53.0 17.8 
 2.35 (pink) 1.6 60.8 16.7 
 0.23 (brown) 4.4 59.5 22.9 
 0.023 (blue) 8.9 51.2 32.9 
 
 
 
 
Figure 7. TEG studies with re-calcified citrate blood from a warfarinised participant. The colour 
code showing concentrations of procoagulants is given in Table 10. 
 
 
In this experiment, OsPA worked significantly better that PtPA for unknown reasons. However, 
the experiment shows that both PtPA and OsPA easily clotted the warfarin containing blood. The 
minimum concentration of PtPA and OsPA capable of providing a clot in the pre-requisite R 
time of < 5 minutes and maximum clot strength were 0.56 – 5.6 nM and approximately 0.2 nM 
respectively.  
 
 
PtPA OsPA 
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4.3.7 Clotting of blood from a patient undergoing citrate anticoagulation  
In previous experiments it has been shown that the PAs were capable of clotting citrate blood 
collected in Greiner citrate tubes. This experiment was to confirm that in vivo citration as a 
therapeutic anticoagulation procedure presented no clotting problems with the PAs.  
Citrate anticoagulation is a fairly new procedure. It was implemented routinely by the Intensive 
Care Unit (ICU) at the PAH in 2009. The patient volunteer was on 3.0 mmol of citrate per litre 
of blood flow. The blood sample was collected from the patient by an ICU clinical consultant in 
a 50 mL plain syringe (BD Plastipak #300866) for routine pathology testing from which < 3 mL 
was left to perform the very limited study with PtPA only. The coagulation parameters were: PT 
13 s (RR 9-13), INR 1.3, APTT 45 s (RR 24-39), fibrinogen (derived) 7.2 g/L (RR 1.7-4.5), 
confirming anticoagulation.  
 
The TEG cup contained 20 L of 0.2 M CaCl2 or saline, 5 L of PtPA and 320 L of the citrate 
blood.   
The results are shown in Figure 8 and Table 10.  
 
Table 11. TEG studies with citrate anticoagulated participant. 
Citrated Anticoagulated participant R(min) MA(mm) TMA(min) 
Re-calcified citrate blood alone (pink) 4.8 77.1 18.0 
2.8 nM PtPA re-calcified (green) 0.6 74.7 15.8 
2.8 nM PtPA non re-calcified (black)  0.8 76.2 18.9 
 
 
Figure 8. TEG studies with citrate anticoagulated participant. The colour code showing 
concentrations of procoagulants is given in Table 11. 
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The results indicated that the citrate concentration used for anticoagulation of patients did not 
present clotting problems when PtPA was used as the procoagulant in re-calcified and non re-
calcified blood.  The citrate concentration in blood collected in Greiner Citrate tubes is 3.2% or 
109 mM [38] which is about 36 times more than the concentration the patient was receiving. 
Additionally, it was not expected there would be any clotting problems as patients being citrated 
are continuously monitored for ionized calcium and ionized calcium is replenished as required. 
The R time in normal pooled citrate blood (with re-calcification) was 6.4 minutes (Table 4) 
compared to the 4.8 min in this patient. The re-calcification adds calcium in excess to 
requirement thus theoretically it should not contribute to the difference. The difference is likely 
to be due to higher concentrations in the patient’s blood of clotting factors including fibrinogen 
which was 7.2 g/L. 
 
4.3.8 Clotting of EDTA plasma and blood obtained from a healthy participant 
A small but significant percentage of samples (serum or lithium heparin plasma) received for 
biochemical analysis is contaminated by EDTA. It was therefore important to determine if the 
procoagulants were effective in clotting EDTA plasma and whole blood. Greiner EDTA tubes 
contain 1.8 mg/mL (6.2 mM) EDTA when filled to the fill mark [39]. At this concentration it is 
able to bind all the divalent metal ions (Ca2+, Mg2+, Fe2+, Zn2+, Cu2+ etc) present in the blood 
sample.    
 
The Clotek tube contained 100 L of EDTA plasma, 100 L of Tris Buffer (150 mM Tris HCl, 
150 mM NaCl, pH 7.4), 50 L of 0.2 M CaCl2 or Tris buffer, and 50 L of procoagulant.  
The TEG cup contained 20 L of 0.2 M CaCl2 or saline, 60 L of PA and 260 L of the EDTA 
blood.  For the BD RST experiment the contents of two tubes were dissolved with 1 and 4 mL of 
distilled water respectively, mixed for five minutes and 60 L of the content used in the TEG cup 
as the procoagulant.  
  
The results of the plasma clotting study are shown in Table 12. The results from the whole blood 
clotting study are shown in Figure 9 and Table 13.  
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EDTA would chelate the calcium and in turn prevent the normal clotting process from 
proceeding. The total calcium in the EDTA plasma was < 0.5 mmol/L (Beckman DxC800, Brea, 
CA, USA). The results showed that the calcium-dependent PAs (CA-1 and CA-2) did not clot 
EDTA plasma even at 50 nM concentration in the pre-requisite time of < 5 minutes, although 
they were able to clot plasma after re-calcification. The effect on ecarin was significant: without 
re-calcification the clotting time was > 5 minutes. The added calcium (50 L of 0.2 mM CalCl2) 
was in excess to the EDTA (100 L of blood with 6.2 mM EDTA). The addition of calcium in 
excess over EDTA caused only a moderate decrease in clotting time with PtPA and OsPA e.g. 
PtPA at 0.1 nM, 190 seconds to 98.6 seconds. Although the notecarin was less effective as a 
procoagulant than PtPA and OsPA, the results showed it was least affected by the absence of 
calcium. The addition of calcium in excess caused a 3-fold increase in the clotting of the plasma 
by thrombin. 
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Table 12. Clotting times for EDTA plasma obtained form a healthy participant with different procoagulants at different concentrations 
with and without calcium. 
With added Ca2+ (secs)  Without added Ca2+ (secs)   Prothrombin 
Activator 
conc (nM)  
Ecarin CA-1 CA-2 PtPA OsPA Notecarin Thrombin Ecarin CA-
1 
CA-2 PtPA OsPA Notecari
n 
Thrombin  
50 68.9 165.4 82.5 6.5 10.0 85.5 12.7 >300 >300 >300 31.7 56.4 132 17.9 
10 127 232 101 13.5 15.8 117 43.0 >300   48.7 68.2 242 53.2 
1 224 >300 151 35.7 42.7 206 >300 >300   86.4 107 >300 >300 
0.1 ND ND ND 98.6 123 ND >300    190 251  >300 
ND – not determined 
BDRST Tube (nM) With added 
Ca2+ (secs) 
Without 
added Ca2+ 
(secs) 
1 mL (23) 12.3 44.9 
4 mL (6) 34.3 101 
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Table 13. Results of the TEG clotting study with blood collected in Greiner EDTA tube from a healthy 
participant. 
Procoagulant (nM) R (min) MA (mm) TMA (min) 
Ecarin  
53 (black: re-calcified) 2.5 56.8 22.1 
53 (green: not re-calcified) 16.9* ND ND 
Carinactivase - 1  
53 (black: re-calcified) 4.8 57.6 29.5 
53 (green: not re-calcified) 16.9* ND ND 
Carinactivase - 2  
53 (black: re-calcified) 2.6 55.7 25.6 
53 (green: not re-calcified) 34.8* ND ND 
OsPA  
53 (black: re-calcified) 1.6 41.5 21.6 
53 (green: not re-calcified) 17.7* ND ND 
PtPA 
53 (green: re-calcified) 0.5 58.2 22.9 
53 (pink: not re-calcified) 17.8* ND ND 
1 (black: re-calcified) 1.6 64.0 22.9 
PtPA 
690 nM (Run 1) (not re-calcified) 50.1* ND ND 
690 nM (Run 2) (not re-calcified) 50.3* ND ND 
Notecarin  
53 (green: re-calcified) 1.9 54.2 25.8 
53 (black: not re-calcified) 17.2* ND ND 
Thrombin  
53 (black: re-calcified) 2.6 49.9 31.5 
53 (green: not re-calcified) 45.4* ND ND 
BD RST   
23 (pink; re-calcified) 1.6 45.4 24.0 
23 (black: re-calcified) 1.8 57.7 28.3 
6 g (brown/green: re-calcified) 30.1* ND ND 
6 g (brown/green: re-calcified) 32.5* ND ND 
Re-calcified EDTA blood alone 
Run 1 11.2 58.5 40.8 
Run 2 10.6 56.7 38.5 
*stopped measurement; ND – not determined    
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Figure 9. TEG traces of EDTA blood with and without the presence of calcium with the 
different procoagulants. The colour code showing concentrations of procoagulants is given in 
Table 13. 
Re-calcified 
EDTA Blood   
Ecarin  
CA-1 CA-2 
PtPA  OsPA  
PtPA 690nM  
Notecarin 
Thrombin   
BDRST    
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This experiment showed that EDTA whole blood (without re-calcification) presents a difficult 
challenge for the procoagulants. Unlike with EDTA plasma, none of the procoagulants was able 
to clot EDTA blood. Clotting was not achieved even with a very high PtPA concentration (690 
nM). However, they were all able to clot the EDTA blood when it was re-calcified. Rapid and 
complete clotting was achieved with a very low PtPA concentration (1 nM). EDTA is the 
anticoagulant of choice for preserving cellular morphology. By chelating calcium it also prevents 
platelet activation and platelet clumping [40]. The reason why the procoagulants were unable to 
clot EDTA blood but able to clot EDTA plasma is unknown. It seems possible that EDTA in 
whole blood chelates other divalent metal ions, in addition to calcium. Addition of excess 
calcium could displace the other ions by saturating the EDTA with calcium.  
 
Two additional plasma clotting experiments using 30 nM PtPA were performed. In the first 
experiment water was added to the Clotek tube instead of Tris buffer and the sample still clotted 
in 6.4 seconds. In the second there was no buffer, 200 L of EDTA plasma plus 50 L PtPA and 
the clotting time was 5.4 seconds. For the TEG study, the following solutions were added to a 
TEG cup 50 L Tris buffer, 60 L PA, 230 L EDTA blood and still no clotting was observed. 
BD RST tube was filled to the fill mark with EDTA blood after 60 minutes it showed very partial 
clotting.  It is obvious from these experiments that whenever EDTA may be present in blood 
samples, addition of calcium with the procoagulant would be necessary to achieve clotting.  
 
4.3.9 Clotting of citrate blood in samples with low platelet counts 
Platelets and fibrinogen both play an important role in enhancing the clotting process. Thus it 
was important to test whether low levels of these components would have an effect on the 
clotting efficiency of added PAs.  
  
Four citrate blood samples were obtained based on having low platelet counts, < 100 (reference 
interval 140-400x109/L). The TEG cup contained 20 L of 0.2 M CaCl2 or saline, 10 L of 
procoagulant or saline and 310 L of the citrate blood. The results from the whole blood clotting 
study are shown in Figure 10 and Table 14. 
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Table 14. TEG clotting parameters from four patient samples (P1-P4) with low platelet counts 
using PtPA or OsPA as procoagulant.  
Patient 
 Procoagulant 
conc inTEG 
cup (nM) R (min) MA (mm) 
TMA 
(min) 
Patient 1  
Re-calcified blood 
(black) 
0 
10 34.6 30.3 
Platelet count 29 x109/L PtPA (green) 0.56 0.4 31.1 20.3 
Fibrinogen 2.7 g/L OsPA (pink) 0.23 1.5 35.3 22.5 
 
  
   
Patient 2 
Re-calcified blood 
(pink) 
0 
9.3 28.2 29.8 
Platelet count 17 x109/L PtPA (green) 0.56 1.5 31.2 24.2 
Fibrinogen 2.1 g/L OsPA (black) 0.23 3.2 28.7 25.3 
 
  
   
Patient 3 
Re-calcified blood 
(black) 
0 
12.8 30.2 32.8 
Platelet count 58 x109/L PtPA (green) 0.56 1.4 33.7 24.5 
Fibrinogen 2.2 g/L OsPA (pink) 0.23 3.3 31.7 24.6 
 
  
   
Patient 4 
Re-calcified blood 
(black) 
0 
9.1 48.2 32.0 
Platelet count 81 x109/L PtPA (green) 0.56 1.7 58.8 24.2 
Fibrinogen 3.7 g/L OsPA (pink) 0.23 3.4 59.7 24.1 
 
  
 
   
 
Figure 10. TEG traces of four patient samples (P1-P4) with low platelet count. The colour code 
showing concentrations of PAs is given in Table 14. 
 
P1 P2 
P3 P4 
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In comparison with normal pooled citrate blood, the R times caused by similar PtPA and OsPA 
concentrations were comparable; however the clot strengths were not. In the normal pooled 
citrate blood, the observed MAs were ~63 mm (Table 2). In the platelet-poor samples with the 
low normal level of fibrinogen concentration (Patient 1-3), the MAs were ~33 mm. Patient 
samples 1-3 have similar fibrinogen concentration and similar MA values suggesting the platelet 
difference does not influence the MA. In contrast, patient samples 3 and 4 have similar platelet 
count but significantly different fibrinogen concentrations. The higher MA was in patient sample 
four associated with the higher fibrinogen concentration. These results are consistent with 
observations by others that higher fibrinogen gives stronger clots [28]. Despite the lower MA 
values, PtPA and OsPA at low concentrations were able to fully clot blood from the four 
patients, with low R times.  
 
 
4.3.10 Clotting of normal citrate blood in different routinely used 
commercial serum tubes 
This experiment was designed to see how three of the venom PAs PtPA, OsPA and ecarin would 
compare with three commercial clotting tubes: Greiner serum, BD SST II and BD RST. Blood 
was collected from a healthy participant (author) into a Greiner citrate tube. For the PA study, 30 
µL of activator (concentration of PtPA and OsPA 0.56 nM; ecarin 5.3 nM in TEG cup), 20 µL of 
0.2 M CaCl2 and 290 µL of citrate blood were added to the TEG cup. 
 
For the commercial serum tubes one mL of distilled water were added and allowed to mix on a 
roller for ~2 hours to dissolve the content of the tube. For the commercial serum tubes 45 µL of 
the dissolved content, 20 µL of 0.2 M CaCl2 and 275 µL of citrate blood was added to the TEG 
cup.  
The results from the whole blood clotting study are shown in Figure 11 and Table 15. 
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Table 15. TEG data with routinely used commercial serum tubes and PtPA with blood from a 
healthy participant.  
Tube  Tube Catalogue # R time (min) MA (mm) TMA 
(mm) 
Greiner Vacuette Serum (black) 455078 2.8 62.5 20.6 
BD SST II (lighter green) 367958 4.3 62.8 23.5 
BD RST (18 nM) (pink ) 368771 0.5 58.8 20.2 
PtPA (0.53 nM) (magenta)  1.4 65.6 19.8 
OsPA (0.53 nM) (blue)  1.5 64.0 19.7 
Ecarin (5.3 nM) (brown)  2.6 64.3 19.3 
Native blood (darker green)  6.4 67.6 27.8 
 
 
 
Figure 11. TEG traces with native blood from a healthy participant in routinely used commercial 
serum tubes in comparison with PtPA, OsPA and ecarin.  The colour code showing 
concentrations of procoagulants is given in Table 15. 
 
The experiment demonstrated that the routinely used commercial serum tubes vary in the time at 
which notable clot formation was detected by the TEG (R time). The R time ranges from 0.5 in 
the BD RST tube to 6.4 minutes for the re-calcified citrate blood from a healthy participant. The 
190 
 
native blood had the highest MA but longest TMA. Taking into consideration the three 
parameters, the OsPA and PtPA overall were most effective in clotting the blood. All 
manufacturers recommend minimum clotting time of 30 minutes prior to centrifugation of the 
serum tubes. The TEG data demonstrates PtPA and OsPA required ~0.5 nM to obtain R time of 
< 2 minutes with equivalent clot strength as re-calcified citrate blood clot which make them very 
suitable for evaluation as a procoagulant to produce rapid quality serum.   
 
 
4.4 General Discussion 
In this study the selected snake venom PAs were evaluated for their ability to clot an array of 
sample types ranging from normal to those with low platelet and fibrinogen levels, and with 
different anticoagulated samples that may be encountered by a biochemistry laboratory. The 
evaluation was used to serve as a tool to select one or more of these activators for further studies 
aimed at producing high quality serum. As discussed earlier biochemistry laboratories and other 
pathology sections utilizing serum for testing require completely clotted serum, containing no 
residual fibrinogen, but they also need it is to be prepared in the shortest possible time.  Clotting 
studies were performed using a Clotek analyser for plasma and a TEG analyser for whole blood. 
These two analysers are very useful tools to ascertain the effect of procoagulant concentration on 
clotting time and completeness of clotting.  
Based on results in Chapter 3 and from experiments in this chapter using normal pooled citrate 
plasma and blood, it is evident that differences exist amongst the four groups of PAs in their 
effectiveness in clotting samples, specifically the concentrations of the activators required to 
achieve the desired clotting time of < 5 minutes. The studies clearly showed that the Group C 
snake venom PAs (PtPA and OsPA) were the most effective, requiring concentration, ~6 nM to 
clot just about all plasma and blood samples. The presence of calcium increased the efficiency of 
the Group C activators. Rao and Kini reported the addition of calcium enhanced the catalysis by 
the Group C activators of purified prothrombin ~4-fold [41]. Although ecarin is said to have no 
calcium requirement [42], ecarin has a zinc-chelating sequence [43] and requires zinc for 
effective clotting function.  Thus the combination of decreased or no zinc or calcium available, 
led to diminishing of its clotting effectiveness.  
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It should be noted that more precise comparison of the clotting effectiveness of the different 
prothrombin activators with various blood and plasma samples must await the availability of 
preparations with a higher degree of homogeneity then those used in the present study. However, 
the large differences in efficiency observed gives confidence that the Group C PAs were superior 
in almost every case.  
ATIII is normally present in plasma at ~3.0 mol/L, over twice the concentration of any potential 
target coagulation enzyme generated by the tissue factor pathway [44]. The two primary targets 
of ATIII are thrombin, FX and FXa. Thus if all the prothrombin was converted to thrombin (1-2 
mol/L) by procoagulants with the addition of FX (0.17mol/L), the combined concentration of 
thrombin and FX would not exceed 2.5 M which is lower than the ATIII concentration. ATIII’s 
inhibitory ability is highly dependent on forming a complex with heparin. Heparin is reported to 
accelerate rates of inhibition of both FXa and thrombin by several fold [45], and by as much as 
1000-fold [46]. The heparin and ATIII stoichiometric binding is 1:1 [46] and the stoichiometric 
binding of the ATIII-heparin complex with thrombin is also 1:1 molar ratio. One IU of heparin 
(5.3 g) if dissolved in 1 mL of plasma has a concentration of 430 nM which indicates ~7 IU 
will completely saturate the ATIII. This in line with the heparin infused in cardiac surgery 
patients which is ~10 IU/mL of blood.  Snake venom can only completely convert the 
prothrombin present in plasma to generate thrombin, there is no other thrombin source. With 
ATIII being in excess the level of inhibition was dependent on the concentrations of heparin and 
the snake venom PAs as demonstrated by the findings in the studies here. This was also found by 
Warrel et al, who showed Echis carinatus venom was able to coagulate blood containing 1 
IU/mL heparin, but inhibition was observed with increasing heparin concentration which in turn 
could be overcome by increasing the venom concentration [47].  
The heparin containing samples (collected in Greiner lithium tubes, normal pooled citrate plasma 
spiked with sodium heparin used in patient medication and lithium heparin from Greiner lithium 
heparin tubes, and from a fully heparinised cardiac surgery participant) re-affirm the findings 
that there was variable clotting effectiveness by the different snake venom procoagulants. The 
heparin used in the different samples was high molecular weight which is more effective in 
inhibiting thrombin than FXa [7, 8]. The most effective were the PtPA and OsPA, and they 
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required the lowest concentrations to achieve clotting of plasma in < 5 minutes, and R times of < 
5 minutes with the strongest clots as indicated by the MA. The fully heparinised cardiac surgery 
patient that had received 37 000 IU of heparin (~7 IU/mL in blood, or ~9.3 IU/mL in plasma) in 
reality was the litmus test, providing a sample likely to contain the highest levels of heparin that 
a laboratory is likely to encounter. The studies with this participant samples indicated for future 
research that the lowest concentrations required of each of the activators to produce completely 
clotted sample were: PtPA and OsPA ~6 nM; Notecarin > 6 nM; CA-2 > 12 nM, ecarin >36  nM, 
CA-1 > 60 nM and thrombin >120 nM.  Another interesting finding was PtPA’s ability to clot 
citrate plasma stored in the Greiner lithium heparin tubes much faster that the plasma spiked with 
lower concentration of pure heparin. This may be due to the surfactant in the Greiner tube 
enhancing the PtPA’s clotting ability.  
 
OsPA and PtPA particularly are able to clot blood samples containing high heparin 
concentrations despite the observations above that the concentration of ATIII-heparin complex 
able to be formed in these samples would exceed the concentration of thrombin that can be 
produced from prothrombin. The likely explanation is that the PAs produced a sustained burst of 
thrombin which was able to convert fibrinogen to fibrin before being completely inhibited by the 
ATIII-heparin complex. Furthermore the PAs will continue to convert prothrombin over time 
and overcome the inhibitory effects of the ATIII-heparin complex.   
 
Although the BD RST contains 15 NIH units of thrombin it was unable to fully clot the blood 
from the cardiac participant. To be effective it would require an increase in the amount of 
thrombin. Partial clotting indicates fibrinogen was only partially consumed, and this would be 
likely to result in latent clotting post centrifugation and subsequent analytical problems. Latent 
clotting can be hazardous for laboratories by blocking sampling probes, result in inaccuracies 
with aspiration of accurate analytical sample volumes, perhaps cause unfavourable spectral 
interferences in the analytical vessel or cause interaction the analytical reaction itself. The ATIII-
heparin complex is able to inhibit clot formation at the thrombin concentration present in these 
tubes. FXa incorporated in the prothrombinase complex is said to be protected from inhibition by 
ATIII and ATIII-heparin complex, independent of the molecular size of heparin [48]. The 
protection estimate ranges from complete protection to 5 to 10 fold protection [51].  Rezaie et al 
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estimated this protection to be 3 fold [49]. The PtPA and OsPA FXas components, being 
structurally different from human FXa [50-52], may be less susceptible to inhibition by the 
human ATIII-heparin complex. For detailed evaluation of the BD RST tube refer to Chapter 5.   
 
The study with the newer anticoagulant, the FXa inhibitor Rivaroxaban, showed it had minimal 
effect on any of the procoagulant’s ability to clot plasma even when present well in excess of 
therapeutic doses. Thus all procoagulants should be able to produce high quality serum from 
blood obtained from patients on Rivaroxaban anticoagulation therapy. The clotting time was 
mostly due to the PAs or the added thrombin and a smaller component was due to the plasma 
clotting factors activated by the thrombin produced or added. The increase in clotting time at 
high Rivaroxaban concentration was most likely due to inhibition of the human plasma FXa that 
contributes to the clotting time that is activated by the thrombin generated by the PAs or the 
added thrombin rather than the FXa in the snake venom PAs.  
 
Warfarin produces its anticoagulation effect by inhibiting the vitamin K conversion cycle, 
thereby causing hepatic production of partially carboxylated and descarboxylated proteins with 
reduced procoagulant activity [53]. Hence the clotting times were extended, and the INR, which 
is a reflection of the increased warfarin concentration. Apart from CA-1 no other procoagulant 
experienced major problems in clotting samples with warfarin. PtPA and OsPA were able to clot 
the blood very fast from the warfarin participant at very low concentrations.  
  
Citrate is used as an anticoagulant in low doses, ~3.0 mM versus 109 mM in blood collection 
tubes. Since the procoagulants tested are able to clot citrate plasma from blood collection tubes, 
citrated plasma from citrate anticoagulant patient as expected did not present clotting problems 
with PtPA. In fact the standard Greiner serum tube used to collect the blood for routine 
pathology testing was able to clot the sample well within the recommended time of 30 minutes 
without any latent clotting.  
 
The clotting studies with EDTA plasma clearly support the findings reported by Yamada et al 
[54] that CA-1 and CA-2 are strongly dependent on calcium thus no clotting was observed in the 
pre-requisite time of < 5 minutes.  Although ecarin has been reported to have no dependence on 
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calcium [42], Rosing and Tans showed that the addition of calcium to ecarin alone almost 
doubled the rate of prothrombin activation [55]. These studies showed that ecarin was unable to 
clot the EDTA plasma without the added calcium in < 5 minutes which supports the findings 
reported by Rosing and Tans that calcium has a significant enhancing effect on ecarin ability to 
activate prothrombin [55].  However, chelation of catalytically essential zinc from the ecarin 
active site when the concentration of EDTA is greater than the concentration of free calcium may 
explain the inhibitory effect of EDTA (rather than chelation of calcium). These same authors 
also showed calcium had a significant effect on the rate of prothrombin activation by OsPA and 
very small by notecarin [55]. With PtPA the clotting time increased almost 5-fold in the EDTA 
plasma without calcium which indicated calcium plays a role in the ability of PtPA to clot 
plasma. Rao and Kini demonstrated that the prothrombin activation catalysed by the PtPA was 
enhanced ~4 fold by the addition of calcium [41]. The most interesting observation was the 
inability of any of the procoagulants to clot EDTA blood. Yonemura reported that ecarin activity 
in plasma was inhibited by EDTA [56]. As indicated earlier the frequency of blood samples 
containing EDTA is very small, 0.46% [2], and almost all of these samples would only be 
partially contaminated with EDTA thus clotting may still to occur with the PAs, particularly 
PtPA and OsPA. Analytes affected by EDTA (e.g. K+, Ca2+, Mg2+, ALP) contamination would 
not be reportable from such samples even if the sample was fully clotted.   
 
Low platelet counts did not affect the clotting ability of the PtPA and OsPA but fibrinogen did 
have an impact on the strength of the clot. Lang et al studied the effect of both platelets and 
fibrinogen concentration on clot strength and they found the clot strength is dependent on the 
fibrinogen level in a concentration-dependent manner and independent of platelet count [28]. 
Bolliger et al report fibrinogen concentration >2.0 g/L provides the optimal clot formation [57]. 
 
Finally, when PtPA in a plain tube was compared with the commercial serum tubes with native 
whole blood was by far the most effective.  
The various experiments indicate PtPA and OsPA concentrations of ~6 nM are minimally 
required to clot fully heparinised patient samples in the desired time of < 5 minutes for future 
studies. Furthermore the data showed samples that may be contaminated by “topping up” of 
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serum tubes with lithium heparin or citrate tube, or contamination from anticoagulated catheters 
should not present a problem with the snake venom procoagulants (except for EDTA).  
 
The TEG studies provided the R-time, MA and TMA values. The fact worth noting was that time 
it took even with normal blood to achieve maximum TMA, ~20 minutes was a lot longer than 
expected.  Visual observations of clotting in tubes suggested complete or almost complete 
clotting in times not much greater than the R times. This may well be due to the pin oscillation 
extending the time for completion of clotting or for the crosslinking. In Chapters 5 the BD RST 
will be fully evaluated against other commercial tubes and its ability to clot samples containing 
various levels of heparin documented.  In Chapter 6, the prothrombin activators, PtPA, OsPA 
and ecarin will be evaluated to determine if they are able to produce high quality serum rapidly.  
 
4.5 Conclusion 
In summary, the prothrombin activators from the four groups were suitable and effective 
procoagulants in clotting plasma and whole blood containing different anticoagulants. The 
findings confirm the Group C PAs (PtPA and OsPA) overall were the most effective in clotting 
normal and anticoagulated plasma and whole blood.  
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EVALUATION OF A 
COMMERCIAL THROMBIN 
CONTAINING TUBE TO PRODUCE 
SERUM FOR BIOCHEMICAL 
ANALYSIS 
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5.1 Evaluation of the Becton-Dickinson rapid serum tube: does it provide a suitable 
alternative to lithium heparin plasma tubes? 
 
Overview 
Historically serum has been the sample of choice utilized for biochemical analysis. Blood 
samples collected at non-laboratory based sites (e.g. collection centres, general practice) were 
dispatched uncentrifuged to the laboratory. However, it became evident that contact of serum 
with cells leads to changes in many serum analytes due to continued cellular activity e.g. K+, LD, 
glucose, lactate, phosphate, bicarbonate etc due cellular activity and breakdown. The K+ changes 
are most notable in patient samples with myeloproliferative disorders (1, 2, 3) due to leakage 
from these increased cells numbers as they are far more metabolically active and easily subjected 
to disintegration. In studies on the temperature effects on K+ with uncentrifuged samples it has 
been demonstrated K+ concentrations increase with decrease in temperature and the reverse 
occurs with temperature increase with seasonal temperature variations (4, 5, 6). This has led to 
increased referral of patients to EDs from primary care settings and admissions. In turn has been 
a driver for increased use of point of care systems in primary care settings. To minimise such 
unfavorable outcomes laboratories implemented different approaches such as increasing the 
frequencies of delivery to the laboratory, storing and transporting samples in refrigerators and 
other temperature regulated containers and even using air conditioned transport vehicles to 
minimise temperature variation and analyte changes. Others introduced on site centrifugation, 
and tube manufacturers have responde by incorporating gel barriers to eliminate serum/plasma 
contact or re-mixing with cells. Increasingly in hospitals, to improve TAT of results and 
minimise loss of sample integrity, rapid delivery of samples to the laboratory has been achieved 
by pneumatic tube transport systems.  
 
It is well accepted that current commercial blood clotting tubes producing serum are unable to 
match the turn-around time in results offered by lithium heparin plasma in meeting the standards 
expected in critical care. This deficiency in current commercial blood clotting tubes is well 
recognised by the tube manufacturers. BD is the market leader in blood collection tubes (7). 
They have recognised this deficiency of their SST II tube and to overcome it have produced the 
BD RST tube. In order to achieve rapid clotting BD have incorporated bovine thrombin (15 NIH 
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units) (8) as the procoagulant rather than using the conventional procoagulant (micronised silica 
particles) alone. 
 
Sera from the BD RST tube has been extensively evaluated on different analytical platforms 
measuring a range of analytes and shown to be effective in clotting blood in < 5 minutes and 
providing analytical stability over 24 hours (9,10). Hence, it is effective in delivering 
improvements in TAT of results with the speed of plasma and quality of serum. What has been 
omitted or was an oversight in all these evaluations was the range of samples that are 
encountered in a laboratory, particularly hospital laboratory when sample containing 
anticoagulants are frequently encountered. The performance of the BD RST tube with a range of 
anticoagulated samples was therefore tested.  
 
The TnI concentration change criteria used in this publication is for identification of myocardial 
injury which was recommended by the international cardiology bodies as referenced in the 
publication. This publication was accepted before the Chapter 2 publication. The view taken in 
the publication in Chapter 2 was that the calculation used in this publication was not necessarily 
ideal way to define duplicate result discrepencies which is dependent on analytical issues, hence 
for the novel statistical approach was developed in Chapter 2. 
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Figure 1. BD advertisement on the BD RST tube.  
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6.1 Introduction  
 
Serum and heparinised plasma specimens are considered equivalent for many assays and it is not 
uncommon for hospital based laboratories to receive and treat serum or plasma specimens 
interchangeably for general chemistry analysis. It is also well documented that there are 
significant differences in the levels of some analytes between serum and plasma, particularly K+ 
and total protein (TP), and that these require different reference intervals. Both of these analytes 
play a critical role in the provision of care for seriously ill patients such as in EDs, ICUs and 
other high dependency units. For both plasma and serum, it is recommended that they be 
physically separated from cells within one hour from the time of collection [1].  
 
As has been demonstrated current commercially available methodologies employed in blood 
collection tubes to produce serum are unable to completely clot all types of blood specimen in a 
timely manner to meet the quality and TAT expectations of clinicians and biochemistry 
laboratories. The newest tube on the market, the BD RST has been shown to allow rapid 
production of serum from blood taken from healthy (non-anticoagulated) participants [2]. Yet 
when we evaluated it in a hospital population, it was found not to meet the needs of patients on 
higher doses of anticoagulants (refer to Chapters 3, 4 and 5) [3].  Thus there is a need to find a 
new solution that will produce high quality serum rapidly from blood taken from all patients. 
 
The parameters which determine the quality of serum with now be discussed.  
 
6.1.2 Fibrinogen 
The clotting process is a cascade of reactions which leads to consumption of fibrinogen (Figure 
2, Chapter 1). Fibrinogen is an acute phase reactant, a plasma protein synthesized in the liver that 
is a substrate for thrombin in the coagulation cascade. The analysis of fibrinogen is clinically 
important in inflammatory states and coagulation disorders and elevated levels have been 
associated with increased risks of coronary heart disease and stroke [4]. Low plasma fibrinogen 
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levels are associated with an increased risk of bleeding. Fibrinogen is a heterodimeric molecule 
and each half contains three different polypeptide chains (A, B and ) linked by disulphide 
bridges [5]. Thrombin cleaves the A and B chains to release fibrinopeptides A and B (FpA, 
FpB), respectively from the aminoterminal ends. The fibrin monomers so formed are 
polymerized and form an insoluble fibrin clot stabilised by cross linking, which is catalysed by 
FXIIIa [6, 7]. The fibrin networks formed along with fibrinogen are subsequently degraded into 
fibrin(ogen) degradation products (FDPs) by proteolytic enzymes, including plasmin and 
neutrophil elastase, Figure 1. Plasmin cleaves fibrin at specific lysine and arginine residues. 
Fibrinogen and fibrin play overlapping roles in blood clotting, fibrinolysis, cellular matrix 
interactions, the inflammatory response, wound healing, and neoplasia [7].  
 
 
 
Figure 1. Modification of the Lowe et al [6] schematic representation of formation and 
breakdown of fibrin.  
 
The clotting process is counter balanced by naturally occurring inhibitors or anticoagulants 
directed against the formation or action of thrombin and also by fibrinolysis. The main clotting 
inhibitors are the ATIII-heparin complex, proteins C, S and Z, and less specific inhibitors 
including 1-protease inhibitor which acts on FXa, and 2-macroglobulin whose primary target is 
thrombin [8]. ATIII is the most important inhibitor of coagulation, and its action is greatly 
enhanced by the administration of heparin or by heparin-like molecules expressed on 
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endothelium [8]. Heparin cofactor II is a plasma serine protease inhibitor (serpin) that inactivates 
thrombin rapidly in the presence of certain glycosaminoglycans (e.g. dermatan sulfate, heparan 
sulfate, heparin) [9, 10] which in turn prevents formation of fibrin from fibrinogen.  
 
In most laboratories fibrinogen is estimated using “functional coagulation assays” notably the 
prothrombin time (PT: PT-derived fibrinogen assay) and Clauss assays [6, 11]. In the PT assay 
the change in “absorbance” (light scattering) as soluble fibrinogen is rapidly converted to 
insoluble fibrin is measured and related to the concentration of fibrinogen. The PT related 
absorbance change of the unknown is related to values for known fibrinogen concentrations. In 
the Clauss assay a high concentration of thrombin (~100 U/mL) is added to diluted plasma and 
the clotting time is measured. Under these conditions clotting time is proportional to the 
fibrinogen concentration. The PT-derived assays may produce slightly higher results than the 
Clauss assay which is considered the most reliable method for general use in clinical laboratories 
[6, 11]. The fibrinogen should be measured in citrate plasma centrifuged in a swing-out bucket 
rotor that can be considered “platelet free” (platelet count is <10 x109/L) [12]. Its concentration 
in healthy individuals is 1.5-4.5 g/L when measured by coagulation methods (this range is 
method/analyser dependent). Alternative to the functional assays are the immunological assays 
that measure the fibrinogen protein concentration rather than functional activity. These include 
automated immunonephelometric assays and enzyme-linked immunosorbent assays (ELISA) 
utilising monoclonal and polyclonal antibodies. With the increasing awareness of fibrinogen as a 
risk factor in prediction of the outcome of myocardial infarction and stroke, recently an 
immunoassay method has been published to measure one pertinent molecular form, the  
polypeptide chain [4]. The study showed that the  fibrinogen chain was significantly higher in 
coronary artery disease (CAD) patients (0.41 ± 0.016 g/L) than in non-CAD patients (0.30 ± 
0.024 g/L) in men and women.  
 
Theoretically serum, being clotted plasma, should be fibrinogen-free meaning that fibrinogen 
concentration should be below the measurable limits of sensitivity of 0.3 g/L, by the current 
coagulation assays, Clauss or immunonephelometric assays [6]. Review of the literature did not 
reveal any attempts to quantitate fibrinogen in serum samples for analysis.  Nor is there any 
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defined fibrinogen level/target in “adequately clotted’ serum for tube manufacturers to meet, so 
as to ensure that the fibrinogen is low enough not to cause latent clotting. With the increased 
usage of anticoagulants as therapeutic agents, hospital laboratories in particular are faced with 
growing frequency of serum samples from anticoagulated patients that exhibit latent clotting. 
Latent clotting can also occur from the so called “topping up” of inadequately filled serum tubes 
with blood from lithium heparin, EDTA, citrate or sodium fluoride tubes. The most recently 
published study estimates that EDTA contamination was present in 0.46% of samples submitted 
for routine biochemical analysis [13]. This problem of incomplete clotting can also be observed 
in specimens collected from anticoagulated taps or cannulas.  Such latent clots in turn can lead to 
errors in aspiration of analytical sample, analyser problems, prolonged TAT of results, and can 
ultimately negatively impact on the accuracy of results and patient outcomes. For latent clotting 
to occur there has to be residual fibrinogen in the serum component. Therefore, the residual 
fibrinogen concentration in serum is an important criterion of sample quality.  
 
6.1.2 Cells and cellular content in serum and lithium heparin plasma samples 
Lithium heparin plasma in tubes containing a gel barrier still contains residual cells in contact with 
plasma (Chapter 2). Cells are present in suspension throughout the sample; on top of the sample 
meniscus, and in the buffy coat layer, cell stroma and fibrin on top of the gel barrier in contact 
with the plasma. Disturbing the cell layer or buffy coat will result in decreased clarity of the 
specimen (Figure 6, Chapter 1). Plasma offers reduced stability upon prolonged storage (Chapter 
2). Certain commonly measured and critical analytes change in concentration as a result of 
cellular metabolic activity (e.g. glucose consumption and lactate production), or due to lysis of 
cells (e.g. lactate dehydrogenase - LD, K+, phosphorus - Pi) [14]. With serum samples a small 
number of cells are lysed during the clotting process, and their analytes (e.g. K+, Pi, LD, 
aspartate transaminase – (AST) are released into the serum. Cellular contaminations and 
presence of fibrinogen in plasma account for the differences that are most commonly observed 
between serum and plasma sample types [14, 15].  
 
The presence of cells in plasma makes it a much less suitable sample type for delayed or 
additional testing, > 2 hours. Serum prepared from healthy participant blood samples in 
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commercial tubes is known to contain fewer cells in contact with serum compared with plasma. 
Cells in the analytical sample (serum or plasma) can be aspirated and transferred into the 
reaction vessel, where they will eventually lyse releasing their content. This has been 
documented to be the cause of significant differences in LD duplicate results [16, 17].  Miles et 
al found in their study that LD was ~20% higher in plasma than in serum on two analytical 
systems and yet both reagent manufacturers stated in their method inserts that both serum and 
plasma are acceptable samples [14]. LD is present in the cytoplasm of all cell types and in some 
cells the concentration is 1500-5000 times greater than that in serum [18]. Glucose is used as an 
energy source by cells [19]. Therefore these two analytes are ideal markers for testing cellular 
contamination and hence stability of samples. Other analytes showing significant difference 
between red cells and plasma are K+ and Pi. What makes these analytes useful indicators of cell 
lysis and content leakage is that Pi and K+ concentrations are ~7 [19] and ~25 [20] times 
respectively greater in red cells than plasma.  
 
Biochemistry laboratories in Australia are required to retain all samples for up to 7 days from 
date of receipt [21]. The presence of cells in a sample used for add-on, reflective testing or 
verification of tests at later times will lead to changes in concentrations of some analytes. Thus 
having a cell free sample will help to ensure result accuracy upon prolonged storage. The degree 
of cellular contamination and the HI are therefore two important quality criteria for samples. 
 
6.1.4 Haemoglobin concentration in serum and lithium heparin plasma samples 
 
In vitro cell lysis commonly occurs during collection of samples or transfer of samples when 
using small gauge needles or transfer devices under pressure. In vivo red cell lysis may occur in 
rare haemolytic anaemias. During the lysis of cells, cellular content is released into the serum or 
plasma, falsely altering the results of analytes present in the sample as discussed above. The 
cellular content may also cause dilution of other analytes if the haemolysis is extensive. 
Haemoglobin may cause spectral problems, and other cellular analytes may cross react.  The 
most specific indicator of red cell lysis is the presence of haemoglobin in plasma or serum. The 
haemoglobin concentrations are on average lower in lithium heparin plasma samples than in 
serum and this is considered to be due to the clotting process, with lysis of a small number of 
cells as the clot expands and contracts [22].  The haemolytic index (HI) is a measure of the free 
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haemoglobin released in serum and plasma samples and it is routinely used in general chemistry 
analysers as a measure of the degree of red cell lysis. Rather than visual judgement, the HI is 
then used as the guide to determine at what level analytes are significantly affected. When an 
analyte is affected the result may not be reported, or a result is corrected and a semi-quantitative 
comment is all that is reported [23].  
 
 
6.1.4 Use of snake venom procoagulants to produce serum for biochemical analysis. 
Comparison with results from serum and lithium heparin plasma prepared in 
commercial tubes.   
Snake venom components have been used in a variety of haematology assays. Lupus 
anticoagulants (LAs) are acquired antiphospholipid antibodies which are associated with a wide 
range of symptoms (arterial and venous thrombosis, thrombocytopenia, recurrent foetal loss) and 
are normally identified by interference with phospholipid dependent coagulation assays [24]. 
Current methodologies for detecting LAs have different sensitivity and specificity. Venoms from 
Pseudonaja textilis [25], and Echis carinatus (Ecarin) [24] have been studied for improved 
screening of lupus anticoagulants in patients on oral anticoagulants. Echis carinatus venom has 
also been used diagnostically to predict the vitamin K response since the Echis time is normal in 
the presence of descarboxyprothrombin in warfirinised patients [26]. Ecarin clotting time has 
been suggested as a suitable assay in monitoring anticoagulation with direct thrombin inhibitors 
(lepirudin, argatroban and melagatrin) instead of activated partial thromboplastin time which can 
produce considerable  reagent-dependent differences [27].  Reptilase is a serine protease similar 
in activity to thrombin from Bothrops atrox. It has been used as a method to remove fibrinogen 
from heparinised plasma for serum protein electrophoresis to ensure no paraproteins are masked 
by the fibrinogen band [28, 29]. A normal reptilase time in follow-up to a prolonged thrombin 
time is also used as a method for confirming gross heparin contamination of samples for 
coagulation evaluation. A prolonged reptilase time may also imply fibrinogen deficiency or 
abnormal fibrinogen such as is produced in liver disease [30].  
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Venom PAs being proteolytic enzymes are potentially capable of cutting peptide bonds in 
prothrombin and other proteins [31]. Reichl et al. have shown that a proteolytic enzyme isolated 
from Bothrops moojeni venom hydrolyzed type I collagen, gelatin, fibrinogen, fibrin and the B-
chain of oxidized insulin [32]. Many analytes of interest in biochemistry are proteins or are 
measured using proteins (e.g. enzymes, antibodies etc) in the analytical process. One major 
analytical principle used for proteins is spectrophotometry, both end point (e.g. total protein and 
albumin); rate such as in measuring enzyme activity (e.g. ALT, AST, LD, lipase, GGT, CK); and 
using enzymes to measure analytes (e.g. urea - urease, urate - uricase). The second major 
analytical principle using proteins is the use of antibodies. These include turbidimetric assays 
(e.g. for CRP, transferrin, haptoglobin, therapeutic drugs), nephelometric assays (e.g. for 
albumin, immunoglobulins IgA, IgG, IgM, IgE etc), and immunoassays (competitive and 
sandwich type) (e.g. for ferritin, TnI, cortisol, TSH, fT4 etc). Despite their procoagulant 
properties, snake venom PAs may not be suitable for use in serum tubes for these tests on the 
basis that their proteolytic activity may degrade analytes being measured (where the analyte is a 
protein), or proteins being used in the reaction to measure analyte levels. While the BD RST tube 
contains thrombin to accelerate clotting, its proteolytic activity is highly specific for cutting 
bonds in fibrinogen and several other blood clotting factors. Therefore, unlike the reported 
trypsin-like activity of the PAs, thrombin activity was not expected nor was it shown to interfere 
with any of the analytes tested.   
The aims of the research reported in this chapter were:  
a) to set up a fibrinogen assay that will measure residual fibrinogen levels in serum samples 
produced in commercial collection tubes and tubes containing snake procoagulants in healthy 
and anticoagulated participants, b) to determine the effectiveness of PtPA during the clotting of 
blood from healthy and anticoagulated participants, in removing cells from the serum and the 
level of cell lysis occurring during clotting by PtPA. The level of cells remaining will be 
determined by the concentration changes in analytes e.g. LD, K+ and glucose post storage for 
extended periods of time. The degree of red cell lysis will be determined by measuring the 
haemoglobin concentration in lithium heparin plasma and serum samples; and c) to evaluate the 
ability of PAs purified from three different snake venoms, Pseudonaja textilis (PtPA), 
Oxyuranus scutellatus (OsPA), and Echis carinatus (Ecarin) to produce serum from blood 
218 
 
collected from both healthy and anticoagulated participants suitable for biochemical analysis 
(general chemistry assays and immunoassay). 
 
6.2 Materials and Methods  
The studies were performed at the Princess Alexandra Hospital, Brisbane, Australia with 
appropriate ethics approval from the hospital and The University of Queensland, and with 
informed consent from all volunteers/participants. All participants were > 18 years of age. For 
some of the studies, de-identified samples were obtained from the Pathology Queensland 
Laboratory, PAH.  
 
6.2.1 Snake venom prothrombin activators  
P. textilis and O. scutellatus crude venoms were purchased from Venom Supplies, Tanunda, 
Australia. The PAs were purified as described in Chapter 3 unless otherwise specified, the PtPA, 
OsPA and ecarin were the same as those used in Chapter 3 and 4. The PtPA stock concentration 
was 4.8 mg/mL stored in 0.05 M Tris-HCl buffer, pH 7.4 with 50% glycerol at -20ºC. The 
working concentration was 1:100 dilution of the stock into distilled water (0.048 mg/mL), and 25 
L of this working solution was added per collection tube with 4.0 mL fill volume, giving a final 
PtPA concentration in the tube of 1.2 g/4.0 mL (1.2 nM) in the blood sample.  
 
The OsPA stock concentration was 1.08 mg/mL stored in 0.05 M Tris-HCl buffer pH 7.4 with 
50% glycerol at -20ºC. The working concentration was 1:100 dilution of the stock into distilled 
water (0.0108 mg/mL), and 25 L of this working solution was added per collection tube with 
4.0 mL fill volume, giving a final OsPA concentration in the tube of 0.27 g/4.0 mL (0.27 nM) 
in the blood sample.  
 
For this study a commercial ecarin preparation was purchased, (Ecarin Cat No E0504-1VL; 50 
units contains ~5 g, Sigma, USA) containing 45-50 units per vial diluted in 100 L of distilled 
water, 5g/ 100L or 50g/ mL or 0.83 M (~0.5 units/ L). One ecarin unit is defined as the 
amount which generates one International Unit (IU) of enzyme activity from prothrombin under 
defined test conditions, and IU is equal to the amount of enzyme which hydrolysis 1 mol of 
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substrate per minute under standard conditions [33]. The stock solution was 50g/ mL and this 
was diluted 1:20 with distilled water (50/20 =2.5g/ mL) to provide a working solution, then 25 
L of this working solution was added to each tube of 4 mL fill volume, giving a final ecarin 
concentration of 0.0625 g/4 mL (0.26 nM) of blood. For cardiac surgery participants 50 L was 
added giving a final ecarin concentration of 0.125 / 4 mL (0.52 nM) of blood sample.  A 
second working solution was prepared from the stock solution, 50 g/ mL was diluted 1:20, 5.0 
g/ mL, then 50 L added to 4 mL tube, giving final ecarin concentration of 0.25 g/4 mL (1.04 
nM). 
 
6.2.2 Commercial Blood Collection Tubes  
The following blood collection tubes were used in these studies. 
1. Greiner Vacuette serum tubes (GS), Cat No 456078, 5.0 mL (Greiner Bio-One, 
Kremsmünster, Austria) (contains surfactant, procoagulant – silica particles and gel 
separator) 
2. Becton Dickinson serum tubes  SST II (BDS), (Ref No 367954, 5.0 mL BD Vacutainer 
Systems, Plymouth, UK) (contains surfactant, procoagulant – silica particles and gel 
separator) 
3. Becton Dickinson rapid serum tubes (BDRST), (Ref No 368771), 4.0 mL (contains 
surfactant, procoagulant – thrombin and gel separator) 
4. Greiner Vacuette No Additive tube (Cat No 454001) used with prothrombin activators, 4.0 
mL (this tube has no additives: surfactant, procoagulant or gel separator)  
5. Greiner Vacuette lithium heparin  tubes for plasma (GRLH), Cat No 456083, 5.0 mL 
(contain surfactant, 90 IU of lithium heparin anticoagulant and gel separator) 
6. Becton Dickinson PST II lithium heparin tubes  for plasma (BDLH),  Ref No 367375, 5.0 
mL (contains surfactant, 77 IU of lithium heparin anticoagulant and gel separator) 
7. Greiner Vacuette citrate 3.2% (CIT), Cat No 454327, (contains surfactant and citrate 
anticoagulant)  
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8. Greiner Vacuette EDTA with  1.5-2.2 mg/mL (EDTA), Cat No 454023, (contains 
surfactant and EDTA anticoagulant)  
 
6.2.3 ELISA for measuring fibrinogen levels in serum and plasma samples  
 
6.2.3.1 Materials 
An ELISA method was set up to determine the total fibrinogen concentration in various serum 
and plasma samples using an anti-fibrinogen antibody  (supplied as a purified IgG fraction; 
rabbit anti-human fibrinogen antibody Cat No 341552, Lot D00050478, purchased from 
Calbiochem, USA), and an enzyme-conjugated, anti-fibrinogen antiserum-horseradish 
peroxidase conjugate (Peroxidase Conjugated Goat IgG fraction to human fibrinogen, Cat No 
55239, Lot 05904, Cappel Research Reagents, 2 mL purchased from MP Biochemicals, USA). 
The polyclonal antibodies when bound to the plastic surface of the microtitre plates capture the 
residual fibrinogen, plus fibrin (ogen) breakdown products, and the added enzyme (horse radish 
peroxidase)-conjugate antibody forms a sandwich, which is then reacted with the enzyme 
substrate (H2O2) to produce colour. The absorbance at 450 nm is proportional to the fibrinogen 
concentration. The system was calibrated by a set of diluted standard to provide a suitable 
working fibrinogen concentration range (10-1000 ng/mL).  
 
6.2.3.2 Samples 
In these studies, blood samples from participants (healthy and patients - cardiac and renal 
dialysis) were collected into the following tubes:  
1. GS – Greiner serum 
2. BDS – BD serum  
3. BD RST – BD Rapid Serum Tube 
4. Greiner No Additive tube (Cat No 454001) with added 1.2 g (300 ng/mL of blood)  
prothrombin activator from P. textilis venom for serum, (PtPA); 
5. Greiner No Additive tube (Cat No 454001) with added 0.27 g (67.5 ng/mL of blood) 
prothrombin activator  from O. scutellatus venom for serum, (OsPA); 
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6. Greiner Vacuette No Additive tube (Cat No 454001) with added Ecarin prothrombin 
activator purified from Echis carinatus venom, for serum:  
6.1 ECARIN: 25 L of 2.5  working solution added to 4 mL, 0.0625 g/4 mL); 
6.2 EC1: 50 L of 2.5  working solution added to 4 mL, 0.125 g/4 mL;  
6.3 EC2: 50 L of 5.0  working solution added to 4 mL, 0.25 g/4 mL  
7. GRLH – Greiner lithium heparin 
8. BDLH – BD lithium heparin 
9. CIT - citrate 
10. EDTA 
 
Once samples were collected, GRS and BDS tubes were allowed to stand for 30 minutes with 
blood samples from healthy participants and 60 minutes with blood samples from anticoagulated 
participants after centrifugation. The lithium heparin tubes, BD RST and the tubes containing 
snake procoagulants (PtPA, OsPA, ecarin) were centrifuged immediately upon delivery to the 
laboratory (between 5-15 minutes post-collection). All samples were centrifuged in a swing-out 
bucket rotor centrifuge for 10 minutes at 3000g and 20ºC (Hereaus 1-RS, Germany). The 
Greiner No Additive tube does not contain a gel barrier. Therefore, the PtPA, OsPA and ecarin 
serum samples were transferred into plain plastic aliquot tubes (Beckman plain plastic tubes, 
#448778, Beckman Coulter, Brea, CA, USA) to prevent prolonged contact and remixing with 
cells.  
Plasma samples were diluted 1:1000 and serum samples 1:20 (or higher if incompletely clotted) 
with wash buffer (0.05 M phosphate buffer, pH 7.4, 0.5 M NaCl, 0.05 % Tween 20 and 1% 
BSA) and then 100 L of each diluted sample was added per well in triplicate. The plasma 
samples were then serially diluted in the wells: ½ (1/2000); ¼ (1/4000); up to 1/2048 (1/204800). 
The serum samples were serially diluted in the wells: ½ (1/10) up to 1/2048 (1/40960). In the 
final calculation three dilutions in the linear region were averaged to calculate the final 
concentration for the sample.   
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6.2.3.3 Standards 
The fibrinogen standard used was the WHO standard (Second International Human Standard Cat 
No 98/612, 2200 mg/L) which was purchased from the National Institute for Biological 
Standards and Control (NIBSC), UK [34]. The standard was diluted to form a working stock 
standard concentration of 1 mg/mL in 50% glycerol/saline. The working stock standard was 
diluted 1/1000 with wash buffer (10 L in 10 mL of wash buffer) to give a stock calibration 
standard with concentration of 1 g/mL or 1000 ng/mL. The standards for the calibration curve 
were prepared as outlined in Table 1. Each standard was plated out in duplicate.  A set of 
standards and standard curve were prepared for each run. Once plated the standards were then 
treated like all other samples.  
 
Table 1. Preparation of standards for fibrinogen calibration curve.  
Standard (ng/mL) Stock calibration standard volume (L) Wash buffer volume (L) 
1000 1000 0 
750 750 250 
500 500 500 
300 300 700 
200 200 800 
100 100 900 
80 80 920 
60 60 940 
40 40 960 
20 20 980 
10 10 990 
 
 
6.2.3.4  ELISA Method 
The working dilutions of the capture anti-fibrinogen antibody were prepared by diluting it 1/500 
in binding buffer (0.1 M bicarbonate buffer, pH 9.6). Wells in the NUNC 96 well Immunosorb 
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plates (Cat No 167008, Thermo Fisher Scientific, Rochester, NY, USA) were coated using 100 
L per well of the working solution of the capture anti-fibrinogen antibody overnight at 4ºC. The 
plates were then blocked with a 2% bovine serum albumin (BSA) (Cat No A4503, Sigma) 
solution in wash buffer at 4°C overnight, followed by washing 3 times with 500 L wash buffer 
per well. The wash buffer composition was: 0.05 M phosphate buffer, pH 7.4, 0.5 M NaCl, 0.05 
% Tween 20 and 1% BSA. 
 
6.2.3.5 Assay Procedure 
1. A 100 L aliquot of each sample (standards and patient samples) was added to the 
antibody coated wells. The plates were covered with parafilm and incubated overnight at 
4°C.  
2. The plates were washed 6 times with 500 L wash buffer to remove unbound 
components. A 100 L aliquot (of 1/501 dilution (100uL/50mL) with wash buffer) of the 
enzyme(horse radish peroxidase)-conjugate was added per well, and the plates were 
covered with parafilm and incubated overnight at 4°C.  
3. The plates were washed 6 times with 500 L wash buffer; then 100 L per well of the 
horse radish peroxidase substrate solution was added (20 mM tetramethylbenzidine, Cat 
No 860336, Sigma Aldrich), plus 0.4 mL of 30% H2O2 and 50 L of 0.05 M citrate 
buffer pH 4.0 in a 50 mL). The development of the blue colour was monitored in a 
darkened environment (covered with alfoil) for 45-60 minutes or until the absorbance at 
450 nm reached 1.0 at a fibrinogen concentration of 1 g/mL.  
4. The reaction was then stopped by adding 100 L per well of the stop solution (1.0 M 
sulphuric acid), yielding a yellow colour.  
5. The absorbances were read at 450 nm in a Thermo Scientific Multiskan Ascent 
microplate reader (Thermo Electron Corporation, USA). Absorbance values of the 
standards were fitted to a nonlinear equation for second degree polynomial by least-
squares error method with use of Ascent software version 1.3.1. 
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6.2.4 Estimation of cells and cell contents in serum and plasma 
 
6.2.4.1 Cellular contamination of plasma compared with serum prepared in commercial 
blood collection tubes 
Blood was collected from 41 participants (outpatients presenting to the phlebotomy section) in 
GS and GRLH tubes with gel barriers. The blood was centrifuged and analysed for LD one hour 
after centrifugation. The serum and plasma samples were allowed to stand at room temperature 
(21ºC) and re-analysed 6 hours later.   
 
 
6.2.4.2 Comparison of PtPA serum with lithium heparin plasma from healthy participants 
prepared in commercial tubes 
Blood was collected from 10 healthy participants in GRLH tubes with gel barrier, and washed 
GS tubes containing PtPA. The inside of the GS tubes was first cleaned to remove the Greiner 
procoagulants/additives. The tubes were filled with sterile de-ionized water, inverted ~20 times, 
allowed to stand 10 minutes, and then the inside wall and inner part of tube cap were scrubbed 
with sterile cotton swab without disturbing the gel barrier. The content was discarded and the 
tubes were further filled/inverted/rinsed three times with de-ionised water. The cleaned tubes 
were finally placed in a drying oven at 40ºC to completely dry any water droplets before the 
PtPA was added (1.2 g PtPA/5 mL of blood). All the PtPA containing blood tubes clotted 
visually within three minutes. The two tubes of blood (plasma and PtPA serum) from each 
participant were delivered to the laboratory within 30 minutes post collection, centrifuged and 
immediately analysed for LD and glucose (zero time measurements). The samples were allowed 
to stand at room temperature (21ºC) and re-analysed ~8 hours later on the same analyser.   
 
The primary tubes were used for analysis of LD, K+, Pi and glucose on the Beckman DxC800 
general chemistry analysers (Beckman Coulter, Fullerton, CA, USA). Samples from each 
participant were loaded on the instrument at the same time.  
 
6.2.4.3 Cellular contamination of serum and plasma prepared from anticoagulated patients 
Blood samples were collected from two participants (P1 and P2) undergoing cardiac surgery who 
had received in total 30000 (P1) and 35000 (P2) units of heparin at the time of the blood 
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collection which was ~ 15 minutes post heparin infusion. The samples were collected in 50 mL 
plain syringes (BD Plastipak REF #300866) filled approximately to the 30 mL mark. The 
syringes were delivered to the laboratory within 15 minutes of collection. The following tubes 
were filled (to the fill mark) with blood: GRLH with gel barrier, GS with gel barrier, and washed 
GS tube (cleaned as per procedure above) containing PtPA.  The lithium heparin and PtPA 
containing tubes were centrifuged within five minutes of being filled with the blood. The GS 
tube was allowed to stand for 60 minutes before centrifugation and analysis. The samples were 
allowed to stand at room temperature (21ºC) and re-analysed 24 hours and 336 hours later on the 
same analyser.   
 
6.2.4.4 Observation of cells in samples from healthy and anticoagulated participants 
Blood was collected from a healthy and a cardiac surgery participant in GRLH, and GS tubes, 
and GS tubes containing PtPA, Figure 7. From each of the three tubes the majority of the plasma 
or serum content was gently removed by transfer pipettes without disturbing the layer on top of 
the gel barrier, leaving about 0.5 mL of the plasma or serum in the tube. The residual plasma or 
serum in each tube was re-mixed with the buffy coat layer and transferred into a slide centrifuge 
(Shandon-Elliott Cytospin, Shandon-Elliott Instruments Limited, UK) to concentrate the cells 
and allow preparation of a slide of the cells, cell stroma etc to be Giemsa stained and studied 
under a microscope. 
 
6.2.4.5 Haemoglobin concentration in serum and lithium heparin plasma samples 
Blood samples were collected from two patients undergoing citrate anticoagulation and nine 
healthy participants. Samples were collected in Greiner tubes with gel barriers: GRLH, GS tube, 
and GS containing PtPA. The samples were brought to the laboratory within 10 minutes and the 
GRLH and GS containing PtPA blood tubes were immediately centrifuged and analysed. The GS 
tube was allowed to clot for 30 minutes. The blood in all the GS tubes fully clotted within 15 
minutes. After 30 minutes the tubes were centrifuged and analysed for haemoglobin. The 
plasma/serum haemoglobin method uses standards ranging in concentration from 0 to 600 mg/L. 
The absorbance of unknowns and samples is measured, and the concentration is determined from 
the standard curve.  The haemoglobin absorbance in the plasma or serum was determined 
spectrophotometrically on a Perkin Elmer Lambda 35 spectrophotometer (Perkin Elmer 
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Waltham, MA, USA) based on the Cripps’s method [35] rather than using the semi-quantitative 
estimate of the haemolytic index on the Beckman DxC800 general chemistry analysers.  
 
6.2.5 Evaluation of snake prothrombin activators as clotting agents in blood collection 
tubes: Comparison with current commercial serum and lithium heparin plasma 
tubes. 
 
6.2.5.1 Samples  
All tubes were centrifuged at 3000 g for 10 minutes at 20ºC in swing-out bucket rotor 
centrifuges, and then stored at ~21ºC. The tubes were visually inspected for latent clotting 
immediately after centrifugation and again just prior to loading onto analysers. The primary 
tubes were used for analysis except in cases where latent clotting was observed. In these cases 
the serum was transferred to a plain plastic aliquot tube, re-centrifuged to remove the clots, and 
the clean serum transferred to another plain plastic aliquot tube.  
 
Series 1: Analytical comparison of sera produced with PtPA, OsPA and Ecarin   
In total seven participants were recruited, five healthy, and two participants undergoing cardiac 
surgery. Blood from the healthy participants was drawn by venipuncture using standardized draw 
order: CIT, GS, GRLH, before filling the plain syringe (Terumo 10 mL #CE0197) for the PtPA, 
OsPA or ecarin containing Greiner Vacutainer® No Additive tube blood collected tubes. For the 
two cardiac participants, blood was collected in a 50 mL plain syringe (BD Plastipak REF 
#300866) filled approximately to the 30 mL mark. The two participants had received 34000 and 
43000 units of heparin and specimens were collected 30 minutes post heparin infusion from 
bypass. The blood was delivered to the laboratory within 15 minutes and dispensed into the 
various tubes. The GS tubes were allowed to clot for the standard time of 30 minutes for healthy 
participants and 60 minutes for the cardiac surgery participants, and then visually inspected for 
clot formation prior to loading in the centrifuge. The PtPA, OsPA and ecarin specimens were 
visually inspected for clot formation at the 3 and 5 minute mark for all participants at the point of 
collection (the phlebotomy section for healthy participants and the laboratory for the cardiac 
surgery participants). The lithium heparin, PtPA, OsPA and ecarin specimens were centrifuged 
immediately on delivery in the laboratory (< 30 minutes from collection).  
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Series 2: Analytical comparison of sera produced with PtPA and commercial tubes in 
healthy participants 
In total 61 participants were recruited, both healthy and anticoagulated patients (cardiac and 
dialysis). Of the 61volunteers, 26 were healthy participants, one was an outpatient on low dose 
warfarin, and 34 were inpatients. Of the 34 inpatients, 11 were undergoing cardiac surgery and 
had received in total 25000-41000 units of heparin at the time of the blood collection which was 
within 30 minutes post heparin infusion. The specimens were collected while participants were 
on bypass. There were eight cardiac care unit participants recruited the night before specimen 
collection, receiving heparin by IV infusion, 950-1450 units of heparin per hour. Seven remained 
on IV heparin infusion ( 12 hours) at the time specimens were collected, and one who was due 
for surgery on the day had the infusion stopped approximately three hours prior to specimen 
collection. From the information in the patient records the heparin concentration in the infusate 
and the infusion rate were unchanged for the participants over that period. The remaining 15 
inpatients were on dialysis: 12 on heparin IV infusion, one on warfarin/heparin (~1750-7000 
units of heparin, initial bolus plus hourly top up dose), and two on clexane (30 and 40 mg per 4 
hour dialysis procedure). The specimens were collected at least one hour after dialysis 
commenced.  
 
Blood was collected using standardized draw order into the following tubes: citrate (CIT), GS, 
BD SST II, BD RST, GRLH, and BDLH. Blood was then collected in a plain syringe (Therumo 
10 mL #CE0197) for the PtPA- containing Greiner Vacuette® No Additive tube. The blood was 
drawn by venipuncture from healthy and cardiac care unit participants, via bypass port from 
cardiac surgery participants and via blood line from dialysis participants. The blood was 
transferred from the syringe into the Greiner tube containing the PtPA without a needle to 
minimise cell lysis. The GS and BS tubes were allowed to clot for the standard time of 30 
minutes for healthy participants and 60 minutes for anticoagulated participants. These tubes were 
visually inspected for clot formation prior to loading in the centrifuge. The BD RST and PtPA 
specimens were visually inspected for clot formation at the five minute mark for all participants 
at the point of collection (phlebotomy or clinical unit). The BD RST specimens from the healthy 
participants and the anticoagulated participants that formed a solid clot at five minutes were 
centrifuged as soon as delivered to the laboratory (< 20 minutes). If clotting was incomplete the 
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specimens were re-checked every 10-15 minutes for clotting and left to clot for 60 minutes 
maximum. The lithium heparin and PtPA specimens were centrifuged immediately on delivery 
in the laboratory (< 20 minutes from collection).  
 
Series 3: Analytical Comparison of sera produced with PtPA in citrate anticoagulated 
participants  
Two participants were recruited and they were receiving 3.0 and 3.2 mmol citrate per litre of 
blood flow through the dialysis machine. Blood was collected in a 50 mL plain syringe (BD 
Plastipak REF #300866) filled approximately to the 20 mL mark, and the blood was transferred 
into GRLH, GS and serum tubes with added PtPA at the point of collection. The tubes were 
delivered to the laboratory within 10 minutes. The lithium heparin tubes and serum tubes 
containing PtPA were centrifuged immediately on delivery to the laboratory, while the Greiner 
serum was allowed to stand as recommended for 60 minutes before centrifugation.    
 
6.2.5.2 Sample analysis 
Samples from the same participant were loaded on the same Beckman instruments at the same 
time and within 2 hours post-centrifugation, except where recurrent latent clotting was 
encountered. The analytes tested plus semi-quantitative haemolysis levels are listed in the result 
tables. The upper limits of imprecision of the between-run coefficients of variation (CVs) from 
the two and three internal quality control concentrations for the  analytes tested on the Beckman 
DxC800 analysers the DxI800 analyser respectively are shown in Table 1. We also measured the 
activated partial thromboplastin time (APTT) on an ACTOPS (Instrumentation Laboratory, 
Lexington MA, USA) as it was difficult to ascertain the exact anticoagulant concentration in the 
participants’ blood samples at the time of the specimen collection in the cardiac care unit and for 
dialysis participants.   
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Table 2. Quality Control (QC) imprecision on the Beckman DxC800 and DxI800 analysers 
(*DxI800) analysers, Chemical Pathology, Princess Alexandra Hospital. 
Analyte QC Level 1 QC Level 2 QC Level 3 
 Mean SD CV % Mean SD CV % Mean SD CV % 
Na+ 132 1.27 1.0 150 1.33 0.9    
K+ 3.9 0.06 1.4 6.0 0.07 1.2    
Cl- 85 1.17 1.4 100 1.19 1.2    
HCO3- 17 0.66 3.8 29 0.85 2.9    
Gluc 4.8 0.12 2.6 16.7 0.28 1.8    
Urea 5.2 0.17 3.3 15.9 0.41 2.6    
Creat 68 3.34 4.9 491 8.93 1.8    
Urate 0.23 0.001 1.9 0.49 0.01 1.5    
TP 41 0.73 1.8 67 1.07 1.6    
Alb 26 0.37 1.4 40 0.54 1.3    
T Bili 21 1.37 6.4 93 1.96 2.1    
ALP 106 2.79 2.6 471 7.93 1.7    
GGT 38.7 2.03 5.3 155 2.88 1.9    
ALT 25 1.52 6.2 94 2.00 2.1    
AST 34 1.35 3.9 201 2.39 1.2    
LD 149 3.21 2.2 408 5.65 1.4    
CK 139 2.53 1.8 459 5.8 1.3    
TCa 2.07 0.03 1.6 2.86 0.04 1.3    
Pi 1.00 0.02 1.9 2.86 0.04 1.5    
Mg2+ 0.84 0.02 2.5 1.63 0.04 2.3    
Lipase 29 2.39 8.2 57 4.05 7.1    
Chol 3.0 0.05 1.7 6.5 0.15 2.3    
Trig 1.0 0.04 3.6 2.0 0.05 2.7    
HDL 1.1 0.04 3.5 1.9 0.05 2.6    
Fe2+ 10 0.29 2.8 34 1.93 5.7    
Trf 1.0 0.04 3.5 2.3 0.08 3.5    
CRP 4.6 0.36 7.9 10.0 0.55 5.4    
TnI* 0.052 0.01 16.1 0.55 0.04 7.9 10.2 0.69 6.7 
Cortisol* 139 8.85 6.4 552 28.48 5.2 906 41.7 4.6 
fT4* 7.51 0.62 8.2 23.93 0.94 4.0 50.9 1.92 3.8 
fT3* 3.49 0.23 6.5 7.38 0.36 4.9 12.76 0.68 5.4 
TSH* 0.71 0.05 7.1 4.17 0.26 6.3 23.1 1.53 6.6 
Ferritin* 19 1.68 8.8 159 9.67 6.1 358 22.42 6.3 
 
 
6.2.5.3 Statistical Analysis 
The mean and standard deviation (SD) were calculated for each test and the percent difference 
between the means of the results from each tube. The individual analyte paired differences were 
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also calculated. If a measurement was not obtained for an analyte in any of the tubes (due to 
recurrent latent clotting leading to insufficient specimen, insufficient specimen collected, not 
requested on analyser, or insufficient reagent), the result was not included in the calculation, and 
thus there was slight variability in the number of specimens analysed per assay.  
 
To calculate the acceptable change limit for each assay or the least significant change (LSC) 
which is considered to be smallest difference between successive measurements that are real the 
following equation was used: LSC= 2.77 CVbiological difference + CV analytical difference) to determine if 
analytical differences existed between the paired differences. With the samples being collected at 
the same time in the different tubes, no biological variation needed to be included in the 
calculation of the least significant change, therefore LSC= 2.77 CV
 analytical difference.  The 
analytical coefficient of variation (ACV) for each assay was obtained from Table 2. The ACV 
used in calculating the LSC was the one that most closely matches the mean of the participants 
result set. The critical allowable limits (CAL) were adopted from a publication by Tanner et al 
[36] or based on clinical knowledge.  
 
 
6.3.1 Results and Discussion 
6.3.1 Fibrinogen levels in samples produced in commercial tubes and snake 
procoagulants 
 
6.3.1.1 Fibrinogen concentration in sera from hospital patients 
In total 48 patient blood samples collected in GS tubes received in the PAH Pathology 
Laboratory which had normal profiles (within the stated pathology reference intervals): 
coagulation profile including fibrinogen concentration and electrolyte/liver function profiles and 
were selected at random as received in the laboratory. The results are shown in Figure 2. 
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Figure 2. Fibrinogen concentration in 48 serum samples collected in GS tubes.   
 
In summary, the results indicated that the serum fibrinogen concentration in sera prepared in GS 
tubes in fully clotted samples from a selected hospital population was within a range of 4-32 
g/mL or 4-32 mg/L. These results provided an indication of the concentration levels of 
fibrinogen in fully clotted serum.  
 
 6.3.1.2 Fibrinogen concentrations in serum samples prepared from healthy participants in 
various commercial tubes and with PtPA 
Blood was collected from 9 healthy participants in GS (GRS), BDS, BD RST and Greiner No 
Additive tubes with added 1.2 g/4 mL tube of PtPA (PtPA). The data demonstrated that the 
PtPA tube was the most effective in removing fibrinogen, followed by the new BD RST tube, 
Figure 3.  
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Figure 3. Fibrinogen concentration in sera from 9 healthy participants collected in 
commercial serum tubes and tube containing PtPA. 
 
In summary, all four tubes produced mean fibrinogen concentration of < 30 g/mL (< 30 mg/L) 
compared with 1.7-4.5 mg/mL in plasma with the lowest being in the PtPA produced sera. The 
differences in fibrinogen concentration between the different sera were small which indicated 
that all collection tubes were capable of removing the soluble fibrinogen, partially degraded 
soluble fibrinogen and unpolymerised fibrinogen. The trace amounts of residual fibrinogen in 
these samples may be damaged in such a way as to prevent polymerisation but still react with the 
antibodies. Based on these results, in healthy participants the BD RST and PtPA do not appear to 
offer any advantage in removing fibrinogen over the standard commercial tubes (GS and BDS) 
other than that the clotting was completed (and fibrinogen is consumed) in < 5 minutes. 
 
6.3.1.3 Fibrinogen concentration in sera from healthy participants prepared in various 
commercial tubes and with snake venom procoagulants PtPA, OsPA and ecarin  
Blood was collected from five healthy participants in GS (GRS), and in Greiner No Additive 
tube containing 1.2 g of PtPA/4 mL sample (PTPA), 0.27 g of OsPA/4 mL (OSPA), and 
0.0625 g /4 mL tube of the commercial purified ecarin (ECARIN). The results in Figure 4 show 
that there was minimal residual fibrinogen in all serum samples. 
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Figure 4. Fibrinogen concentrations in sera from a healthy participant group prepared in GS tube 
and in Greiner Vacuette No Additive tubes containing PtPA, OsPA or ecarin. 
 
In summary, the difference in the fibrinogen concentration in the different sera was minimal. The 
three snake venom procoagulants were therefore capable of clotting blood rapidly at the 
concentrations used with no significant soluble fibrinogen remaining to cause latent clotting.  
 
 
 
6.3.1.4 Fibrinogen concentration in sera from dialysis participants prepared in various 
commercial tubes and with PtPA 
Blood was collected from three renal dialysis participants who had received heparin (4000-7000 
units) collected in GS (GRS), BDS, BDRST and Greiner No Additive tubes with 1.2 g/4 mL 
tube of PtPA. Residual fibrinogen results are shown in Figure 5.  
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Figure 5. Serum fibrinogen concentration in three dialysis participants receiving heparin 
collected in commercial serum tubes and tubes containing PtPA. 
 
The fibrinogen results indicated that clotting was incomplete in the commercial tubes but 
complete in the PtPA tubes. This was even after the tubes were left for > 60 minutes to clot 
before being centrifuged. These levels of residual fibrinogen indicate that latent microclot 
formation is likely in the sera prepared in the commercial tubes including the BD RST tube.  
 
6.3.1.5 Fibrinogen concentration in two cardiac surgery participants in various commercial 
tubes and in tubes containing PtPA, OsPA and ecarin  
Blood was taken from two cardiac surgery participants (P1 and P2) in various tubes (P1 received 
34000 and P2 43000 units of heparin ~ 30 minutes prior to the sample collection) in GRLH tubes 
for plasma, GS (GRS), BDRST, and Greiner No Additive tubes with added 1.2 g of PtPA/4 mL 
tube (PTPA), 0.27 g of OsPA/4 mL tube (OSPA), and 0.125g /4 mL tube of ecarin (EC 1) or 
0.25 g /4 mL tube of  ecarin (EC 2) plasma and sera. The results are shown in Figure 6.  
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Figure 6. Fibrinogen concentration in lithium heparin plasma and serum samples from two 
cardiac bypass surgical participants prepared in various commercial tubes and Greiner No 
Additive tubes containing added PtPA, OsPA or ecarin at two different concentrations (EC1 and 
EC2). 
 
The results demonstrated that the commercial serum tubes were unable to clot the blood. Thus 
the concentration of the fibrinogen in the commercial tubes (GS – 1940 g/mL or 1940 mg/L and 
BD RST - 1740g/mL or 1740 mg/L) was similar to what was found in plasma (GLH – 1620 
g/mL or 1620 mg/L). The blood of cardiac patients is usually diluted prior to surgery thus lower 
fibrinogen levels seen in the plasma. These fibrinogen concentrations would be expected to 
produce latent clotting. In contrast, the snake venom PAs were capable of clotting the blood as 
demonstrated by the significantly lower fibrinogen concentrations (mean concentrations PtPA - 
248g/mL or 248 mg/L; OsPA - 145g/mL or 145 mg/L; EC1 - 72 g/mL or 72 mg/L and EC 2 
- 299 g/mL or 299 mg/L). These levels could still cause some latent clotting. Therefore, longer 
clotting times, higher concentrations of PA or both will need to be evaluated for such patients. 
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These results are consistent with the results in Chapter 3 and 4 showing the need for higher PA 
concentrations to give rapid clotting of highly heparinised samples. The EC2 serum contained a 
higher fibrinogen concentration than the lower ecarin concentration tube, EC1. This may suggest 
an impurity in the ecarin preparation which interferes with the immunoassay (i.e. a non-specific 
protease).  
 
6.3.2 Absence of cells and cell contents 
 
6.3.2.1 Comparison of LD and glucose levels in PtPA serum and lithium heparin plasma 
from healthy participants 
Blood was collected from 10 participants in GRLH and in GS tubes containing 1.2 g PtPA / 5 
mL. The LD and glucose were determined immediately post centrifugation (at zero time), and 
after 8 hours storage at 21ºC. Results are shown in Table 3. In PtPA serum samples the LD and 
glucose results showed 0.6% and 1.5% changes compared with 12.5% and 9.1% changes for the 
lithium heparin plasma samples. For the plasma both of these changes are well outside the 
expected LSC limits of 4.4% for LD and glucose. In the plasma, presence of cells results in 
glucose consumption, and the LD increased due to leakage from the cells which lyse during 
storage.  
 
Table 3. A: LD activity and B; Glucose concentration of samples from 10 participants measured 
at 0 and 8 hours post centrifugation stored at 21ºC.  
Plasma LD (U/L) PtPA Serum LD (U/L) LSC (%) A 
0  
hour  
8 
 hours  
Dffce 
(8-0 
hrs) 
% Dffce 
(8-0 hrs) 
0  
hour  
8 
 hours  
Dffce 
(8-0 
hrs) 
% Dffce 
(8-0 hrs) 
 
Mean 177 199 22 12.5 175 173 1.3 0.6 4.4 
SD 14 23 16 9.2 19 16 3.4 2.0  
Plasma Glucose (mmol/L) PtPA Serum Glucose (mmol/L)  B 
0  
hour  
8 
 
hours  
Dffce (8-
0 hrs) 
% Dffce 
(8-0 hrs) 
0  
hour  
8 
 hours  
Dffce 
(8-0 
hrs) 
% Dffce 
(8-0 hrs) 
 
Mean 5.1 4.7 0.5 9.1 5.2 5.1 0.08 1.5 4.4 
SD 0.8 0.9 0.2 5.1 0.8 0.8 0.04 0.9  
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The results confirmed that clotting of the blood with PtPA removed cells effectively for samples 
from healthy participants and this prevented any significant changes in the most affected 
analytes, glucose and LD, for up to 8 hours. Thus, inclusion of PtPA provided high quality stable 
serum from the healthy participants’ blood samples. The sera produced by the GS tube and the 
GS tube containing PtPA from such samples have been shown by these two separate studies to 
contain minimal cellular contamination.  
 
6.3.2.2 Observation of cells in samples from a healthy participant  
Blood was collected from a healthy participant in GRLH, and GS tubes, and GS tubes containing 
PtPA, photograph of the tubes is shown in Figure 7. The slides from each of the tubes are shown 
in Figure 8 and 9, and they clearly indicated presence of red and white cells along with platelets 
in abundance in the plasma, and much smaller numbers of cells in the serum samples.   
 
 
Figure 7. Blood samples from a healthy participant in A-Greiner lithium heparin plasma tube; B-
Greiner serum tube; and C- Greiner serum tube with added PtPA.  
 
 
 
A B C 
Cell layer above 
gel barrier 
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Figure 8.  Cytospin slides and pictures at x10 magnification of the material above the gel barrier 
(A - Greiner lithium heparin plasma; B - PtPA serum; C - Greiner serum).  
A B C 
A B C 
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A- diluted Greiner lithium heparin plasma preparation 
 
 
 
 
B – Greiner tube with added PtPA serum 
Red Cells  
Platelets 
White Cells 
 
Red Cells  
White Cells 
Platelets 
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C - Greiner serum preparation 
 
Figure 9. Cytospin slide at x100 magnification obtained from respective tubes from a healthy 
participant: A) Greiner lithium heparin plasma; B) Greiner serum tube with added PtPA serum, 
and C) Greiner serum. 
 
 
6.3.2.3 Cellular contamination of serum and plasma prepared from heavily anticoagulated 
patients 
Blood was collected in syringes from two cardiac surgery participants, and then transferred to 
GRLH, GS tubes and GS tubes containing 1.2 g PtPA/5 mL. In the GS tube no blood clotting 
was observed nor was any latent clotting detected visually or by analysers over the 24 hours 
post-centrifugation. The PtPA containing GS tubes clotted visually within 3-5 minutes. The GS 
samples did not clot. The three tubes of participant P1 were photographed to indicate the 
presence of cells in the gel barrier and on top of the gel barrier which indicated less than optimal 
sample quality, Figure 10 and 11. Figure 10 indicates the blood was well haemodiluted as 
indicated by the plasma or serum to cell ratio which was very high compared with healthy patient 
blood samples. Figure 12 demonstrates that in the GS tube containing PtPA very few cells were 
Red Cells  
Platelets 
White Cells 
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present above or within the gel barrier, in contrast to the other two tubes where cells were visible 
throughout and above the gel barrier. Figure 13 revealed only one small clump containing almost 
entirely platelets in a microclot, a handful of standalone white cells and no red cells. In the 
GRLH plasma and GS serum samples all three cell types were much more abundant.  
 
The LD and glucose were measured immediately after centrifugation (zero time) and post 24 
hours storage at 21ºC. The results are shown in Table 4. In the PtPA serum samples, the LD and 
glucose results showed changes of -3 and -0.9% at 24 hours compared with the 9%, and -14.8% 
changes in the lithium heparin plasma, and 13% and -13.9% for serum samples respectively. The 
changes in the GS serum and GRLH plasma samples exceed the LSC limits. Similar to the 
healthy participant group, in the plasma the presence of cells results in glucose consumption and 
with cell lysis the leakage of LD is increased. The GS tubes show plasma-like results, expected 
since the samples never clotted.  
 
Table 4.  LD activity (A) and glucose concentration (B) of samples from two cardiac surgery 
participants measured at 0 and 24 hours post centrifugation stored at 21ºC.  
Plasma LD (U/L) Greiner Serum LD 
(U/L) 
PtPA Serum LD (U/L) LSC 
(%) 
A 
0 
hr 
24 
hrs 
Dffce 
(24-0 
hrs) 
% 
Dffce 
(24-0 
hrs) 
0 
hr 
24 
hrs 
Dffce 
(24-0 
hrs) 
% 
Dffce 
(24-0 
hrs) 
0 
hr 
24 
hrs 
Dffce 
(24-0 
hrs) 
% 
Dffce 
(24-0 
hrs) 
 
Mean 87 94 8 9 87 98 11 13 84 81 -3  -3 4.4 
SD 11 1 9 12 8 9 1 1 9 10 1  1  
Plasma Glucose 
(mmol/L) 
Greiner Serum Glucose 
(mmol/L) 
PtPA Serum Glucose 
(mmol/L) 
 B 
0 
hr 
24 
hrs 
Dffce 
(24-0 
hrs) 
% 
Dffce 
(24-0 
hrs) 
0 
hr 
24 
hrs 
Dffce 
(24-0 
hrs) 
% 
Dffce 
(24-0 
hrs) 
0 
hr 
24 
hrs 
Dffce 
(24-0 
hrs) 
% 
Dffce 
(24-0 
hrs) 
 
Mean 5.4 4.6 -0.8 -14.8 5.4 4.7 -0.8 -13.9 5.3 5.3 -0.1 -0.9 4.4 
SD 0.1 0.1 0.0 0.4 0.1 0.1 0.1 1.0 0.1 0.1 0.1 1.3  
 
 
This experiment confirmed clotting of the blood was completed with PtPA even in so called 
“fully heparinised” participants, in a very short time, < 5 minutes. The centrifugation was 
capable of removing cells effectively to prevent any significant changes in the most affected 
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analytes, glucose and LD for up to 24 hours. After the centrifugation the number of residual cells 
was minimal and insufficient to have analytically significant effect on analyte concentrations.   
 
 
 
 [  
 
Figure 10. Blood samples from a fully heparinised (anticoagulated) participant in A - Greiner 
lithium heparin tube; B - Greiner serum tube; and C – Greiner serum tube with added PtPA.  
 
A B C 
Cells above gel 
barrier  
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Figure 11. A close up view of the blood samples in:  A - Greiner lithium heparin plasma tube; B 
- Greiner serum tube; and C – Greiner serum tube with added PtPA.  
A B C 
Cells 
throughout gel 
barrier  
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Figure 12.  Cytospin slides and pictures at 10x magnification of the material above the gel 
barrier (A – PtPA serum; B – Greiner serum; C – diluted Greiner lithium heparin plasma; and D- 
undiluted Greiner lithium heparin plasma).  
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A  - diluted Greiner lithium heparin preparation 
 
 
 
B - Greiner serum preparation 
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C – Greiner serum tube with added PtPA preparation (showing a few white cells on the slide) 
 
 
 
D - Greiner serum tube with added PtPA preparation (showing one of the very few and small 
platelet rich microclots)  
 
Figure 13. Cytospin slide at 100x magnification of the material above the gel barrier in the tubes 
from a fully anticoagulated participant: a) diluted Greiner lithium heparin plasma; b) Greiner 
serum, and c) and d) Greiner serum tube with added PtPA.   
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6.3.2.4 Effect of prolonged storage of serum and plasma samples from one cardiac surgery 
participant on analyte concentrations 
The three samples (GS, GRLH and GS with PtPA) from cardiac surgery participant 2 (see 
6.3.2.3) after 24 hours at room temperature (21ºC) were stored in the primary tubes at 4ºC for 13 
additional days (total time of 14 days or 336 hours), and then were re-analysed for K+, glucose, 
LD and Pi. Results are shown in Table 5. The glucose results clearly indicated that the large 
number of cells in the GRLH plasma and serum remain active, consuming glucose even at 4ºC. 
As the cells gradually lyse they release their content including LD and Pi. The K+ is maintained 
more or less at the same level in the short period of time and gradually rises as the cells lyse. The 
LD in the PtPA serum showed a decrease at 336 hours which is in line with published findings 
[37]. Kreutzer and Fennis showed that the decrease in serum LD activity is due to fraction 4 
instability on storage at 0-4°C, which falls rapidly in the first week, and disappears within 3 
weeks [37]. In the PtPA serum there would be very little if any new LD release as there would 
have been absolute minimal cells present, and the amount released would have been far less than 
the degradation rate of LD fraction 4, hence accounting for the decrease in LD concentration. 
 
Unlike the lithium heparin plasma and serum from the Greiner tubes, the PtPA serum sample 
showed clinically and analytically insignificant changes in the K+ and glucose results, while the 
LD and Pi results showed minimal change.  
 
In this extreme case scenario, serum produced using PtPA provided easily the most stable sample 
type. This indicates that additional analyte testing after storage of PtPA serum samples should 
give reliable analytical results, unaffected by cellular contamination.  
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Table 5.  Concentration of analytes from a cardiac surgery participant measured at 0, 24 and 336 
hours post centrifugation (tubes were stored at 21ºC for the first 24 hours and then at 4ºC).  
Analyte 0 hr 24 hrs 336 hrs Dffce 
(24-0) 
%Dffce 
(24-0) 
Dffce 
(336-0) 
%Dffce 
(336-0) 
LSC 
(%) 
Plasma   
K+ (mmol/L)  4.7 4.6 4.9 -01 -2.1 0.2 4.3 3.2 
Glucose 
(mmol/L) 
5.5 4.1 3.1 -1.4 -25.5 -2.4 -43.6 4.4 
LD (U/L) 79 93 208 14 17.7 129 163.0 4.4 
 
Pi (mmol/L) 0.59 0.6 0.69 0.01 1.7 0.1 16.9 4.4 
Greiner Serum   
K+ (mmol/L)  4.7 4.7 5.2 0 0 0.5 10.6 3.2 
Glucose 
(mmol/L) 
5.5 4.7 3.8 -0.8 -14.5 -1.7 -30.9 4.4 
LD (U/L) 81 91 180 10 12.3 99 122.2 4.4 
Pi (mmol/L) 0.58 0.63 0.74 0.05 7.8 0.16 27.6 4.4 
Greiner serum tube with PtPA  
K+ (mmol/L)  4.6 4.6 4.6 0 0 0 0 3.2 
Glucose 
(mmol/L) 
5.4 5.3 5.3 0.1 1.9 -0.1 -1.9 4.4 
LD (U/L) 77 74 64 3 3.9 -13 -20.3 4.4 
Pi (mmol/L) 0.57 0.58 0.65 -0.01 -1.8 0.08 12.3 4.4 
 
 
6.3.2.5 Haemoglobin concentration in serum and lithium heparin plasma samples 
Blood was collected from 11 participants (9 healthy and 2 citrated) into GRLH and GS tubes and 
GS tubes containing 1.2 g PtPA/5 mL. The GRLH and the GS containing PtPA tubes were 
centrifuged immediately on delivery to the laboratory, while the GS was allowed to stand the 
mandatory 30 minutes then centrifuged. The samples were analysed for haemoglobin within 30 
minutes post centrifugation; the means were then determined for each sample type and the results 
are shown in Table 6.  
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Table 6. Haemoglobin concentration in lithium heparin plasma and serum samples.    
Sample Greiner Lithium 
Heparin Plasma 
haemoglobin (mg/L) 
Greiner Serum 
haemoglobin  
(mg/L) 
Greiner Serum with 
added PtPA 
haemoglobin  (mg/L) 
Number of samples 
(2 citrated and 9 healthy 
participants) 
11 11 11 
Mean 55 67 46 
SD 26 28 25 
 
The data confirmed that the PtPA produced sera had lower haemoglobin levels than the standard 
sera or lithium heparin plasma samples produced in Greiner tubes. The GRLH and GS tubes 
contain a surfactant on the inner wall to minimise cellular material and proteins from adhering to 
the tube wall. In contrast, the GS tube containing the PtPA underwent a washing process to 
remove the Greiner Serum tube procoagulant and surfactant. The removal of surfactant would be 
expected to enhance adherence of cells and proteins to the wall in these washed tubes. During the 
centrifugation they will quite likely lyse, increasing the Hb concentration. Therefore it is 
anticipated that the presence of a surfactant in tubes containing PtPA may lead to a further 
lowering of the Hb concentration.  
 
The data was tested for statistical difference between the tubes using paired t-test analysis. The 
difference was taken as statistically different if the p was < 0.05. The paired t-tests results are as 
follows: 
Greiner lithium heparin v Greiner serum: p = 0.1243 
Greiner lithium heparin v PtPA serum: p = 0.1038 
PtPA serum v Greiner serum:  p = 0.0188  
This analysis confirmed that the PtPA produced sera contained significantly lower haemoglobin 
levels than the sera produced in Greiner serum tubes. The likely explanation for decreased cell 
lysis is that PtPA leads to very rapid and solid clot formation which minimises the ability of the 
clot to contract and lyse cells. During centrifugation the solid clot is likely to move as a whole 
with minimal deformation under centrifugal force, protecting the cells from further lysis.  The 
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data also suggested that it may be possible to produce serum using PtPA which has lower 
haemoglobin than plasma, in tubes that include surfactant.  
 
6.3.3 Analytical results from serum samples produced using snake venom prothrombin 
activators. Comparison with results from serum and plasma prepared in 
commercial tubes.  
So far it has been shown that production of serum in blood collection tubes containing snake 
venom prothrombin activators has certain advantages, specifically faster clotting of blood 
containing a wide variety of anticoagulants and anticoagulant concentrations, lower residual 
fibrinogen, lower cellular contamination and lower haemoglobin as a result of lower cell lysis. 
However, it was necessary to demonstrate that production of serum with snake venom 
procoagulants does not alter analyte concentrations. This is particularly important as the 
procoagulants could potentially cause proteolytic degradation of analytes, proteins and proteins 
used in analyses. Three series of experiments were performed as set out below. Experimental 
details have been provided in this Chapter in Materials and Methods.      
 
Series 1: Analytical comparison of sera produced with PtPA, OsPA and Ecarin in healthy 
and anticoagulated participants  
The blood of five healthy and two anticoagulated (heparin - cardiac surgery) participants clotted 
within five minutes in the PtPA, OsPA and ecarin containing tubes. The different snake venom 
produced sera, GS sera and GRLH plasma were analysed. Table 7 lists all the analyte results 
determined in the five different tubes: GS, GRLH, Pt-PA, Os-PA, and ecarin. In the four serum 
tubes there was generally good agreement between the analyte concentrations determined. 
Differences between GRLH and the different sera that showed results above the LSC limits were 
for K+, HCO3-, TP, GGT, AST, Pi, and TnI. The differences observed in K+, AST and Pi are 
common findings between lithium heparin plasma and serum specimens. The K+, AST and Pi are 
expected to be higher in the serum samples due to increased haemolysis as a result of the clotting 
process. The Greiner tubes containing the snake venom PAs did not contain any additives or gel 
barrier. To minimise cellular impact on serum analytes the sera were transferred into aliquot 
tubes. The HCO3- is lower probably due to loss of CO2 to air during the transfer of the sera from 
the primary tube to an aliquot tube for analysis. The TP results were lower in the sera due to the 
PAs being able to remove the fibrinogen from the samples, resulting in lower TP concentration.  
251 
 
 
The GGT differences were not analytically significant at this low level; it is within the analytical 
performance limits of the assay. To demonstrate this a random patient specimen was analysed for 
GGT 10 times and produced a mean of 19.6, SD 1.84 and a CV of 9.4%, giving an LSC limit of 
8.5% rather than 7.3% as indicated in Table 8. Furthermore some samples had GGT values as 
low as 11 U/L, which means the CV at lower level would be even higher than 9.4%. The 
triglyceride differences in the PtPA and OsPA tubes were due to PtPA and OsPA being stored in 
50% glycerol, since glycerol cross reacts in the triglyceride assay.  
 
Although the raw differences in TnI suggest they were significant, the concentration levels of 
five of the samples were very low (<0.025 g/L). The difference in TnI results between the 
different tubes may be attributed to the high imprecision (>20%) at this low level and due to 
contribution from the effects of microclots. In fact, both analytically and clinically, the 
differences in the results were not significant as they are below the reference cut off limit of 
<0.04g/L. The imprecision at just above the cut off limit was significantly decreased, at a mean 
of 0.051g/L the CV was 14.1%.  
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Table 7. Analytical data for samples prepared using three venom prothrombin activators and for serum and lithium heparin plasma 
prepared in Greiner tubes. * Analysis performed on a DxI800 immunoassay analyser.  
 
 
Mean ± SD 
 
GS - PtPA GS - OsPA GS - Ecarin GS – GRLH  LSC 
(%) 
CAL 
(%) 
No of 
Samples  
Analyt
e 
Units  GS Pt-PA OS-PA Ecarin  GRLH Mean dffce 
between pairs 
(%) 
Mean dffce 
between 
pairs (%) 
Mean dffce 
between pairs 
(%) 
Mean dffce 
between pairs 
(%) 
  
7 Na+ mmol/L 138.1±1.5 137.3±1.3 136.7±2.4 137.1±1.6 138.1±1.2 0.6 1.0 0.7 0.0 2.8 3 
7 K+ mmol/L 4.61±0.71 4.53±00.77 4.50±0.76 4.49±0.79 4.40±0.82 0.1 0.1 0.2 4.9 3.3 5 
7 Cl- mmol/L 104.0±2.6 103.0±2.6 102.9±2.34 103.4±2.4 104.0±2.8 1.0 1.1 0.6 0.0 3.3 5 
7 HCO3- mmol/L 25.3±3.5 23.9±2.4 24.1±2.7 23.3±2.2 25.1±3.2 5.1 4.1 7.3 0.4 4.8 10 
7 Gluc mmol/L 5.69±0.94 5.63±0.0.81 5.60±0.80 5.64±0.0.90 5.76±0.88 0.6 1.1 0.6 -1.5 4.4 10 
7 Urea mmol/L 4.66±0.80 4.64±0.85 4.54±0.83 4.54±0.88 4.63±0.82 0.5 2.7 2.8 0.7 5.0 10 
7 Creat mol/L 76.7±12.35 75.9±12.10 76.29±12.54 75.0±12.7 75.1±10.9 1.0 0.5 2.3 1.7 5.5 10 
7 Urate mmol/L 0.33±0.08 0.33±0.08 0.32±0.07 0.32±0.08 0.33±0.08 0.4 1.8 1.4 0.1 3.8 10 
7 TP g/L 63.0±11.0 63.4±12.5 62.4±14.1 63.4±13.4 68.5±11.0 -0.3 1.8 0.0 -4.6 3.5 5 
7 Alb g/L 38.3±5.5 38.6±5.8 38.4±6.0 38.6±5.8 38.3±5.5 -0.3 -0.1 -0.3 0.0 3.2 5 
7 T Bili mol/L 16.6±4.7 16.4±4.5 16.1±4.6 15.7±5.2 15.6±4.6 -0.9 1.6 5.6 5.2 7.0 10 
7 ALP U/L 66.0±18.4 66.1±20.7 66.7±18.6 67.9±18.7 65.7±18.6 0.4 -1.1 -2.9 0.4 4.8 10 
7 GGT  U/L 25.1±15.0 25.4±14.7 25.7±15.8 24.9±15.8 27.4±15.2 -2.8 -2.7 1.4 -14.7 7.3 10 
7 ALT U/L 31.0±11.8 32.0±11.4 31.7±12.2 32.1±11.8 30.4±11.4 1.3 -4.2 -2.2 -4.4 6.8 10 
7 AST U/L 25.0±8.3 24.1±7.2 24.9±6.5 24.9±6.7 22.6±7.8 1.9 -1.9 -1.4 9.4 6.2 10 
7 LD U/L 193.6±41.6 195.6±22.4 189.0±18.9 192.7±21.2 194.4±23.1 -3.1 0.3 -1.6 -2.2 3.7 15 
7 CK U/L 97.9±37.5 98.6±36.8 97.1±34.0 98.0±36.1 98.9±34.9 -1.2 -0.3 -0.8 -2.1 3.7 15 
7 TCa mmol/L 2.23±0.245 2.22±0.255 2.20±0260 2.21±0.25 2.20±0.236 0.7 1.4 1.1 1.2 3.5 5 
7 Pi mmol/L 1.18±0.14 1.19±0.13 1.16±0.14 1.17±0.13 1.13±0.13 -0.6 1.3 1.1 4.1 3.8 10 
7 Mg2+ mmol/L 1.06±0.22 1.03±0.20 1.03±0.19 1.04±0.21 1.04±0.23 2.1 2.6 1.3 1.5 4.4 10 
7 Chol mmol/L 4.3±1.7 4.3±1.7 4.3±1.7 4.3±1.7 4.3±1.7 -1.2 0.1 -0.1 0.3 3.6 10 
7 Trig mmol/L 1.41±1.0 2.1±1.0 2.9±1.9 1.4±1.1 1.4±1.1 -69.4 -159.2 -0.4 -1.5 5.3 10 
7 HDL-C mmol/L 1.04±0.23 1.01±0.27 1.03±0.28 1.01±0.06 1.07±0.27 4.8 2.6 3.9 -1.7 5.2 10 
7 Fe2+ mol/L 16.3±5.9 16.4±5.8 16.4±5.7 16.1±5.8 16.1±5.8 -1.5 -1.8 0.6 0.6 3.7 10 
7 Trf g/L 2.18±0.51 2.21±0.54 2.20±0.53 2.21±0.55 2.18±0.51 -1.3 -0.8 -1.1 -0.2 4.8 10 
7 CRP g/L 1.9±1.6 1.7±1.5 1.9±1.6 1.7±1.5 1.7±1.5 4.8 0.0 4.8 7.1 8.8 10 
7 Cortiso
l* 
nmol/L 379.7±247.2 373.6±256.9 366.3±241.2 359.3±237.7 382.1±251.4 -0.7 3.4 4.0 6.3 6.4 15 
7 FT4* Pmol/L 13.56±3.26 13.46±1.2.39 13.76±3.17 14.23±3.13 13.53±2.63 -0.6 -1.7 -5.6 -0.7 6.5 30 
7 TSH* IU/mL 1.88±0.56 1.72±0.30 1.75±0.30 1.73±0.32 1.86±0.48 6.0 4.4 7.2 0.2 7.3 15 
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7 Ferritin
* 
g/L 234.9±304.8 226.4±280.8 221.6±272.2 225.3±280.1 236.6±297.2 -0.3 0.9 0.0 -3.8 7.2 15 
7 TnI* g/L 0.071±0.137 0.091±0.165 0.092±0.170 0.093±0.174 0.079±0.136 -342.8 -245.5 -192.7 -186.1 8.8 10 
7 Haem 
Index 
 0.6±0.8 0.6±0.5 0.4±0.5 0.4±0.5 0.4±0.5       
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Series 2: Analytical comparison of sera produced with PtPA in healthy and anticoagulated 
participants  
 
Visual Observations 
There were 61 samples, 26 from healthy participants and 35 from anticoagulated participants 
(warfarin, heparin, and clexane). The blood of all the healthy and anticoagulated participants 
clotted within five minutes in the PtPA (1.2 g/4 mL) containing tubes. The blood of the healthy 
participants and one low dose warfarin participant clotted within ~ 5 minutes in the Greiner, 
BDS and BD RST serum tubes, forming a solid immobile clot, with no latent clotting 
encountered. Blood samples from 11 cardiac surgery participants receiving 25000-41000 units of 
heparin had APPTs > 200 seconds. These samples did not clot at all in GS and BD SST tubes, 
and no latent clotting was visually observed or detected by the analysers. Whereas in the BD 
RST tubes, blood samples did not form a firm clot but limited latent clotting was visually 
observed after centrifugation. None was detected by the analysers. Blood specimens from eight 
cardiac care unit participants who received 950-1450 units of heparin per hour took 20 minutes 
or longer to form a visibly semi-solid or solid clot in the GS and BDS, and up to 20 minutes in 
the BD RST specimens. When the APTT was < 60 seconds there was no latent clotting visually 
observed or detected by the analysers. Similarly, the GS and BDS specimens from the dialysis 
participants who received 3250-7000 units heparin (plus taking 100-150 mg salicylate daily) 
took 20 minutes or longer to form a visibly semi-solid or solid clot. The BD RST specimens 
visibly clotted within ~20 minutes. No latent clotting was visually observed or detected by the 
analysers in the specimens with < 5000 units of heparin and APTT < 150 seconds or in 
specimens from two participants on clexane. In contrast, latent clotting was visually observed 
and detected by the analysers in GS, BDS and BD RST specimens in the two participants who 
received 6000-7000 units of heparin, APTT > 150 seconds. With the single participant on 6x4 
mg/day warfarin plus ~5000 units of heparin (APTT >150 seconds), latent clotting was only 
detected by the analysers in the BD RST specimen. For the blood sample from the one dialysis 
participant who received 1750 units of heparin, the BD RST specimen visibly clotted in ~ 5 
minutes, and the GS and BDS in ~30 minutes and no latent clotting was  encountered, yet the 
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APTT was > 200 seconds. This may well have been due to increased heparin concentration 
arising from the well as the citrate tube was the first tube collected.  
 
Analytical Comparison 
Table 8 lists all the analyte results determined in the six different tubes: PtPA, GS, BDS, 
BDRST, GRLH, and BDLH. For the analytes tested in the six tubes there was generally good 
agreement between the concentrations determined, particularly between the sera. Therefore, 
PtPA did not interfere or cause proteolytic degradation of any of the protein analytes being 
measured or proteins used as reagents, at least not to the extent which would have produced 
analytical differences. The differences that were observed were directly associated with 
differences in analytes between serum and lithium heparin. Small differences may be due to the 
effect of using Greiner No Additive tubes (no surfactant) with PtPA resulting in increased 
cellular lysis from cellular adhesion to the tube wall. Differences that were outside the LSC 
limits were: a) PtPA vs. GRLH and BDLH – K+, TP, ALP, Pi, HDL-C, and TnI; and b) PtPA vs. 
GS, BDS and BDRST (serum tubes) AST, and TnI. The PtPA sera results when compared with 
GS sera were outside the LSC limit (AST and TnI) but within the clinically allowable limit. The 
TnI differences are explained later in this chapter.  
 
Results from the healthy and anticoagulated groups were then separately analysed (Table 9) for 
analytes exceeding the LSC limits (K+, TP, Pi, AST, ALP, and HDL-C) to check if the healthy 
and anticoagulated PtPA serum results showed differences compared with lithium heparin 
plasma specifically. The data showed that the K+, AST and Pi differences were greater in the 
normal participants. The normal samples had higher cell and protein concentrations. The Greiner 
No Additive tube containing the PtPA, not having a surfactant on the wall, may allow more cells 
to adhere to the tube wall and lyse during the centrifugation as force is applied to release the 
bound cells from the wall, thus increasing these analytes. This is likely to account for the AST 
differences observed above the estimated LSC limit but within acceptable CAL limit with 
normal participants.  
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It is well documented that serum has a lower protein concentration than plasma due to removal 
of fibrinogen. The TP results were lowest in the PtPA produced serum compared with the other 
serum samples. This was probably because PtPA gave complete clotting all of the anticoagulated 
samples, thus removing more of the fibrinogen from the samples, resulting in lower mean TP 
concentration. The ALP difference in PtPA sera was highest when compared with the lithium 
heparin plasma specimens perhaps due to heparin binding the ionised zinc which is necessary for 
ALP activity. This binding would be similar to the effects heparin has on ionsed Ca2+ and ionised 
Mg2+ [38].  
 
All specimens, irrespective of the tube type, showed minimal haemolysis. All of the haemolysis 
results were either zero or 1 (< 50 mg/dL free haemoglobin), which is very low and unlikely to 
influence clinically any of the analyte determinations. 
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Table 8. Analytical data on samples prepared in six different tubes. The difference is the mean from individual paired results. * Analysis 
performed on a DxI800 immunoassay analyser.  
   Mean ± SD PtPA - GS PtPA – 
BDS 
PtPA - 
BDRST 
PtPA - 
GRLH 
PtPA – 
BDLH 
LSC  CAL 
Number 
of 
samples 
Analyte Units  PtPA GS BDS BDRST GRLH BDLH % 
dffce 
% 
dffce 
% dffce   % 
dffce 
% 
dffce 
(%) (%) 
61 Na+ mmol/L 136.9 
± 2.2 
137.5 
±2.3 
137.5 
±2.3 
137.4 
±2.4 
137.4 
± 2.4 
137.2 
±2.4 
-0.5 
 
-0.5 
 
-0.4 
 
-0.4 
 
-0.3 2.8 3 
61 K+ mmol/L 4.09 
± 0.59 
4.13 
± 0.62 
4.15 
± 0.60 
4.07 
± 0.60 
3.91 
± 0.63 
3.93 
± 0.65 
-0.9 
 
-1.3 
 
0.5 
 
4.3 
 
3.9 
 
3.3 5 
61 Cl- mmol/L 104.1 
± 3.8 
104.6 
±4.0 
104.8 
±3.8 
104.7 
±3.9 
104.6 
± 4.2 
104.8 
±4.1 
-0.5 
 
-0.7 
 
-0.6 
 
-0.5 
 
-0.7 
 
3.3 5 
61 HCO3- mmol/L 24.8 
± 2.8 
25.7 
±3.1 
25.1 
±2.9 
25.0 
±3.0 
25.8 
± 3.0 
25.3 
±2.7 
-3.7 
 
-1.3 
 
-0.9 
 
-4.1 
 
-2.1 
 
4.8 10 
61 Gluc mmol/L 6.2 
±2.09 
6.2 
±2.07 
6.2 
±2.11 
6.3 
±2.08 
6.3 
±2.15 
6.3 
±2.11 
-0.4 
 
-0.2 
 
-1.3 
 
-2.5 
 
2.6 
 
4.4 10 
61 Urea mmol/L 5.3 
±2.0 
5.3 
±2.1 
5.4 
±2.1 
5.3 
±2.1 
5.3 
±2.0 
5.4 
±2.0 
0.3 
 
-0.6 
 
-0.4 
 
-0.3 
 
-0.6 
 
5.0 10 
61 Creat mol/L 134.1 
±112.8 
137.1 
±116.0 
136.7 
±116.0 
138.1 
±116.6 
135.1 
±115.0 
136.3 
±114.7 
-2.2 
 
-1.9 
 
-2.9 
 
-0.7 
 
-1.6 
 
5.5 10 
60 Urate mmol/L 0.27 
±0.11 
0.28 
±0.11 
0.28 
±0.11 
0.27 
±0.12 
0.27 
±0.12 
0.27 
±0.12 
-1.1 
 
-1.4 
 
-0.8 
 
-0.6 
 
-0.9 
 
3.8 10 
61 TP g/L 62.6 
±13.0 
63.0 
±12.6 
63.0 
±12.5 
62.8 
±12.6 
65.0 
±13.2 
65.5 
±13.3 
-0.6 
 
-0.7 
 
-0.2 
 
-3.9 -4.5 
 
3.5 5 
61 Alb g/L 36.1 
±8.3 
36.1 
±8.3 
36.1 
±8.3 
36.2 
±8.3 
35.9 
±8.1 
35.9 
±8.1 
0.2 
 
0.1 
 
-0.1 
 
0.5 
 
0.7 
 
3.2 5 
58 T Bili mol/L 13.5 
±3.8 
13.3 
±3.6 
13.4 
±4.0 
13.2 
±3.8 
13.6 
±3.7 
13.4 
±3.4 
1.2 
 
-0.3 
 
1.9 
 
-0.8 
 
-0.4 
 
7.0 10 
61 ALP U/L 74.1 
±26.9 
71.3 
±26.9 
71.7 
±27.5 
71.4 
±26.9 
68.9 
±26.5 
69.4 
±26.6 
3.7 
 
3.3 
 
3.7 
 
7.0 
 
6.3 
 
4.5 10 
61 GGT U/L 27.9 
±17.6 
27.3 
±17.1 
28.1 
±17.1 
27.8 
±17.5 
28.3 
±17.0 
28.1 
±16.9 
2.3 
 
0.4 
 
0.5 
 
-1.5 
 
-0.8 
 
6.8 10 
61 ALT U/L 30.4 
±19.9 
30.4 
±19.1 
29.8 
±19.2 
30.7 
±20.1 
29.6 
±18.8 
29.6 
±19.1 
-0.1 
 
1.8 
 
-1.0 
 
2.6 
 
2.5 
 
6.8 10 
59 AST U/L 34.2 
±37.7 
32.0 
±34.9 
32.6 
±38.7 
32.4 
±39.1 
32.5 
±37.5 
32.6 
±36.9 
6.5 
 
5.5 
 
5.3 
 
5.1 
 
4.7 
 
5.5 10 
58 LD U/L 212.9 
±110.0 
213.8± 
106.0 
222.8 
±120.0 
212.5 
±119.2 
215.4 
±113.1 
215.3 
±110.7 
-0.5 
 
-4.7 
 
0.2 
 
-1.2 
 
-1.2 
 
5.0 10 
59 CK U/L 147.1 
±250.3 
146.0 
±241.3 
149.4 
±259.6 
147.7 
±253.3 
146.6 
±250.0 
145.3 
±242.8 
0.7 
 
-1.6 
 
0.5 
 
0.3 
 
1.2 
 
3.7 10 
61 TCa mmol/L 2.19 2.20 2.20 2.19 2.17 2.17 -0.4 -0.72 -0.1 0.81 0.62 3.5 5 
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±0.26 ±0.26 ±0.26 ±0.26 ±0.24 ±0.24     
61 Pi mmol/L 1.07 
±0.28 
1.08 
±0.30 
1.08 
±0.30 
1.08 
±0.30 
1.02 
±0.28 
1.02 
±0.28 
-0.6 
 
-0.8 
 
-0.5 
 
4.9 
 
4.3 
 
3.8 10 
57 Mg2+ mmol/L 0.94 
±0.19 
0.94 
±0.18 
0.94 
±0.20 
0.93 
±0.20 
0.95 
±0.20 
0.94 
0.19 
-0.98 
 
-0.11 
 
0.02 
 
-1.26 
 
-0.23 
 
4.4 10 
59 Lipase U/L 28.2 
±9.0 
28.2 
±9.0 
28.6 
±9.2 
28.2 
±9.0 
28.3 
±9.0 
28.3 
±8.9 
0.2 
 
-1.3 
 
0.1 
 
-0.1 
 
-0.3 
 
7.9 10 
57 Chol mmol/L 4.2 
±1.6 
4.3 
±1.6 
4.3 
±1.6 
4.3 
±1.6 
4.2 
±1.6 
4.2 
±1.6 
-0.9 
 
-1.0 
 
-1.1 
 
1.1 
 
1.1 
 
3.6 10 
58 HDL-C mmol/L 1.17 
±0.6 
1.20 
±0.58 
1.21 
±0.58 
1.21 
±0.59 
1.25 
±0.58 
1.26 
±0.60 
-2.8 
 
-3.7 
 
-3.8 
 
-7.1 
 
-8.3 
 
5.2 10 
59 Fe2+ mol/L 14.6 
±6.6 
14.7 
±6.7 
14.9 
±6.7 
14.6 
±6.6 
14.5 
±6.5 
14.6 
±6.7 
-1.2 
 
-2.2 
 
-0.2 
 
-0.4 
 
0.0 
 
4.8 10 
59 Trf g/L 2.17 
±0.74 
2.17 
±0.73 
2.19 
±0.73 
2.18 
±0.77 
2.13 
±0.71 
2.14 
±0.72 
0.3 
 
-0.7 
 
-0.4 
 
1.8 
 
1.7 
 
5.2 10 
57 CRP g/L 14.4 
±49.3 
14.2 
±46.8 
15.0 
±52.3 
15.1 
±52.4 
14.5 
±49.5 
14.6 
±50.5 
-1.7 
 
-3.6 
 
4.5 
 
-0.3 
 
-1.1 
 
6.4 10 
59 Cortisol
* 
nmol/L 356 
±247 
356 
±249 
352 
±248 
358 
±250 
354 
±241 
356 
±254 
0.1 
 
1.2 
 
-0.5 
 
-0.5 
 
0.5 
 
6.5 30 
60 FT4* Pmol/L 13.6 
±4.1 
12.7 
±3.9 
12.7 
±3.9 
12.8 
±3.7 
12.7 
±3.7 
12.7 
±3.6 
6.5 
 
6.8 
 
6.2 
 
6.7 
 
6.8 
 
7.3 15 
61 TSH* IU/mL 1.81 
±2.12 
1.83 
±2.10 
1.82 
±2.02 
1.86 
±2.08 
1.87 
±2.05 
1.89 
±2.12 
-0.8 
 
-0.8 
 
-2.6 
 
-3.6 
 
-4.3 
 
7.2 15 
43 Ferritin* g/L 204 
±191 
208 
±203 
207 
±198 
204 
±187 
199 
±191 
202 
±192 
-3.8 
 
-1.3 
 
-0.0 
 
5.5 
 
1.8 
 
6.8 15 
60 TnI* g/L 0.873 
±5.33 
0.782 
±4.77 
0.869 
±5.25 
0.951 
±5.75 
0.994 
±6.06 
0.945 
±5.75 
10.4 
 
-0.5 
 
-8.9 
 
-13.8 
 
-8.1 
 
7.8 10 
61 Haem 
Index 
 0.2 
±0.7 
0.3 
±0.7 
0.2 
±0.7 
0.2 
±0.7 
0.2 
±0.7 
0.3 
±0.7 
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Table 9. Analytical data from Table 8 samples, split into a - normal and b - anticoagulated participants. The difference is the mean from 
individual paired results. The difference is the mean from individual paired results.  
   Mean ± SD PtPA - 
GS 
PtPA - 
BDS 
PtPA - 
BDRST 
PtPA - 
GRLH 
PtPA - 
BDLH 
LSC  CAL  
Number 
of 
samples 
Analyte Units  PtPA GS BDS BDRST GRLH BDLH % 
Mean 
dffce 
% 
Mean 
dffce 
%  
Mean 
dffce  
 % 
Mean 
dffce 
% 
Mean 
dffce 
(%) (%) 
61 K+ mmol/L 4.09 
± 
0.59 
4.13 
± 
0.62 
4.15 
± 
0.60 
4.07 
± 0.60 
3.91 
± 0.63 
3.93 
± 0.65 
-0.9 
 
-1.4 
 
0.5 
 
4.4 
 
4.0 
 
3.3 5 
26 aK+ mmol/L 4.07 
±0.25 
4.14 
±0.30 
4.14 
±0.27 
4.07 
±0.29 
3.83 
±0.28 
3.84 
±0.30 
-1.7 
 
-1.7 
 
0.0 
 
6.0 
 
5.6 
 
3.3 5 
35 bK+ mmol/L 4.11± 
0.76 
4.12 
±0.78 
4.15 
±0.76 
4.07 
±0.76 
3.98 
±0.79 
4.00 
±0.81 
-0.3 
 
-1.1 
 
0.9 
 
3.3 
 
2.8 
 
3.3 5 
61 TP g/L 62.6 
±13.0 
63.0 
±12.6 
63.0 
±12.5 
62.8 
±12.6 
65.0 
±13.2 
65.5 
±13.3 
-0.9 
 
-1.0 
 
-0.4 
 
-3.9 
 
-4.7 
 
3.5 5 
26 aTP g/L 70.0 
±4.3 
70.8 
±3.4 
70.5 
±3.9 
70.2 
±3.5 
72.2 
±4.4 
72.8 
±4.0 
-1.2 
 
-0.8 
 
-0.3 
 
-3.1 
 
-4.1 
 
3.5 5 
35 bTP g/L 57.1 
±14.5 
57.2 
±13.9 
57.5 
±13.8 
57.2 
±14.0 
59.6 
±15.0 
60.0 
±15.1 
-0.6 
 
-1.1 
 
-0.5 
 
-4.5 -5.1 
 
3.5 5 
61 ALP U/L 74.1 
±26.9 
71.3 
±26.9 
71.7 
±27.5 
71.4 
±26.9 
68.9 
±26.5 
69.4 
±26.6 
4.0 
 
3.9 
 
4.0 
 
7.5 
 
6.8 
 
4.5 10 
26 aALP U/L 69.2 
±18.9 
66.3 
±18.5 
66.6 
±18.8 
66.2 
±18.1 
63.7 
±18.3 
64.3 
±19.3 
4.2 
 
3.9 
 
4.2 
 
8.0 
 
7.5 
 
4.5 10 
35 bALP U/L 77.7 
±31.4 
75.1 
±31.6 
75.5 
±32.2 
75.2 
±31.7 
72.7 
±30.9 
73.2 
±30.7 
3.9 
 
4.0 
 
3.8 
 
7.2 
 
6.3 
 
4.5 10 
61 AST U/L 34.2 
±37.7 
32.0 
±34.9 
32.6 
±38.7 
32.4 
±39.1 
32.5 
±37.5 
32.6 
±36.9 
6.5 
 
5.5 
 
5.3 
 
5.1 
 
4.7 
 
5.5 10 
26 aAST U/L 28.0 
±6.8 
24.1 
±5.9 
23.7 
±6.4 
24.1 
±5.8 
24.5 
±6.0 
24.3 
±6.0 
13.0 15.3 13.3 12.2 12.5 5.9 15 
33 bAST U/L 38.8 
±49.3 
39.2 
±50.8 
38.9 
±57.4 
39.1 
±50.0 
39.1 
±48.4 
38.2 
±45.7 
0.8 2.0 1.7 0.5 -1.7 5.5 10 
59 Pi mmol/L 1.07 
±0.28 
1.08 
±0.30 
1.08 
±0.30 
1.08 
±0.30 
1.02 
±0.28 
1.02 
±0.28 
-0.3 
 
-0.5 
 
-0.3 
 
5.1 
 
4.5 
 
3.8 10 
26 aPi mmol/L 1.26 
±0.20 
1.28 
±0.22 
1.28 
±0.21 
1.28 
±0.21 
1.19 
±0.22 
1.20 
±0.21 
-1.2 
 
-1.1 
 
-1.2 
 
5.9 
 
5.4 
 
3.8 10 
35 bPi mmol/L 0.93 
±0.25 
0.93 
±0.26 
0.93 
±0.26 
0.92 
±0.26 
0.89 
±0.25 
0.90 
±0.26 
0.3 
 
-0.1 
 
0.5 
 
4.5 
 
3.8 
 
3.8 10 
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58 HDL-C mmol/L 1.17 
±0.6 
1.20 
±0.58 
1.21 
±0.58 
1.21 
±0.59 
1.25 
±0.58 
1.26 
±0.60 
-3.3 
 
-3.6 
 
-3.7 
 
-8.0 
 
-8.6 
 
5.2 10 
26 aHDL-
C 
mmol/L 1.53 
±0.43 
1.56 
±0.48 
1.57 
±0.48 
1.59 
±0.47 
1.62 
±0.46 
1.65 
±0.50 
-1.9 
 
-2.5 
 
-3.8 
 
-6.5 
 
-7.8 
 
4.6 10 
32 bHDL-
C 
mmol/L 0.88 
±0.48 
0.90 
±0.47 
0.92 
±0.49 
0.91 
±0.50 
0.95 
±0.49 
0.95 
±0.49 
-4.4 
 
-4.5 
 
-3.7 
 
-9.2 
 
-9.3 
 
5.5 10 
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The HDL-C finding was intriguing and could be due to the heparin in lithium heparin tubes 
enhancing reactions leading to the slightly higher HDL-C results in the plasma samples. The 
results of the PA sera were lower than the lithium heparin plasmas but within limits, and lowest 
with PtPA. The PtPA sera HDL-C results were lower than the sera from the commercial tubes 
but wihin limits. To determine if the PtPA had any direct inhibitory effect on the results variable 
concentrations of PtPA (dilution of PtPA stock 1:25 = 4.8 g/4mL; 1:50=2.4g/4mL; 1:100=1.2
g/4mL: and 1:200=0.6 g/4mL) were prepared and used to prepare serum from blood collected 
from a healthy participant (author). Table 10 shows the results of HDL-C determination.  
 
Table 10. Effects of increasing PtPA concentration on HDL-C results. 
Sample  HDL-C (mmol/L) 
Greiner Lithium Heparin 0.91 
PtPA (1:25 dilution - ) serum 0.81 
PtPA (1:50 dilution) serum 0.78 
PtPA (1:100 dilution) serum 0.85 
PtPA (1:200 dilution) serum 0.81 
 
PtPA at different concentrations did not produce any apparent effect on the HDL-C estimation.  
 
 
Troponin Results  
The TnI exceptions were due to false positive TnI results (one in BD plasma, two in BDSST 
serum samples, and one in BD RST serum sample) (Table 11). When automatically repeated, the 
results matched those from the other tubes.  
 
The cause of false positive TnI results is likely to be due to method robustness. It is likely there 
is non-specific binding of the TnI antibodies to other proteins or microclots and the inability of 
the method wash process to break up such non-specific binding. To test this hypothesis a study 
was conducted to determine if false positive results were induced by insoluble fibrin, non-
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specific binding and the findings were published “Evidence on the cause of false positive 
troponin I results with Beckman AccuTnI method”. 
 
 
Table 11. Analytical data for troponin (TnI) showing false positive results. The TnI cut off is 
0.04 g/L. The results from two specimens with TnI concentration >1.8 g/L were excluded in 
the correlation analysis to provide more accurate analysis of the relationship for the remaining 
specimens.  
Original TnI Result (Repeat TnI result) g/L Original Correlation data 
(Correlation data with repeat TnI 
result) 
Total 
Number of 
Participants  
= 64 PtPA  GRLH BDLH GS BDS BD 
RST 
Linear regression of log 
transformed data 
r2 
Participant 
18 (healthy) 
0.003 0.000 0.000 0.000 0.053 
(0.004) 
0.000 PtPA v BDS 
y= 0.8584x+0.0286 
(y=0.8914x+0.0009)  
 
0.6576 
( 
0.9918) 
Participant 
20 (cardiac 
surgery on 
heparin) 
0.007 0.015 0.093 
(0.015) 
0.013 0.013 0.004 PtPA v BDLH 
y= 1.0298x-0.0024 
(y=1.0351x-0.0018)    
 
0.976 
( 0.985) 
Participant 
38 (healthy) 
0.009 0.000 0.006 0.006 1.334 
(0.002) 
0.004 PtPA v BDRST  
y= 1.1047x+0.0048 
(y=1.0413x+0.0033)   
 
0.9475 
(0.9930) 
Participant 
63 (cardiac 
surgery on 
heparin) 
0.675 
(0.690) 
0.665 
(0.704) 
0.643 
(0.665) 
0.652 
(0.650) 
0.542 
(0.579) 
1.251 
(0.734) 
PtPA v GRLH 
y=0.9695x+0.0027 
PtPA v GS 
y= 0.8815x+0.0024 
 
0.9840 
 
0.9883 
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Series 3: Analytical comparison of sera produced with PtPA in citrate anticoagulated 
participants  
The Greiner serum tube with the added PtPA was able to clot both citrated samples in < 3 
minutes. The Greiner serum tube achieved clotting within 12 to 20 minutes, and no latent 
clotting was visually observed or detected by analysers in these samples. The results are 
summarised in Table 12. The results indicate there was generally good agreement, particularly 
between the sera. The differences that were above the LSC limits were: a) PtPA v GRLH – TP, T 
Bili and AST; and PtPA v GS – T Bili and AST. The TP difference between serum and lithium 
heparin plasma is in line with expectations. The AST is as explained above most likely to due 
increased cell lysis from the Greiner No Additive tube containing no surfactant. The T Bili 
differences were influenced by the very low concentrations in the samples, the actual results 
(PtPA, GRLH and GS) were: participant one - 20, 21 and 22, participant two - 10, 11 and 11 
mol/L.  
 
Table 12. Data for each analyte from the 3 different tubes from two citrate anticoagulated 
participants. The difference is the mean from individual paired results.  
    Mean ± SD PtPA - 
GS 
PtPA - 
GRLH 
LSC CAL 
Number 
of 
samples 
Analyte Units  PtPA GS GRLH % 
dffce 
% 
dffce 
(%) (%) 
2 Na+ mmol/L 133.5±0.7 133.0±1.4 132.5±0.7 0.4 
 
0.8 
 
2.8 3 
2 K+ mmol/L 4.15±0.07 4.25±0.07 4.1±0.14 -2.4 
 
1.2 
 
3.3 5 
2 Cl- mmol/L 104.5±2.1 104.0±2.8 105.0±2.8 0.5 
 
1.4 
 
3.3 5 
2 HCO3- mmol/L 22.5±0.71 22.5±0.71 21.5±0.71 0.0 
 
4.4 
 
4.8 10 
2 Gluc mmol/L 5.5±0.85 5.55±0.92 5.7±0.85 -0.8 
 
-3.7 
 
4.4 10 
2 Urea mmol/L 10.2±2.2 9.95±2.3 10.25±2.2 2.6 
 
-0.6 
 
5.0 10 
2 Creat mol/L 177.8±43.4 176.0±42.6 172.5±41.7 0.5 
 
2.5 
 
5.5 10 
2 Urate mmol/L 0.15±0.00 0.15±0.00 0.15±0.00 0.0 
 
0.0 
 
3.8 10 
2 TP g/L 48.5±13.4 49.0±14.1 52.0±15.6 -0.9 
 
-6.8 
 
3.5 5 
2 Alb g/L 17.0±2.8 16.5±2.1 17.0±2.8 2.6 
 
0.0 
 
3.2 5 
2 T Bili mol/L 15.0±7.1 16.5±7.8 16.0±7.1 -10.0 
 
-7.5 
 
9.2 20 
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2 ALP U/L 89.0±39.6 87.0±38.2 85.5±33.2 2.1 
 
2.6 
 
4.5 10 
2 GGT U/L 128.5±149.2 128.5±147.8 125.0±141.4 -2.0 
 
-2.4 
 
3.8 10 
2 ALT U/L 43.0±26.9 42.5±27.6 42.0±26.9 2.1 
 
2.9 
 
6.8 10 
2 AST U/L 44.5±20.5 41.0±19.8 41.5±20.5 8.4 
 
7.5 
 
5.5 10 
2 LD U/L 328.5±20.5 330.0±15.6 322.5±23.3 -0.5 
 
1.9 
 
5.0 10 
2 CK U/L 54.5±54.5 56.5±54.5 54.5±51.6 -7.3 
 
-5.2 
 
9.1 10 
2 TCa mmol/L 2.40±0.14 2.41±0.16 2.41±0.13 -0.4 
 
0.02 
 
3.5 5.0 
2 Pi mmol/L 1.15±0.14 1.165±0.18 1.135±0.13 -1.1 
 
1.3 
 
3.8 10 
2 Mg2+ mmol/L 0.71±0.10 0.705±0.11 0.705±0.09 0.8 
 
0.6 
 
4.4 10 
2 Lipase U/L 119.0±56.6 118.5±54.5 121.0±56.6 0.0 
 
-1.9 
 
7.9 10 
2 Chol mmol/L 3.7±1.8 3.75±1.8 3.6±1.6 -2.1 
 
0.9 
 
3.6 10 
2 HDL-C mmol/L 0.49±0.11 0.49±0.11 0.425±0.06 0.0 
 
9.3 
 
5.6 10 
2 Fe2+ mol/L 5.0±4.2 5.0±4.2 5.0±4.2 0.0 
 
0.0 
 
7.5 10 
2 CRP g/L 87.0±74.9 85.5±74.3 82.5±71.4 2.2 
 
5.4 
 
6.4 10 
2 Haem 
Index 
 0 0 0 0 0   
 
 
6.4 General Discussion 
The data presented in this chapter allowed for evaluation of sera produced by the use of PtPA 
and other snake venom PAs. This in turn allowed for comparison of venom procoagulant sera 
with sera and plasma produced in commercial tubes. These comparisons were of two types: 
1. The speed with which serum can be prepared. 
2. The quality of the serum as assessed by residual fibrinogen, contamination by cells and 
haemoglobin and analytical data.  
6.4.1 The speed with which serum can be prepared 
The aim of these studies were to produce high quality sera with a clotting time of five minutes or 
less. The data reported in this chapter and earlier chapters showed that this aim can be achieved 
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using low concentrations of snake venom PAs as procoagulants. The current gold standard of 
serum tubes, the BDR RST tube met the recommendation in clotting blood from healthy, 
warfarin and low dose heparin participants in the recommended time of five minutes. The BD 
RST tubes either failed to clot at all or only partially clotted samples on higher doses (cardiac 
unit and dialysis) and fully heparinised samples (cardiac surgery patients) even after allowing the 
clotting to proceed for at least 60 minutes. This was likely as a result of the thrombin 
concentration being insufficient to overcome inhibition by the heparin ATIII-complex, inhibition 
was complete before clotting was complete. A higher concentration of thrombin in the BD RST 
tube may lead to improved clotting in higher heparin doses but it would appear to require much 
higher concentration to be able to clot the fully heparinised samples from cardiac surgery 
patients. This may then cause other analytical problems and may be uneconomical. As expected 
the standard serum tubes, BDS and GS were plagued with clotting problems in low, high and 
fully heparinised samples. In the fully heparinised samples in most instances they failed to clot 
the samples at all. Latent clotting was observed with numerous samples with all three 
commercial serum tubes.    
 
For complete clotting of blood from healthy participants the amount of PtPa or OsPA required 
would be less than or equal to 1 g/4mL tube and ~5 g/4mL tube for blood from heavily 
anticoagulated patients, and perhaps longer clotting time.  
 
6.4.2 The quality of the serum   
6.4.2.1 Residual fibrinogen  
The estimation of the fibrinogen concentrations provided conclusive data to confirm if the 
clotting process was completed. Reducing the fibrinogen concentration in serum during the 
blood clotting process removes the fuel for latent clotting formation and the subsequent removal 
of analytical inaccuracies and unfavourable patient outcomes originating from poor serum 
sample quality. The results suggested that an apparent fibrinogen concentration of ~30 mg/L is 
the expected outcome in completely clotted serum samples. The three prothrombin activators 
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tested (PtPA, OsPA, and ecarin) were able to produce serum samples with a lower concentration 
of residual fibrinogen than commercial serum tubes, particularly in anticoagulated samples.  
 
6.4.2.2 Contamination by cells and haemoglobin 
The cell and cell content results clearly indicated that the PtPA produced serum that was superior 
in quality to the lithium heparin plasma from the healthy participant group, and to both the 
lithium heparin plasma and serum from the anticoagulated participants. The serum in the Greiner 
serum tubes from the cardiac surgery anticoagulated patient was in fact plasma as the samples 
failed to clot at all. The ability of PtPA to form rapid and strong clot entraps all the cells and 
enables almost absolute separation of the cells and the serum; minimises the number of cells 
dispersed throughout the gel barrier and number of cells that remained above the gel barrier in 
the serum sample, minimises cellular lysis, leakage of cellular compounds e.g. K+, LD and 
haemoglobin, as well as cellular activity with the solid entrapment of the cell, minimising 
cellular movement during handling and transport, an important downside with current serum 
producing blood collection devises and methods. If cell stroma and intact cells are transferred as 
part of the analytical sample into cuvettes they are capable of causing interferences and 
inaccuracies which can affect any analyte.  
 
The almost complete removal of cells from the PtPA produced serum permits samples to be 
stored for prolonged periods at all temperatures without significant effect on analytes as 
confirmed by the studies in this chapter. PtPA and the other snake procoagulants offer a simple 
advantage, a high quality serum formed rapidly with unmatched stability for all patients, from 
healthy to the most heavily heparinised, which can provide confidence to laboratories and 
clinical staff that original requests and “add-on” or reflective testing requests will produce more 
reliable results for patient care decisions.   
 
The haemoglobin concentrations in the lithium heparin plasma and serum samples were in line 
with those reported by the IFCC that serum contains a higher haemoglobin concentration [21]. 
However, the PtPA produced serum haemoglobin concentration was lower than either the plasma 
or sera produced with Greiner tubes. Therefore, analytical results from the PtPA sera are more 
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likely to be representative of the in vivo concentrations of analytes. A limitation of the present 
study was that the Greiner serum tubes with added PtPA had the inner wall scrubbed to remove 
the Greiner procoagulant and the surfactant that prevents cell adhesion to the wall. PtPA 
containing tubes with surfactant may lead to further reduction in cells, cell content (e.g. 
haemoglobin release) and improve the quality of the PtPA sera.   
 
 
6.4.2.3 Analytical data comparison of the serum produced from snake venom 
procoagulants 
The analytical findings indicated that the use of snake venom PAs represents a potential solution 
to enable all biochemistry laboratories to standardise on serum as the specimen of choice for 
both healthy and anticoagulated patients for analytes. The anticoagulated population was 
estimated to be up to 10 % of the total specimens received in the Chemical Pathology laboratory 
at the PAH [3], and increasing with the increased use of anticoagulants [39]. Currently at PAH, 
serum is used in all but the most critical clinical units (ED, operating theatres, ICU, high 
dependency, transplant, cardiac and dialysis units) which represent ~30% of the total samples on 
a set day. Out of the 70% (~700 samples per day), from 2-15 serum samples with latent clotting 
may be detected, either by staff prior to loading the specimens on the analysers or due to 
analytical errors with results or analyser problems with latent clot problems. To add to the 
complexity for clinicians, the laboratory information system is unable to accommodate the 
different sample types; it is only capable of identifying the sample as blood. Thus results for K+ 
and TP are provided with serum reference intervals when plasma is the analytical sample. 
Understandably this has led to some confusion and enquiries from clinicians, and could result in 
inappropriate patient care decisions.  
 
Visible clotting was achieved rapidly in the tubes with added PtPA (1.2 g / 4 mL tube) within 
3-5 minutes from both healthy and anticoagulated participants. This included samples collected 
from cardiac surgery patients who had received highest doses of heparin, 25000-45000 units, in 
clinical samples that may be encountered in a laboratory (APTT > 200 seconds at the time of the 
specimens collection). No latent clotting was visually observed or detected by the analysers in 
any of the specimens containing PtPA.  
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Differences in the concentrations of analytes K+, Pi and TP between the lithium heparin plasma 
and serum are well established and previously reported [14, 40]. For most samples, sera 
produced by PtPA, OsPA and ecarin gave almost identical analytical results to sera produced by 
commercial serum tubes. Serum tubes have been shown to minimise K+ release in fragile 
leucocytosis, since the clotting process locks the leucocytes in the clot, eliminates cell movement 
during mechanical stress processes and minimizes lysis [41]. Unlike the commercial tubes, the 
TnI results from the PtPA sera produced no duplicate result discrepancies that were analytically 
significant. The false positive and discrepant TnI results in the commercial tubes are most likely 
due to fibrin which may be from latent clots or incomplete removal during centrifugation. The 
ability of PtPA to complete the coagulation in such rapid time removes fibrinogen and prevents 
subsequent fibrin formation, eliminating the possibility of such errors.  
The frequency of encountering patients on anticoagulation is increasing and will continue to 
increase as new anticoagulants are identified and become routinely used, and more patients 
undergo complex procedures requiring anticoagulation. Thus the problems from incompletely 
clotted specimens for laboratories, hospital laboratories in particular will grow proportionally, 
which will no doubt influence the choice of sample used for routine analysis. 
 
6.5 Conclusion  
Prothrombin activators were able to clot blood samples containing the highest concentration of 
heparin encountered in a hospital environment. They convert blood prothrombin to thrombin 
with an efficiency that overrides the blood antithrombin activity, even in the presence of excess 
heparin, achieving a rapid conversion of fibrinogen to cross linked fibrin.  No unfavourable 
protein degradation was observed in any of the assays tested either with protein/enzyme analytes 
or on the proteins used in the reagents.  
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OUTCOMES AND FUTURE 
STUDIES  
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Outcomes  
It was demonstrated current samples (serum and lithium heparin plasma) for biochemical 
analysis can present analytical problems. The research reported in this thesis has shown that the 
use of snake venom prothrombin activators as procoagulants, the Group C (PtPA and OsPA) 
specifically in blood collection tubes have the potential to achieve the following: 
• excellent agreement of analytical data on serum samples prepared using venom 
prothrombin activators and using commercial serum and plasma tubes; 
• production of high quality serum with a clotting time of < 5 minutes from all blood 
samples; 
• elimination of all fibrinogen from serum samples, thereby avoiding the latent clotting 
problems often encountered currently in both serum and plasma; 
• and elimination of the vast majority of contamination by cells and cell components, so as 
to allow storage of samples and re-analysis with confidence in analytical results, unaffected 
by sample integrity factors upon prolonged storage. 
If true serum could be produced from all patient samples in a short time, the need for lithium 
heparin plasma would be negated. The frequency of false troponins with the Beckman AccuTnI 
assay are likely to be reduced, minimizing inappropriate treatment and improving patient safety. 
The rapid clotting of blood by PAs will at least be equivalent in minimizing leucocyte rapture 
like current commercial serum tube in fragile leucocytosis. Using PAs as procoagulants will 
provide a significant advantage, minimise changes in analytes which can be observed when 
serum and cells are in contact for extended clotting time (minimal 30 minutes) as is required with 
current commercial serum tubes. The PAs will produce serum containing very minimal number 
of cells and cellular debri, providing a higher sample quality which can be stored for extended 
periods at various temperatures. Additionally, it will provide results, specifically of critical care 
nature in faster TAT to minimise adverse outcomes for patient and healthcare providers. 
These procoagulants offer an opportunity to define a more specific definition of serum to what is 
currently used by the World Health Organisation, as follows: serum is the undiluted, 
extracellular portion of blood after adequate coagulation is complete” [1]. A suggested 
enhanced definition is “serum is the undiluted, extracellular portion of blood after complete 
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coagulation, that is devoid of fibrinogen (< 30 g/mL), and which the cell and cell content 
contamination low enough so that changes in K+, LD, glucose and Pi upon prolonged storage of 
> 8 hours at 21ºC are below the least significant change limits when collected, stored analysed 
in the primary tube containing a gel barrier”.   
 
Further research will also seek to optimise the purification of the most promising of the 
prothrombin activators (PtPA, OsPA) and to undertake comprehensive molecular and activity 
characterisation of them. 
 
Our research group is actively working towards the commercialisation of our plans for improved 
serum tubes. The invention has been the subject of a provisional patent application (lodged 20th 
of September 2010), followed by a PCT lodged 20th of September 2011. 
 
The major issues which remain to be addressed are: 
• availability of sufficient quantities of the venoms;  
• the optimum amounts of prothrombin activators per tube;  
• the cost of a prothrombin activator containing tube; 
• the stability of the PAs in the tubes, which need to be stored at room temperature for up 
to 12 months prior to use; 
• and test wider range of analytes and on different methods from other diagnostic suppliers. 
 
Preliminary communications with two commercial tube manufacturers have taken place. To 
progress this process of incorporation of the PA in tubes another issue that requires studying is 
the effects of standard surfactants used by tube manufacturers on the OsPA activity.   
 
Future directions 
In addition to further development of higher quality serum, the plan is to investigate the use of 
prothrombin activators for point of care testing devices. This may involve a syringe of the design 
shown below.  The syringe would be divided in compartments as illustrated in the diagram. 
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A – entry port that will have blood collection needle adapter that would unscrew to 
minimising protruding component  
B – port for dispensing serum or entry port for point of care sample needles 
C – valves to allow for one way entry of blood and prevent blood being pushed into 
serum compartment 
D – plunger filter that would allow serum to be pushed out into the serum compartment 
(front part of the syringe) 
E – opening for blood to enter blood compartment  
The pink block would be coated with PtPA on the inside to set the clotting process in 
place. It would then be pushed to force the serum across the filter (D) 
F – blood clotting compartment  
1. Determine reason(s) why PtPA produced faster clotting in Greiner lithium heparin tube 
then OsPA. It is hypothesised that the surfactant somehow enhances the PtPA activity but 
not the other Group C prothrombin activator, OsPA.  
2. As was shown the PtPA even at very high concentration was unable to clot EDTA whole 
blood. It would be important to unravel the exact mechanism of EDTA inhibition in 
whole blood of the prothrombin activators. Additionally different concentrations of 
EDTA as they are encountered with contamination of samples should be studied to 
determine EDTA concentration where the PAs activity is inhibited.    
3. Determine the exact structure of notecarin FXa in comparison with human FX as it has 
adopted so well to form a prothrombinase complex with mammalian FV.  
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4. Determine how well the PAs clot blood samples containing the newer and emerging 
anticoagulants e.g. dabigatrin, etexilate – direct thrombin inhibitor; apixaban - direct FXa 
inhibitor etc.  
5. Use of these procoagulants in clinical use instead of human, bovine and other forms of 
thrombin to improve clotting of wounds. 
 
A second approach would be to develop a capillary flow system of the serum from clotted blood 
across a membrane for point of care systems.  
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